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 “I conclude that this disorder (asthma) starts with a common cold,
especially in the rainy season,
and that the patient is forced to gasp for breath day and night”
(Maimonides, 1170 A.D.)
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RSV is a single stranded enveloped RNA virus. It is a member of the genus pneumoviri-
dae within the family of paramyxoviridae. Other paramyxoviridae include morbillivirus
(measles), mumps virus and parainfluenzae viridae. The RSV genome comprises 15,222
nucleotides yielding ten major proteins[1]. The F (fusion) and G (attachment) glycopro-
teins are the major surface antigenic determinants[2]. Two antigenic subtypes of RSV are
distinguished, designated A and B[3;4]. Distinction is mainly based on polymorphisms
of the G protein[3;5]. During yearly winter epidemics both strains usually circulate
within the community[6]. Although several studies have also shown that RSV type A is
associated with more severe disease, others have not been able to confirm this [7-11].
 	
More than 50% of all infants are infected with RSV during the first year of life and at age
2 more than 90% of infants have been infected[12;13]. RSV is the most important cause
of viral lower respiratory tract infection (LRTI) during infancy worldwide[2]. Hospitali-
zation is required in up to 3% of infants < 1 year of age with RSV infection [14-16]. In
hospitalized infants with RSV infection mechanical ventilation is needed in 7-21% of
cases[17-19]. In developing countries mortality rates up to 7% have been mentioned,
mortality in industrialized countries is low and probably < 1%[20;21].
 
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RSV bronchiolitis predominantly occurs in children aged less than six months of age.
Typically, the child first experiences a mild upper respiratory tract infection with serous
nasal discharge. After a few days this is followed by severe coughing, shortness of breath
and an audible wheeze on expiration. Impaired oxygen saturation is a key phenomenon
in the disease resulting occasionally in cyanosis, tachypnea, inter- and sub-costal retrac-
tions and nasal flaring. Gradual recovery may take several weeks, however in case of
hospitalization the child can usually be discharged after less than one week. 
 
Bronchiolitis is a common disease of the lower respiratory tract of infants resulting from
inflammatory obstruction of the small airways [22]. Bronchiolitis is a clinical diagnosis,
that may be suspected in infants with clinical symptoms of bronchiolitis during the
winter season. To confirm RSV infection in infants with bronchiolitis, direct immunoflu-
orescence for RSV in swabs or washings from the nasopharynx has proven high sensitiv-
ity and specificity[23;24]. More recently, RSV can also be detected in nasopharyngeal
specimens by polymerase chain reaction PCR[25-28].
 
Evidence suggests that RSV bronchiolitis has an immune-mediated pathogenesis in
which an aberrant immune response to the virus facilitates the development of
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disease[29]. In hospitalized infants with natural RSV bronchiolitis elevated IgE and eosi-
nophilic cationic proteins (ECP) in airway secretions have been reported, suggesting that
immunological host factors may enhance severity of disease during lower respiratory
tract infection with RSV[30;30;31;31-33]. In addition, the relation between RSV and
subsequent recurrent wheezing suggests that atopy could underlie both RSV bronchiolitis
and the subsequent sequelae. Indeed, it was reported that RSV bronchiolitis is a risk
factor for the subsequent development of allergic asthma[34]. However, others did not
find an association between RSV and atopy[30;31;35-39]. Moreover, an immune-medi-
ated pathogenesis is further supported by the vaccine-enhanced illness observed during a
trial with formalin-inactivated RSV[40]. Finally, data from RSV infection in the mouse
model have shown that both CD4+ and CD8+ T cells are required for full development
of illness and pulmonary inflammation[41]. In addition, it was shown in the mouse
model that RSV infection after immunization with the RSV G protein is characterized by
Th2-type immune responses[42], which are associated with the atopy syndrome[43;44].
Immune-mediated enhancement of disease does not easily explain age distribution of
infants with RSV bronchiolitis. In particular, the occurrence of RSV infection necessitat-
ing mechanical ventilation in neonates and healthy preterm infants suggests that matura-
tion-related mechanisms could play a role[45;46]. The immune response of neonates is
characterized by immature cellular immunity which makes these infants more suscepti-
ble for severe infections with intracellular pathogens[47-50]. 
 !
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There is no specific treatment for RSV bronchiolitis[51;52]. Anti-viral medication has
not been proven to be effective[53-55]. Conflicting results have been reported on the
effect of systemic corticosteroids[52]. A recent meta-analysis showed a borderline signifi-
cant benefit of the use of systemic corticosteroids in RSV bronchiolitis[56]. No evidence
exists that bronchodilators, such as β2-agonists, are indicated for routine use, but may be
considered on a trial and error base in individual patients[51;52;57]. Symptomatic treat-
ment consists of oxygen suppletion. Fluid administration may be used to prevent or
correct dehydration. 
Currently, no vaccine for RSV is available. In the 1960s a formalin-inactivated vaccine
was used in infants[40]. No protection against naturally-acquired RSV was observed. In
contrast, enhanced disease and increased mortality were observed during RSV infection
following vaccination. Several strategies for save and effective vaccination, including
immunization with attenuated strains and sub-unit vaccines are under investigation at
the moment[58-61].
In the absence of a vaccine, passive immunization strategies were developed. Both donor-
derived (RSV-IG) and RSV-specific monoclonal antibodies (palivizumab) have been
proven to be safe and effective in reducing hospitalization in case or RSV infection in
high-risk infants[62;63]. However, some questions about the use of RSV prophylaxis still
have to be addressed. No data are available whether passive immunization can prevent
RSV bronchiolitis in non-high-risk infants. In addition, it is not known whether RSV
prophylaxis in high-risk infants results in a lower risk for mechanical ventilation and
intensive care admission.
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The development of short-term prognostic models for RSV bronchiolitis are relevant,
because clinicians can use them for practical preventive and treatment strategies. Knowl-
edge on estimated risk factors for adverse outcome of disease in case of RSV bronchiolitis
are valuable when developing algorithms for patient management. Prognostic models
help to identify children who have the greatest benefit of RSV prophylaxis. In addition,
prognostic models may be used to identify infants requiring hospitalization in case of
RSV infection. Currently, hospitalization will often be considered in case RSV infection is
diagnosed in a preterm neonate with only upper respiratory tract symptoms, because of
suspected risk for clinical deterioration. Whether it is actually necessary to advocate
hospitalization in this case is not known. Furthermore, it is not known whether RSV
infection is associated with sudden infants death syndrome (SIDS) and if so, which group
of infants has the highest risk. Some evidence exists that such an association exists but
accurate estimation of risk in individual infants is not yet possible[64;65]. In addition to
the use for decision making by clinicians, parents are obviously interested in the future
course of disease. Parents usually wish information on the expected duration of hospital-
ization as well as the chance their child will develop “asthma”?
In addition to the direct practical use, predictive models for the clinical outcome of RSV
bronchiolitis may lead to a better perception of pathogenetic mechanisms that could play
a role. The high risk for adverse outcome in case of RSV infection in healthy neonates has
lead to the hypothesis that maturation related mechanisms play a role in severe RSV
bronchiolitis in this age group[46;66]. The studies on RSV bronchiolitis in infants with
congenital heart disease have indicated that pulmonary hypertension could be a pathoge-
netic factor in this group of infants[67]. 
Predictive models can also be used in intervention studies. Inclusion of high-risk infants
will lead to an over-all higher incidence of RSV bronchiolitis observed in the study group.
This will reduce the number of subject required for the study to draw statistically signifi-
cant conclusions. Efficacy studies of RSV-specific immunoglubulines and monoclonal
antibodies as prophylaxis for severe RSV have been performed in high-risk infants[62;63]
would not have been feasible when performed in a general pediatric population. Other
subgroups identified to be at high risk for severe disease based on a prognostic model
might benefit in the future from prophylactic or therapeutic possibilities. Finally, predic-
tive models can be applied when stratification of patients prior to the intervention is
warranted.
$ %



The principal aim of this thesis was to elucidate the potential role of regulatory cytokines
produced by lymphocytes and antigen-presenting cells in the pathogenesis of RSV bron-
chiolitis in relation to short-term (severity) and long-term outcome (recurrent wheezing)
of disease. Therefore, cytokine profiles were studied in a cohort of hospitalized infants
with RSV bronchiolitis in relation to outcome of acute disease as well as long-term seque-
lae. Furthermore, we investigated whether simple clinical observation, such as post-
conceptional age and the presence or absence of airflow limitation during RSV bronchi-
olitis can be used as practical predictors for short-term respectively long-term outcome.
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In the studies of this thesis the following hypotheses are tested:
The duration of the period that prematurely born children are at risk for severe RSV
infection resulting in mechanical ventilation (MV) is determined by the post-concep-
tional age (Chapter 5).
Clinical and immunological parameters during RSV are associated with disease severity
(Chapter  6  to 8).
Cell-mediated immunity mounted during RSV bronchiolitis provides protection against
subsequent reinfection (Chapter 9).
Long-term airway morbidity following RSV bronchiolitis can be estimated using clinical
and immunological predictors (Chapter 10, 11).
& '



1.9.1  Short-term airway morbidity following RSV infection
Clinical and immunological determinants of RSV bronchiolitis resulting in MV are
discussed in Chapter 2. Risk factors for RSV bronchiolitis resulting in the requirement of
MV include neonatal status and prematurity with or without chronic lung
disease[19;46;67-70]. Although these risk factors are well established, pathogenetic
mechanisms that lead to this most severe form of RSV bronchiolitis are largely unidenti-
fied. 
Safe and effective RSV prophylaxis is currently available for prematurely born infants.
Widespread administration to all preterm infants could be considered. However, the need
for such a strategy can be criticized since the majority of preterm infants will never
develop severe RSV infection when they do not receive RSV prophylaxis. Chapter 5
describes until what age prematurely born children have most benefit of RSV prophylaxis
to prevent RSV bronchiolitis resulting in MV.
In this thesis an attempt is made to asses a potential role for cellular immunity in the
development of RSV bronchiolitis resulting in MV. Chapter 6 describes differences in T
cell responses upon non-specific stimuli in the peripheral blood between mechanically
ventilated and non-ventilated hospitalized infants with RSV bronchiolitis. In Chapter 7
local differences in in vivo T cell cytokine levels differences between ventilated and non-
ventilated infants are analyzed. 
Antigen-presenting cells, including monocytes and macrophages, have a regulatory role
in the development of cellular immunity. In particular, IL-12 has been mentioned to play
an important role in the initiation of cellular immunity. In Chapter 8 the predictive value
of monocyte IL-12 production for duration of MV is shown. Subsequently, we present
the first predictive model for duration of MV in RSV infection.
1.9.2  Long-term airway morbidity following RSV bronchiolitis
In long-term follow-up studies it has been appreciated that 30-70% of the infants will
have recurrent episodes of wheezing during early childhood (reviewed in Chapter 3).
Little is known about clinical and non-clinical factors that determine long-term airway
morbidity following RSV bronchiolitis. Therefore, this prospective follow-up study was
undertaken to identify prognostic factors for the occurrence of recurrent episodes of
wheezing during early childhood following RSV bronchiolitis.
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Previous studies attempted to delineate clinical risk factors for airway morbidity follow-
ing RSV LRTI[37;71]. However, no clinical risk factors were identified thus far. Chapter
10 describes the predictive value of signs of airflow limitation during RSV bronchiolitis
for subsequent recurrent wheezing. 
Studies have indicated that atopic status plays an important role in long-term airway
morbidity following RSV bronchiolitis, however other studies could not confirm this
finding [34;39;72]. Atopy is considered a condition that is the result of Th2-like cytokine
responses[44]. We therefore investigated whether Th2-type immune responses during
RSV bronchiolitis in the peripheral blood (Chapter 11) are associated with subsequent
recurrent wheezing. Furthermore, in line with our study on the predictive value of
monocyte IL-12 response for duration of MV[73], we assessed whether monocyte
cytokine responses in the peripheral blood during RSV bronchiolitis may be of predictive
value for long-term airway morbidity (Chapter 11).
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RSV bronchiolitis resulting in respiratory insufficiency is frequently encountered during
the winter season at Paediatric Intensive Care Units. Pre-existent cardiac or pulmonary
compromise have been documented as clinical risk factors for severe RSV bronchiolitis.
In addition to this group of infants with pre-morbidity, a large proportion of mechani-
cally ventilated RSV bronchiolitis patients are previously healthy full term infants or
premature neonates without predisposing risk factors. In general, infants at this early age
have maturation-related deficient cellular immunity. Several studies show an association
between decreased cellular immunity and severe RSV bronchiolitis, indeed suggesting
that a maturation-related defect of the cellular immune system facilitates severe RSV. In
addition, low virus-specific antibody titres prior to RSV bronchiolitis have been shown to
be a risk factor for severe RSV bronchiolitis. Conflicting data have been reported on the
role of the virus strain in severe RSV bronchiolitis, but it is suggested that host factors are
of greater importance. Studies in the mouse model have demonstrated that the immune
system, in particular T cells, can enhance pulmonary inflammation during RSV infec-
tion. It is not yet clear how RSV infection in the animal model bears relevance for RSV
bronchiolitis during infancy. In conclusion, severe pre-existent cardiac, pulmonary and
immunological morbidity are important determinants of severe RSV bronchiolitis result-
ing in MV in a subgroup of patients. In healthy preterm infants and neonates immaturity
of physiological functions, in particular the immune system, appears to be an important
factor in the pathogenesis of RSV bronchiolitis resulting in MV.
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Respiratory syncytial virus (RSV) is the most important cause of bronchiolitis during
infancy world-wide[1]. Hospitalisation rates for RSV illness are 1-30 cases per 1000
infants < 1 year of age[2-4]. In hospitalised infants with RSV bronchiolitis mechanical
ventilation is required in 7-21% of cases[5-7].
The pathogenesis of RSV bronchiolitis necessitating mechanical ventilation (MV) is not
well understood. Congenital heart disease, prematurity with or without chronic lung
disease, age < 6 weeks and compromised immune function are well established clinical
risk factors for severe disease[7-12]. The presence of pre-existent severe cardiac or
pulmonary compromise likely explains the development of respiratory insufficiency in
case of RSV bronchiolitis in some of these patients. Difficult to explain is the occurrence
of RSV bronchiolitis resulting in MV in healthy neonates. It has been suggested that
anatomically immature airways play a role[13;14]. Swelling of bronchial epithelium in
relatively small airways could lead to severe respiratory distress. However, direct evidence
for this hypothesis is still lacking. RSV bronchiolitis has been considered as an, at least
partially, immunopathological condition[15;16]. However, it was already questioned by
Hall et al. whether an immune-mediated pathogenesis fully explains the high frequency
of severe RSV disease in neonates[8]. 
In the present paper we review determinants and possible pathophysiological mecha-
nisms that have been described in RSV lower respiratory tract infection resulting in
mechanical ventilation.
 


Infants with congenital heart disease, chronic lung disease and to a lesser extent compro-
mised T-cell function are at risk for severe RSV bronchiolitis[7;9;9-12;17]. It has been
well established that many other pathogens can cause severe bronchiolitis at young age in
these patient populations. It may well be that the pre-existent morbidity in combination
with a vigorous immune response facilitates severe respiratory compromise in these
infants during infection due to various pathogens, including RSV. Why neonates and
prematurely born infants without chronic lung or heart disease are at risk for severe RSV
bronchiolitis resulting in MV is more puzzling. Recurrent apneas and respiratory insuffi-
ciency are the main causes of initiating MV. We recently showed that preterm infants are
at high risk for MV until a post-conceptional age of 44 weeks[18]. We also investigated
the distribution of post-conceptional age in healthy term infants who were ventilated for
RSV infection. Again, the vast majority of these healthy term infants had not reached a
post-conceptional age of 45 weeks. Thus, a common characteristic of both healthy term
and healthy preterm infants seems to put them at increased risk for RSV bronchiolitis
resulting in MV until a post-conceptional age of 44 weeks is reached.
Although the mortality of RSV bronchiolitis resulting in MV is low, the clinical course on
PICU varies. In particular, duration of mechanical ventilation varies from a few days to
more than one month[19-22]. To date, two observational studies have attempted to iden-
tify clinical predictors for duration of MV[20;22]. Tasker et al. demonstrated that the
combination of a high mean airway pressure (MAP) and a high alveolar-arterial oxygen
gradient (AaDO2) during the first 48 hours accurately identified infants with the longest
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duration of MV[20]. In addition, we have shown the prognostic value of the ventilation
index (VI) during the first 48 hours for duration of MV[22]. Of interest is that both stud-
ies were able to identify predictors for duration of MV during the first 48 hours after
initiation of MV. Together, these observations suggest that events that occur early in the
course of RSV bronchiolitis resulting in MV are more important determinants of disease
outcome than events that occur later during MV.
 +
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Studies on pulmonary pathology would provide more direct insight in the immune
response as well as anatomical characteristics of children during RSV bronchiolitis.
However, bronchial biopsy studies or bronchoalveolar lavage (BAL) studies in the very
young infants can not be performed because of obvious ethical reasons. Sparse post-
mortem studies are found in literature[23-25]. Lack of pathological studies is explained
by the low mortality rate of RSV bronchiolitis. The estimated mortality in hospitalised
patients with RSV bronchiolitis varies from <0.5% in healthy infants to 0.5-2% in high-
risk infants[26]. Two reports on post-mortem findings after RSV bronchiolitis were
provided by British investigators in the early 70s[23;24]. These studies describe histologi-
cal changes in infants dying with respiratory illness caused by RSV. Aherne et al. showed
the general histological picture of peribronchial lymphocyte infiltration, necrosis of
bronchial epithelium and mucus plugs in the small bronchioles[24]. Downham et al.
assessed viral load in 5 infants by quantifying fluorescent viral antigen. Interestingly, in 3
of 5 infants scanty amount of RSV was found, suggesting that large viral load is not
required for most severe RSV bronchiolitis [23]. However, some limitation of these stud-
ies should be noted. Some of the children had severe congenital cardiac abnormalities, a
history of asthma or strong microbiological signs of secondary bacterial infection. In
addition, a period of ≥ 48 hours between death and post-mortem examination might
have diminished the quantity of epithelial cells showing RSV-specific immunofluores-
cence. As a result of the non-uniform inclusion criteria and the delay between death and
autopsy, careful interpretation of the histological findings in the studies described is
warranted.
 
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Virological studies in infants with RSV bronchiolitis resulting in MV have focused on
quantification of RSV in the airways. In general, higher RSV titres are found in nasopha-
ryngeal samples from mechanically ventilated infants than in hospitalised non-ventilated
infants[27;28]. These findings appear to be in contradiction with the autopsy studies
mentioned earlier. However, the differences may be explained by different methods of
quantification of viral load (fluorescence versus titration) and the high prevalence of pre-
existent severe morbidity in the autopsy study.
In addition to viral load, it was attempted to relate virus type to the risk for MV among
hospitalised infants with RSV bronchiolitis. Two antigenic variants of RSV circulate
concomitantly during epidemics, type A and B[29]. Walsh et al. investigated the infecting
type (A or B) among 265 hospitalised infants with a respiratory tract infection caused by
RSV[30]. They showed that RSV types were equally prevalent in this group of patients,
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but that MV was required more often in infants infected with type A than type B. It was
suggested that among infants requiring MV, type A was seen most often in infants with-
out underlying medical conditions (congenital heart disease, chronic lung disease),
whereas type B was found mainly in infants with underlying medical conditions. Some
other studies have also shown that RSV type A is associated with more severe disease, but
the subject remains controversial[31-34]. One study indicated that disease severity in a
group of hospitalised non-ventilated infants was associated with viral genotype[31]. In
this study, a specific genotypic variant of antigenic type B RSV was strongly associated to
disease severity .
 *
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The role of cellular immunity has been mentioned in the pathogenesis of RSV bronchi-
olitis [16]. It has been speculated that cell-mediated immunity against RSV contributes
importantly to disease manifestations. Two clinical observations lead to the view that
disease manifestations during RSV infection are at least partially caused by the immune
response. The first observation that specific immunity against RSV may be harmful came
from the trials with a formalin-inactivated experimental vaccine in the 1960s[35]. Vacci-
nation resulted in augmented disease upon subsequent natural RSV infection in vacci-
nated infants as compared to controls. An immune-mediated pathogenesis of RSV
bronchiolitis is further supported by the clinical and epidemiological similarity between
RSV bronchiolitis and childhood asthma. The clinical picture of both RSV bronchiolitis
and childhood asthma is characterised by upper respiratory tract symptoms, such as
rhinitis, followed by wheezing respiration as a sign of airflow limitation. In addition, RSV
bronchiolitis is followed in 30-70% of the cases by recurrent episodes during early child-
hood[13;36-38].
In apparent contrast with the assumption that pathology in RSV is primarily mediated
through the immune system, are the following clinical observations. Infants, but also
older children and adults with a primary immunodeficiency disorder or impaired cell-
mediated immunity due to chemotherapy have increased risk for severe course of disease
[39;40;40-44]. In these patients severe viral pneumonia is seen and wheezing respiration
is unusual. This clearly indicates that cellular immunity can protect against severe RSV
bronchiolitis. However, considering the differences in age at onset of RSV and clinical
presentation of these patients it is questionable whether RSV lower respiratory tract
illness in patients with an immunodeficiency is the same disease entity as RSV bronchi-
olitis during infancy.
The role of humoral immunity against RSV has been questioned over time. The
commonly held view in the early seventies was that serum antibody could be responsible
in part for enhanced disease[45]. Chanock et al. observed that disease occurred during
early infancy when maternal antibodies are universally present[45]. In addition, it was
shown by Welliver et al. in the 80s that virus-specific IgE in the respiratory tract during
RSV bronchiolitis is associated with disease severity[46;47]. However, it is conceivable
that high virus-specific antibody levels mounted during RSV do not cause severe disease,
but reflect a protective immune response. More recent data have indeed suggested a
protective role for naturally occurring virus-specific antibodies. Low cord blood neutral-
ising antibodies have been shown to be associated with severe disease[2]. However, to our
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knowledge, it has not been shown that low neutralising antibodies result in increased risk
for RSV bronchiolitis resulting in MV. In addition to the observation that transplacental
transfer of RSV-specific antibodies may prevent RSV bronchiolitis, it was shown that
prophylactic administration of RSV-specific immunoglobulines or monoclonal antibod-
ies to high-risk infants can prevent hospitalisation in this specific group of infants[48-
50]. Whether antibody prophylaxis prevents RSV bronchiolitis resulting in MV is not
known.
Immunological studies have shown that lower peripheral blood T cell counts are seen in
infants during RSV bronchiolitis resulting in MV than in hospitalised non-ventilated
infants with RSV bronchiolitis[51]. In addition, we and others showed that the immune
response during RSV bronchiolitis resulting in MV is characterised by low T cell prolifer-
ative responses and IFN-γ production upon non-specific stimuli[52;53]. Recently, we
performed the first study on cytokine levels in nasopharyngeal aspirates in a large group
of mechanically ventilated infants. Our findings showed that also in vivo interferon (IFN)-
γ levels in nasopharyngeal aspirates are severely decreased in mechanically ventilated
infants as compared to hospitalised non-ventilated infants (unpublished observations).
In a different study in mechanically ventilated RSV bronchiolitis infants, we investigated
the role of monocyte interleukin (IL)-12, a cytokine produced by antigen-presenting cells
that is required for the initiation of cellular immunity[22;54]. Duration of mechanical
ventilation of infants with RSV bronchiolitis was strongly inversely related to monocyte
IL-12 production at initiation of MV, suggesting a crucial role for cellular immunity
during recovery from RSV bronchiolitis requiring MV [22]. 
Animal studies have indicated a possible role of Th2-like cytokine profiles in the patho-
genesis of RSV bronchiolitis[55]. Controversial results have been found in human
RSV[53;56-58]. In most human studies Th1/Th2 cytokine profiles are expressed as IFN-
γ/IL-4 ratios. In hospitalised RSV infected infants decreased IFN-γ/IL-4 ratios were found
after polyclonal stimulation as compared to healthy controls[57]. In a similar study,
decreased IFN-γ/IL-4 ratios after in vitro allergen stimulation were found five months
after hospitalisation for bronchiolitis[56]. In contrast, we recently reported normal IFN-
γ/IL-4 ratios after polyclonal stimulation on admission, and again 3-4 weeks later during
the convalescent phase in RSV infected non-ventilated infants [53;58]. In mechanically
ventilated, however, no IFN-γ/IL-4 ratio could be calculated of on admission because
both IFN-γ and IL-4 production were below detection limits[53]. To date no data are
available on Th1/Th2 cytokine profiles during RSV bronchiolitis resulting in MV.
" %

Murine models have provided insight into the possible mechanisms by which RSV could
lead to disease[59-64]. It was shown by Graham et al. that T cell depleted BALB/c mice
showed prolonged viral excretion after intranasal infection with human RSV but became
less ill than immunocompetent BALB/c mice[59]. In T cell transfer experiments in
murine models the differential role of CD4+ and CD8+ cells was studied[62]. After injec-
tion of RSV specific CD4+ T cells into BALB/c mice, the recipient mice developed more
respiratory distress and weight loss upon RSV infection than non-transferred normal
mice. The effect of injection of RSV-specific CD8+ cells prior to RSV infection were simi-
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lar but moderate. Altogether, these animal experiments show that T cells are capable of
enhancing disease during RSV infection in mice. 
In murine models, most previous studies have shown a predominance of Th2 over Th1
cytokines during RSV infection[55]. However, it has not been established how these
cytokine profiles relate to disease in mice. Administration of exogenous IL-12 lead to a
complete alteration of cytokine profiles in CD4+ T cells in the lungs of mice subsequently
challenged with RSV[65]. IL-12 treatment caused CD4+ T cells to make higher levels of
IFN-γ and lower levels of IL-4 and IL-5 and reduced the pulmonary eosinophilia found in
the lungs of the challenged mice, but IL-12 treatment did not decrease disease severity.
These experiments illustrate the complex relation between immune pathology during
RSV infection and clinical disease. 
To what degree the animal model bears relevance to human RSV remains to be estab-
lished. Most animal model studies were performed in BALB/c mice. In various infectious
and non-infectious models BALB/c have shown to have a strong preferential activation of
Th2 immune responses, including allergic responses[66-69]. To our knowledge, no
animal model exists for respiratory insufficiency caused by RSV. RSV in animal models,
including BALB/c mice, does not lead to animal death. Moreover, it was established that
young mice develop less pulmonary inflammation upon natural primary infection than
older mice[70]. Consequently, the BALB/c mouse appears not a very suitable model for
either neonatal RSV bronchiolitis or RSV bronchiolitis resulting in MV. 
$ ,	
Different patient groups need to be distinguished in order to understand the pathophysi-
ology of RSV bronchiolitis resulting in MV (Figure 2.1). In infants with severe pre-exist-
ing pulmonary or cardiac morbidity pathophysiological mechanisms underlying the
occurrence of RSV bronchiolitis resulting in MV are likely comparable to those in lower
respiratory tract infections caused by other pathogens. Pathogenesis of disease can be
well explained without an immune-mediated pathogenesis. The most intriguing question
is why healthy neonates without chronic lung or heart disease are at risk for RSV bronchi-
olitis resulting in MV.
Airway inflammation is the hallmark of RSV bronchiolitis resulting in MV. Two different
mechanisms appear to contribute to the development of airway inflammation. On the
one hand, airway inflammation results from necrosis of airway epithelial cells which is
directly caused by the cytopathological effect of RSV[71-73]. Decreased cellular immu-
nity in young infants would hereby allow for more widespread viral replication resulting
in more extensive damage to the airways. On the other hand, the immune response to
RSV may directly damage the airways resulting in inflammation and more airway
destruction. Indeed, animal studies support the concept that T cells can directly cause
airway inflammation. Immunopathogenetic factors contributing to respiratory insuffi-
ciency during human RSV, however, are largely unidentified. 
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Immaturity of the immune system in preterm infants and neonates could play a role in
RSV bronchiolitis resulting in MV. Fetal and early post-natal life is associated with a
physiological immune deficiency[74-76]. A consequence of this immune deficiency is
susceptibility to infections with intracellular pathogens, including cytomegalovirus
(CMV), Toxoplasma gondii, herpes simplex virus (HSV), enteroviruses, human immun-
odeficiency virus (HIV) and Mycobacterium tuberculosis during the first 4 to 8 weeks after
birth[77-82]. Deficient immune function in neonates is characterised by relative deficient
functioning of innate and antigen-specific immunity[76;83]. Defective functions of cells
of the innate immune system consist of delayed recruitment of neutrophils and mono-
cytes to infected tissue and diminished NK cell cytotoxicity[84]. During the neonatal
period antigen-presentation by macrophages and dendritic cells is less efficient, possibly
due to deficient IL-12 production, resulting in slow development of antigen-specific
immunity[75;76;85]. In addition, T cell-mediated responses are delayed during the first 4
to 8 weeks of postnatal age, accompanied by impaired capacity to produce IFN-
g[74;76;83;86;87]. Some evidence described in the current paper has shown that, indeed,
immature cellular immunity could play a role in RSV bronchiolitis resulting in MV.
Whether all immune functions mentioned, however, are involved in RSV bronchiolitis
resulting in MV is uncertain. 
In addition to maturation of immune responses neonatal maturation includes physiolog-
ical changes in airway anatomy and functioning. Little is known about normal ontogeny
of airway anatomy and physiology in young infants[88-90]. It was shown in a large birth
cohort study that impaired airway function at birth is associated with increased risk for
wheezing illness[91]. In addition, it has been suggested that the same mechanism could
Figure 2.1 Schematic presentation of pathogenetic pathways in the development of RSV
bronchiolitis resulting in respiratory insufficiency
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underlie the occurrence of RSV bronchiolitis [13]. Whether this is true, in particular for
RSV bronchiolitis resulting in MV, needs further study.
RSV research in infants has traditionally put most emphasis on hospitalised non-venti-
lated infants. A minority of immunological and virological studies on RSV bronchiolitis
have included mechanically ventilated infants. Due to severe pre-existent medical condi-
tions a number of patients with RSV bronchiolitis requiring MV would be less eligible for
such studies. However, the majority of infants with RSV bronchiolitis requiring MV are
term or preterm infants without any pre-existent morbidity. The possibility to take
tracheobronchial aspirates allows for more detailed study of pathological conditions in
the lower airways in this sub-group of infants with RSV bronchiolitis.
We conclude that differences exist in the pathogenesis of RSV bronchiolitis resulting in
MV between infants with and without severe pre-existent morbidity. Cardiac, pulmonary
or immunological compromise prior to RSV infection is probably the most important
pathogenetic factor in the latter. In healthy preterm and term infants maturational factors
are most important in the development of RSV bronchiolitis resulting in MV. Matura-
tional factors mechanisms in RSV resulting in MV include small airways, and perhaps
more important, immaturity of the immune system.
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Despite differences in study design, follow-up studies consistently show that approxi-
mately half of the patients with respiratory syncytial virus (RSV) lower respiratory tract
infection (LRTI) during infancy go on to have recurrent wheezing episodes during child-
hood. Respiratory symptoms are associated with abnormal lung function, including
bronchial hyperresponsiveness. Wheezing symptoms following RSV LRTI gradually
decrease and it appears that during school age airway morbidity is no longer related to
RSV LRTI during infancy. Mechanisms underlying the association between RSV LRTI
and long-term airway morbidity are poorly understood. On the one hand, abnormal
airway function that is congenitally present or acquired before RSV LRTI occurs could be
the cause of both RSV LRTI and subsequent recurrent wheezing. On the other hand, it is
possible that RSV LRTI causes changes in the lower airways or the immune system that
result in long-term airway morbidity. Animal models suggest RSV infection can promote
the development of allergic sensitisation, but most studies in humans do not indicate a
role for atopy in the development of recurrent wheezing following RSV LRTI.
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Maimonides wrote in 1170 A.D.: “I conclude that this disorder (asthma) starts with a
common cold, especially in the rainy season, and that the patient is forced to gasp for
breath day and night”[1]. This observation might well be the first description of the rela-
tion between bronchiolitis and recurrent wheezing. Infants who recover from respiratory
syncytial virus (RSV) lower respiratory tract infection (LRTI) have an increased risk for
the subsequent development of recurrent wheezing during early childhood[2;3]. Recur-
rent wheezing is accompanied by functional abnormalities of the airways, such as bron-
chial hyperresponsiveness[4;5]. Although knowledge on clinical, infectious and
immunological factors in the pathogenesis of RSV LRTI increases rapidly, mechanisms by
which RSV LRTI results in long-term airway morbidity are still poorly understood.
Insight in these mechansims is required in order to develop innovative intervention strat-
egies to prevent or treat long-term airway morbidity following RSV LRTI. The aim of this
article is to provide an overview of clinical and experimental studies on the relation
between RSV LRTI and long-term consequences. 
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During the last 40 years a number of prospective follow-up studies have focused on the
relation between RSV LRTI and subsequent airway morbidity[2-16]. Although these
studies have generally confirmed that such a relation exists, differences in the incidence of
long-term airway morbidity following RSV LRTI and differences in the magnitude of
involved risk factors were found. These differences may be explained, at least partially, by
the study design used to investigate the relation between RSV LRTI and subsequent
airway morbidity. Moreover, the definitions used for the different disease entities that
have been used in the studies may be confusing. Definitions used in this article are shown
in table 3.1.
A number of large-scale follow-up studies were performed before immunofluorescence
for RSV became generally available for RSV diagnosis (table 3.2). In these studies, which
are still cited in current literature, bronchiolitis patients were included regardless of the
infectious agent. It can not be excluded that even patients with bacterial infections have
been included.
Historical (retrospective) follow-up studies have shown the possible epidemiological
relation between RSV LRTI and childhood asthma. Since childhood asthma is a heteroge-
neous disease, longitudinal follow-up studies were required to obtain more valid infor-
mation. In addition, well defined (matched) control children were needed to estimate the
relative risk for airway morbidity following RSV LRTI.
Another explanation for the observed differences in outcome variables in the studies on
long-term airway morbidity following RSV bronchiolitis is that severity of the initial RSV
LRTI differs between the studies. Most studies focus on hospitalised infants. Only
recently, new data of long term consequences of RSV LRTI in non-hospitalised infants
have been published[16]. The presence of respiratory wheeze is required in studies focus-
ing on classical RSV bronchiolitis, in other studies any sign of LRTI is sufficient for inclu-
sion. For example, “chest cough” as the sole symptom of LRTI caused by RSV in a 3-year-
old child, was sufficient for inclusion in a recently published large longitudinal study on
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airway morbidity following RSV LRTI[16]. For practical reasons mechanically ventilated
infants are usually excluded. Therefore, little data are available on long term conse-
quences of this group of patients. It may well be that the severity of the initial disease
influences the outcome in the long term.
Two types of outcome parameters for airway morbidity can be distinguished: airway
symptoms and lung function. To date, most follow-up studies have used standardised
questionnaires focusing on airway symptoms. However, bias can occur when question-
naires are filled out by parents. Most importantly, parents might in retrospect forget the
occurrence of symptoms that are related to the respiratory state of their chilld (recall
bias) or over-report in a certain time-frame. Parents might not understand the questions
when they are not put very simple or they might not report the occurrence of events in
the past because it is socially unaccepted (for example exposure to cigarette smoke). 
Airway symptoms as experienced by the infants or parents are probably best assessed
using daily diaries for airway symptoms, because it is a chronological report of symptoms
as they are experienced. It is time-consuming to note airway symptoms in a diary for a
long period of time, which allows for more non-compliance and dropouts during follow-
up. Our experience is that regular contact with parents is time consuming for investiga-
tors but can provide parental motivation to note the presence or absence of simple airway
symptoms (runny nose, cough, wheeze) in a diary for at least up to two years (Bont and
colleagues, submitted for publication).
In addition to symptoms, lung function can be assessed as an objective outcome parame-
ter. Since RSV LRTI is related to airway morbidity up to the age of 6 years, lung function
abnormalities are predominantly expected during these years. However, at the age of 0-4
Table 3.1 Terms and definitions used throughout the article
Term Definition
Asthma[64] an inflammatory disease of the airway of the lung, characterised by 
intermittent airway narrowing and variable symptoms of chest 
tightness, wheeze and shortness of breath
Airway 
hyperresponsiveness[64]
Characteristic physiological abnormality in asthma with 
exaggerated airway narrowing in response to bronchoconstrictor 
stimuli
Allergy[64] Th2-associated immune reactions to allergens
Atopy[64] Familial syndrome of asthma, eczema and hay fever. Can be 
recognised by elevated serum IgE levels, and positive skin prick 
tests or ELISA tests which detect IgE directed against allergens. 
Virtually synonymous with allergy.
RSV bronchiolitis[65] Lower respiratory tract infection with characteristic expiratory 
wheeze caused by RSV in young infants without history of 
wheezing respiration.
Lower respiratory tract 
infection[16]
Infectious disease of the airway of the lung, characterised by 
shortness of breath, wheezing or severe cough
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years only non-conventional techniques for lung function measurement are available.
Tidal breathing analysis can be used to assess airway resistance [17;18]. Bronchial hyper-
responsiveness can be assessed using trachea auscultation to determine the methacholine
concentration to induce wheezing[19]. However, the validity and reliability of these tech-
niques have not yet been fully established. To study airway resistance and compliance,
most techniques analyse tidal breathing. In addition, these techniques can measure the
effect of bronchodilators. Improvement of lung function analysis techniques during early
childhood will enable investigators to focus on the evolution of airway function abnor-
malities following RSV LRTI on the long term.
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An overview of relevant epidemiological studies analysing the relation between RSV LRTI
and airway morbidity is shown in table 3.3. Wheezing episodes following RSV LRTI are
found in 42-71% of patients. It is generally assumed that wheezing episodes following
RSV LRTI are associated with viral upper respiratory tract infections[5], and not allergen
exposure in contrast to children who suffer allergic asthma. This is in line with data from
a community based longitudinal study (not focused on RSV) that showed that viral URTI
also have been associated with asthma episodes in asthmatic school children[20;21].
Infants who will go on to have wheezing episodes will do so within 12-24 months after
the first episode of RSV LRTI[5]. Less than 10% of children with recurrent wheezing
following RSV LRTI began to have wheezing episodes after they were 2 years old. 
A large number of studies attempted to identify clinical risk factors that determine the
development of airway morbidity following RSV bronchiolitis. To date, these risk factors
are not well understood. Disease severity and age at the moment of RSV LRTI could not
Table 3.2 Study design and inclusion criteria used in 13 RSV follow-up studies
Year Reference Pros-
pective 
inclusion
Controls Hospital-
isation
RSV 
diagnosis
Bronchial 
ob-
struction
Age 
(months)
n
1963
1978
1981
1982
1984
1984
1986
1989
1992
1995
1997
1997
1999
2000
Eisen[2]
Sims[3;24]
Gurwitz[4]
Pullan[5]
McConnochie[7]
Hall[6]
Welliver[11;23]
Sly[10]
Murray[22]
Sigurs[12]
Dezateuz[66]
Renzi[14]
Stein[16]
Bont[40]
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
no
yes
no
yes
yes
yes
no
no
yes
yes
yes
no
yes
no
yes
yes
yes
yes
no
yes
yes
yes
yes
yes
yes
yes
no
yes
no
yes
no
yes
no
yes
yes
yes
no
yes
yes
no
yes
yes
yes
yes
yes
no
yes
no
yes
yes
no
yes
yes
yes
no
no
<24 
<12
<24
<12
<24
<24
<6
<12
<12
<12
<12
<12
<36
<12
248
35
48
130
177
29
38
48
73
52
29
26
207
50
n: number of RSV patients
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be related to subsequent airway morbidity[3;5;6;22]. Male sex appeared to be a risk factor
for recurrent wheezing following RSV LRTI in some, but not all studies[7;23;24]. It has
been shown by Martinez and colleagues that pre-existent lower levels of lung function in
newborns are associated with subsequent incidence of lower respiratory tract illness with
or without wheezing in the first year of life[17]. In line with this finding, it has been
suggested that infants with recurrent wheezing following RSV LRTI have lower lung
function early in infancy, before any respiratory tract infection has occurred[16].
However, this hypothesis needs to be confirmed. In addition to premorbid lung function,
atopy is a possible risk factor, that was studied extensively, but results were inconclusive
(table 2). Another risk factor for recurrent wheezing is exposition to cigarette smoke
Table 3.3 Relation between RSV LRTI during infancy and subsequent development of
airway morbidity and atopy
First author Main outcome
parameter
Duration 
follow-up
(years)
Main finding Percentage 
wheeze
Lung 
function 
peformed
Relation 
with 
atopy
Eisen[2]
Sims[3]
Gurwitz[4]
Pullan[5]
McConnochie[7]
Hall[6]
Welliver[11;67]
Sly[10]
Murray[22]
Sigurs[12]
Renzi[14]
Dezateux[66]
Stein[16]
Bont[40]
Questionnaire
Questionnaire
Bronchial reactivity
Lung function
Questionnaire
Physician diagnosed 
wheeze
Physician diagnosed 
wheeze
Questionnaire
Wheeze
Skin prick test, 
allergen-specific IgE
Diary
Lung function
Questionnaire
Wheeze
(diary)
14
8
8
10
8
8
2.0
5
5.5
3
0.25
0.7
13
1.0
Bronchiolitis related to 
recurrent wheeze
Atopy not related to 
wheeze following RSV
Hyperresponsiveness 
after bronchiolitis
RSV related to 
subsequent wheeze and 
low lung function
9.4% of wheeze in 
children related to RSV
wheeze after RSV 
related to low lung 
function, but not atopy
Nasal RSV-specific IgE 
predicts wheeze
Family atopy not 
related to wheeze after 
RSV
Personal atopy not 
related to wheeze after 
RSV
RSV risk factor for 
allergy
Th2 cytokine profile 
predict wheeze
Diminished ttpef:te ratio 
after RSV
Wheezing after RSV up 
to age 11, not at age 13
no relation with atopy
Monocyte IL-10 related 
to recurrent wheeze 
after RSV
49
56
52
42
44
45
53
71
43
60
65
55
1
58
no
yes
yes
yes
no
yes
yes
yes
yes
no
no
yes
yes
no
no
no
–
no
no
no
–
no
no
yes
–
–
no
no
(1) Odd’s ratio at age 6 for frequent and infrequent wheeze: 4.3 and 3.2, respectively
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before or after RSV LRTI[3;6;7]. Cigarette smoke has also been shown to be a risk factor
for airway morbidity in childhood in the general population[25;26]. Because maternal
smoking during pregnancy is a determinant of lung function during early infancy, smoke
exposure could contribute to the risk for both hospitalisation for RSV LRTI and the
subsequent development of airway morbidity[25]. Parental history of asthma, in particu-
lar maternal asthma, has been mentioned as a risk factor for childhood asthma[27;28].
Although parental history of asthma has been associated with RSV bronchiolitis[22], to
our knowledge the predictive value of parental history of asthma for recurrent wheezing
following RSV LRTI has not yet been investigated. 
A few studies have followed infants for more than 10 years to study the evolution of
symptoms or lung function abnormalities following RSV LRTI[2;5;16]. These studies
generally show that the risk for wheezing following RSV LRTI decreases with age. Stein
and colleagues recently published the first prospective longitudinal study of a large
cohort that was drawn from the community. Infants were followed for 13 years[16]. They
compared infants with RSV LRTI with infants without any LRTI during the first three
years of life. The presence of recurrent wheezing was assessed using standardised ques-
tionnaires when children in the study were 6, 8, 11 and 13 years old. In addition, lung
function tests were performed when children were 11 years old. These lung function tests
included assessment of the response to inhaled salbutamol. Frequent wheeze (≥4 wheez-
ing episodes during the last year) and infrequent wheeze (<4 wheezing episodes during
the last year) were found more frequently at age 6 in infants with RSV LRTI than in
infants without LRTI (relative risk 4.3). Subsequently, the risk decreased markedly and
was not significant when infants were 13 years old. Forced expiratory volume in 1 second
(FEV1) at age 11 was significantly lower in infants who suffered from RSV LRTI in the
past than in infants without LRTI, but this difference was not observed after salbutamol
inhalation, suggesting reversible airflow limitation. 
Several studies investigated whether treatment of initial RSV bronchiolitis can influence
the long-term outcome. The use of ribavirin during initial RSV have been found to
reduce the occurrence of wheezing following RSV bronchiolitis by some investiga-
tors[29]. However, these data could not be confirmed by others[30]. Similar to the use of
ribavirin during RSV bronchiolitis to prevent recurrent wheezing, conflicting data have
been reported in the use of inhaled corticosteroids[31;32]. 
Palivizumb is a humanized monoclonal antibody that reduces hospitalisation rates from
10.6% to 4.8% in preterm infants with and without chronic lung disease[33]. Of interest
would be follow-up data of airway symptoms of infants from the trial with palivizumab.
These follow-up data may provide evidence whether prevention of RSV also results in the
prevention of long-term airway morbidity. This would support the idea that RSV LRTI
results from pre-morbid pathology, at least in this specific high-risk group.
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3.5.1  Human studies
It has been suggested that children with RSV LRTI in early childhood have pre-existing
abnormalities of lung function that manifest during the initial illness and again during
recurrences of wheezing episodes[16]. An alternative explanation for the association
between RSV LRTI and the subsequent development of recurrent wheezing is that RSV
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itself causes changes in the lower airways or caused changes in the immune system that
result in long-term airway morbidity. In line with this latter hypothesis, it has been
suggested that RSV results in allergy, which subsequently leads to allergic asthmatic
symptoms.
Airway damage during RSV LRTI might well be a factor in the pathogenesis of long-term
airway morbidity. It is likely that severity of disease during RSV LRTI is related to the
magnitude of destruction of airway epithelium. Therefore, studies have attempted to find
an association between severity of disease during RSV LRTI and subsequent long-term
airway morbidity, but this was not found[3;5]. In a prospective cohort study, we found
that mechanically ventilated infants with RSV LRTI without pre-existing airway disease
have no larger risk for recurrent wheeze or physician diagnosed asthma than other hospi-
talised infants with RSV LRTI (unpublished data). This suggests that other mechanisms
than destruction of airway epithelium during RSV LRTI are important in the pathogene-
sis of long-term airway morbidity following.
Allergy is a Th2-driven syndrome of which IgE-mediated disease manifestations are a
hallmark (table 1). Considering the clinical similarities between recurrent wheezing
following RSV and allergic asthma, the relationship between allergy-related immune
responses and recurrent wheezing following RSV LRTI has been studied. For long, it has
been believed that RSV bronchiolitis and subsequent airway morbidity are associated
with the same or similar pathogenetic mechanisms that cause atopy and allergy. In a
prospective cohort study with 47 infants with RSV bronchiolitis in the first year of life
and 94 matched controls, Sigurs and colleagues analysed the risk to develop a positive
skin prick tests and increased serum IgE against common inhalant and food allergens at
age 3 years as signs of atopy[12]. Signs of atopy were found in 32% of infants with a
history of RSV bronchiolitis and in 9% of controls. This apparent risk for allergic sensiti-
sation following RSV bronchiolitis was independent of family history of atopy. Contrast-
ing data were found in the study by Stein and colleagues, in which it was shown that RSV
LRTI before the fourth birthday is no risk factor for positive skin prick test for common
food or inhalation allergens or increased serum IgE after age 6[16]352. 
Eosinophils play a clear role in allergic asthma. Therefore, eosinophils and eosinophil
activity during RSV LRTI have been studied in relation to the development of recurrent
wheezing. In two different studies, Reijonen and Koller found that eosinophilic cationic
protein (ECP) levels during bronchiolitis in nasopharyngeal secretions (NPS) and serum,
respectively, were associated with recurrent wheezing in the first year of life[13;34-36].
However, in these studies RSV infection was not required for inclusion. A prospective
follow-up study by Ehlenfield and colleagues showed that eosinophilia during RSV bron-
chiolitis is associated with persistent wheezing after 6 years of age, but not with transient
wheezing in early childhood[37]. 
Similar to allergic asthma, Th2-like cytokine responses have been put forward as a poten-
tial mechanism by which RSV results in long-term airway morbidity. Renzi showed that
peripheral blood lymphocytes of 26 bronchiolitis infants, produced less IFNγ in response
to IL-2 and more IL-5 in response to Dermatophagoides farinae five months after the
acute bronchiolitis in children who developed recurrent wheezing[14], indicating a
blunted Th1 response in confirmation with Th2 predominance. However, RSV was diag-
nosed in only half of the infants. In a different study decreased ex vivo IFNg/IL-4 ratios in
response to non-specific stimuli were found during RSV LRTI[15]. However, from this
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study no follow-up data are available. In contrast with the previous 2 studies, we have
recently shown that ex vivo IFNg/IL-4 ratios in a whole blood culture system stimulated
with phytohemaglutinin (PHA) during RSV LRTI was comparable with normal controls.
In addition, IFNγ/IL-4 ratios were not associated with recurrent wheezing during one
year follow-up. These apparent differences found in our study may be explained by
different inclusion criteria and different culture assays.
During RSV LRTI RSV-specific IgE is secreted in the respiratory tract and correlates with
disease severity[38;39]. In addition, it was shown in a cohort of 38 infants that peak titres
of RSV-specific IgE in nasopharyngeal secretion (NPS) during RSV LRTI predicted
wheezing during a 48 months follow-up period[23]. RSV-specific IgE in NPS are not
related to allergic sensitisation during the follow-up period. Thus, the production and
release of RSV-specific IgE in the respiratory tract appears to be regulated by mechanisms
that are unrelated to atopy. More research is required to investigate the potential role of
RSV-specific IgE in airway morbidity following RSV LRTI.
Recently, we have shown that monocyte cytokine profiles in the blood during RSV LRTI
are related to disease severity, and also to subsequent airway morbidity[40;41]. In a group
of 30 RSV infected infants requiring mechanical ventilation, IL-12 production in whole
blood cultures at initiation of mechanical ventilation had predictive value for duration of
respiratory insufficiency[41]. In a different study, we investigated whether monocyte
cytokine responses during RSV LRTI are also associated with subsequent long-term
airway morbidity[40]. Results showed that monocyte IL-10 production 3-4 weeks after
hospitalisation was associated with recurrent wheezing during a one year follow-up
period and with physician diagnosed asthma. Sherran and colleagues have shown that IL-
10 concentrations in NPS are increased during LRTI RSV but no attempt was made to
relate IL-10 levels in NPS to subsequent airway morbidity[42]. Further study is required
to elucidate by what mechanism monocyte IL-10 responses during RSV may contribute
to recurrent wheezing. 
3.5.2  Animal studies
In studies of experimental infection with RSV, replication of the virus within the lung has
been demonstrated in several animals, including monkey species, mice, rats and guinea
pigs[43-46]. None of these animals develop signs of respiratory illness resembling human
RSV bronchiolitis. For this reason, discussion persists as to whether animal models are
relevant for human RSV infection. Murine RSV infection is the animal model that has
been studies most extensively. Signs of illness in mice include weight loss and decreased
activity[47]. Objective evidence of respiratory illness was observed in RSV infected
BALB/c mice using whole body plethysmography[48]. With this method increased respi-
ration rate and abnormal breathing patterns were observed. Increased responsiveness to
methacholine following RSV infection was seen in mice, rats and guinea pigs[48-50].
Consequently, these animals could be suitable models, since increased hyperresponsive-
ness is also seen in infants with airway morbidity following RSV infection[4]. The major
limitation of animal models to study long-term airway morbidity following RSV infec-
tion is that persistence of abnormal lung function has not yet been established. Therefore,
the major challenge for animal studies in the future is to establish the relevance for the
human situation.
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From experiments in the mouse model, it has been suggested that RSV infection may
interact with immunological mechanisms involved in the development of Th2-like
immune responses, including allergic sensitisation[51-57]. In mice who were sensitised
to the G protein, RSV infection enhances allergic airway sensitization, resulting in lung
eosinophilia and in airway hyperresponsiveness[54;58]. It was shown that transfer of T
cells, in particular CD8+ cells, of RSV infected mice into naive mice result in increased
eosinophil influx and production of Th2 cytokines following challenge with ovalbu-
mine[59]. In order to reduce morbidity caused by RSV in the animal model, experiments
have been designed to induce Th1-like immune responses during RSV infection[60].
Treatment with IL-12 of BALB/c mice, primed with RSV G protein, reduced lung eosi-
nophilia and the production of Th2 cytokines following RSV infection, but did not
reduce acute illness, as assessed by weight loss. The latter experiment nicely shows that
immune responses can be modified, but indicates that morbidity caused by RSV is much
more complex. In addition, we note that most studies were performed in BALB/c mice,
which have a genetic predisposition to develop Th2-like immune responses. Further
study is required to investigate the interaction between RSV infection and the develop-
ment of allergy in animal models without a predisposition for Th2-like immune
responses.
Animal models have indicated that also non-immune mechanisms could be involved in
the pathogenesis of airway hyperresponsiveness following RSV infection. The increased
responsiveness to bronchodilators following RSV LRTI observed by Stein and colleagues
can not easily be explained by aforementioned immune-mediated mechanisms that
might be involved in airway morbidity following RSV LRTI. In different animal models
persistent alterations in the development of non-adrenergic non-cholinergic inhibitory
neural pathways were seen following RSV infection[61-63]. This change was associated
with increased contractility of airway smooth muscle. To test the relevance of these
models for humans, future studies on neural regulation of airway tone in humans follow-
ing RSV are required.
 
In the present article we reviewed clinical and experimental data on the relation between
RSV LRTI and long-term airway morbidity. Remarkable differences in design, inclusion
criteria and measures of clinical outcome exist between follow-up studies. However, most
studies show that approximately half of infants with RSV LRTI will have recurrent
episodes of wheezing during early childhood. Both early and more recently published
data indicate that airway morbidity following RSV LRTI is transient and subsides during
school age. 
The pathogenesis of recurrent wheezing following RSV bronchiolitis is still poorly under-
stood. Present studies focus on pre-existing lung function defects as the major cause of
both RSV bronchiolitis and long-term airway morbidity. Although it appears that atopy
does not play a large role in the development of airway morbidity following RSV bron-
chiolitis, immunological studies on the role of Th2 cytokine responses are still subject of
conflict. Immunological research needs to focus on alternative mechanisms in the patho-
genesis of airway morbidity following RSV bronchiolitis. Potentially, antigen presenting
cells as well as epithelial cells play an important role in the development of airway
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morbidity following RSV bronchiolitis. Animal studies provide the opportunity to obtain
detailed observations of pathogenetic changes in immune responses and pulmonary
function following RSV infection. However, it is urgently required that the relevance of
different animal models for human RSV bronchiolitis are established. Better knowledge
of the pathogenesis of long-term consequences of RSV bronchiolitis will facilitate the
development of innovative intervention strategies to prevent or treat long-term airway
morbidity following RSV bronchiolitis.
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Children were included prospectively during two winter epidemic in 6 hospitals in the
Netherlands: (1) Wilhelmina Children’s Hospital, University Medical Center, Utrecht, (2)
Beatrix Children’s Hospital, Academic Hospital, Groningen, (3) Rijnstate Hospital,
Arnhem, (4) St. Elisabeth Hospital, Tilburg, (5) St. Antonius Hospital, Nieuwegein, (6)
Diakonessen Hospital, Utrecht.
Inclusion criteria were: hospital admission, lower respiratory tract symptoms, age < 13
months and immunofluorescence for RSV infection of epithelial cells in nasopharyngeal
secretions. Infants with wheezing illness prior to RSV bronchiolitis were not included.
One investigator (L.B.) took the history of atopy of parents, grandparents and siblings
(asthma, documented food allergy, eczema, hay fever) and inquired whether either
parent had smoked in the presence of the infant during the follow-up period. Control
children aged < 13 months without evidence of atopy or infection were selected for this
study during the same winter season. Included were infants prior to minor surgery, prior
to cardiac surgery in the absence of hemodynamic compromise, healthy prematurely
born infants, healthy infants screened for congenital disorders and infants with mild
anemia. The study was approved by the Medical Ethical Committee in all participating
centers. Parents of subjects and controls gave written informed consent.
In Chapter 5, patients were included retrospectively. All infants < 13 months of age that
were mechanically ventilated for RSV infection between during a 5-year period were
included.
 ,	


Patients with severe illness and with non-severe illness were distinguished by the need for
mechanical ventilation (Chapter 6 and 7).
 


4.3.1  Blood
Within 24 hours after admission venous or arterial blood was taken from all patients.
From all subjects blood was obtained in tubes containing ethylenediamine tetracetic acid
(EDTA). Tubes were directly put on ice, plasma was separated and stored at -80ºC. In
addition white cell counts were performed (Technicon H1, Bayer Technicon, New York).
From subjects of University Medical Center, Utrecht and Diakonessen Hospital, Utrecht
heparinized blood was taken simultaneously for whole blood cultures. Three weeks later,
in the convalescent phase, heparinized blood and plasma were taken from all subjects. 
4.3.2  Nasopharyngeal aspirates (NPA)
Nasopharyngeal secretions were aspirated using a 3,3 mm suction catheter (Vygon,
Ecouen, France). Aspirates were placed on ice immediately and stored at -80ºC. Before
cytokine measurement, the amount of NPA was weighed, diluted in dilution buffer (4ºC)
of the ELISA kits that were used for the cytokine assays (CLB, Amsterdam, The Nether-
lands), sonicated on ice for 2x6 seconds (amplitude 6 µm) and subsequently centrifuged
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at 13,000 rpm for 10 minutes at 4ºC. For IL-8 measurement, NPA was diluted 1:15000,
for measurement of other cytokines NPA was diluted 1:15.
Cytokine levels in NPA were used as an approximation for cytokine levels in fluids of the
lower airways. The validity of cytokine measurements in NPA can not be estimated accu-
rately, because real measurements of cytokine levels in the lower airways can not be
obtained. However, the potential systematic error caused by the sampling site of NPA was
estimated in a subset of mechanically ventilated RSV bronchiolitis patients. In these
infants the correlation between cytokine levels in NPA and tracheobronchial aspirates
(TBA), collected simultaneously and using the same methods of aspiration and subse-
quent analysis, was determined[1;2]. 
 
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Long strain RSV was cultured in Hep-2 cells (courtesy of Dr. A.M. van Loon, dept of
Virology, University Medical Center, Utrecht,) and 1:1 diluted in sucrose-gelatone solu-
tion Z7725a (Laboratory of Vaccine Research, National Institute of Public Health and
Environment, Bilthoven, The Netherlands). Titers were determined in Hep-2 cells using
the TCID50 method described by Karber (TCID50 105)[3]. A control antigen was
prepared similarly from uninfected Hep-2 cultures. Virus and control antigen were stored
in aliquots at -80°C.
 /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Freshly taken heparinized blood was diluted 1:10 in RPMI 1640 medium (Life Technolo-
gies, Grand Island, NY) and aliquoted (150 µl) into 96-well culture plates (Nunc Interna-
tional, Denmark). The whole blood culture stimulated is a suitable ex vivo method to
study cytokine production under conditions in which many of the physiologically rele-
vant cellular interactions remain intact (23). All cultures were performed in quadrupli-
cate. Pooled supernatants were kept at -70ºC.
4.5.1  Monocyte cytokine responses 
To induce monocyte IL-10 and IL-12 production, lipopolysaccharide (LPS) (100ng/
ml)+IFNγ (20 ng/ml) was added and cultures were incubated for 48 hours at 37ºC in 5%
CO2. It has been shown that maximal monocyte IL-10 production is observed after 48
hours, which is relatively late compared to that of monocyte pro-inflammatory cytokines
(20). Also monocyte IL-12 production is (sub)optimally induced after 48 hours stimula-
tion (24). Furthermore, it has been established that monocytes are the main producers of
IL-10 and IL-12 in LPS stimulated whole blood cultures (25). 
4.5.2  T-cell cytokine responses
To induce lymphocyte cytokine production, phytohaemagglutinin (PHA) (50µg/ml) or
anti-CD2,1 (1:12000)+anti-CD2,2 (1:12000)+anti-CD28 (1:3000) monoclonal antibod-
ies (anti-CD2/28 Moabs, CLB, Amsterdam, The Netherlands) were added and cultures
were incubated for 48 hours at 37ºC in 5% CO2. 
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4.5.3  RSV-specific immune responses
Whole blood was infected with RSV at a multiplicity of infection (MOI) of 0.1 - 1.0 or
control suspension added and cultures were incubated for 6 days at 37ºC in 5% CO2
(Chapter 9). Forty-eight hours after infection, pooled supernatants were collected for
cytokine measurement. Five days after infection lymphocytes were pulsed with 0.25 µCi
3H-thymidine for 18 hours and thymidine incorporation was measured (lymphoprolifer-
ative response). Stimulation index was defined as the ratio between lymphoproliferative
responses in cultures stimulated with RSV and control antigen. A memory response was
defined as a stimulation index ≥ 2.0. 
 	0
4.6.1  Cytokines measured
In NPA and plasma levels of IL-4, IL-8, IL-10, IL-12 and IFN-γ were determined. 
In supernatants of LPS+IFNγ stimulated blood cultures IL-12 and IL-10 were measured.
In supernatants of PHA and αCD2+αCD28-stimulated cultures IFNγ and IL-4 were
measured. Cytokines that were measured in supernatants of RSV-stimulated whole blood
cultures were IL-4, IL-10, IL-12 and IFN-γ. 
4.6.2  Cytokine assays
Concentrations of IL-4, IL-8, IL-10 and IFNγ were determined using ELISA kits supplied
by the Dutch Laboratory for Blood Transfusion (CLB, Amsterdam, the Netherlands). The
detection limit for IL-4 was 1 pg/ml, for IL-8 2.5 pg/ml, for IL-10 2.5 pg/ml and for IFNγ
25 pg/ml. Concentrations of IL-12 were determined using ELISA kit from R&D (Oxon,
United Kingdom), the detection limit was 7.8 pg/ml. This assay recognizes only the IL-12
heterodimer and not the individual sub-units of the dimer. When cytokine values were
not detectable, for statistical analysis the minimum detectable level was used. When IL-10
responses were above the maximum detectable level (300 pg/ml), this level was used.
To study possible skewing of the Th1-Th2 cytokine balance, IFN-γ/IL-4 ratios (Chapter 6
and 11) ratios were calculated.
When cytokine values were not detectable, the minimum detectable level was used for
statistical analysis.
" 1-.
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Follow-up data were collected during one year following discharge (Chapter 10 and 11).
Follow-up was performed using diaries, which were developed for this study. One investi-
gator instructed parents how to use the diary. Starting three weeks after discharge from
the hospital, parents noted the presence of “coughing” and “wheezing” on a daily base. A
disease episode was defined as the presence of symptoms for two or more consecutive
days. At the end of the follow-up period, patients were classified as “recurrent wheezing”
if more than one episode of wheezing was noted following discharge. In addition, at the
end of the study period, one investigator contacted the general practitioners of the
patients by telephone and inquired if “asthma” had been diagnosed. 
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Methods used to describe and analyze data are described in the “Statistical analysis”
section of each study.
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Prematurity, with or without the presence of chronic lung disease, is considered a risk
factor for severe RSV infection, often resulting in the need for mechanical ventilation[1].
In addition, term healthy neonates as well as infants with congenital heart disease may
have severe course of disease in case of RSV infection[2;3]. 
New strategies have become available to prevent severe RSV infection in prematurely
born infants, including palivizumab, a humanized monoclonal antibody[4]. For
neonates and infants with congenital heart disease no effective prophylaxis is yet availa-
ble. It is not known for how long prevention of RSV infection in preterm infants should
be considered. We hypothesized that the duration of the period that children are at risk
for severe RSV infection, is determined by the PCA. 
 2
We studied PCA (in weeks) on admission in all preterm infants without congenital heart
disease admitted to our pediatric intensive care unit (PICU) for mechanical ventilation
during a period of 5 years. Infants with chronological age > 12 months were not
included. Prematurity was defined as gestational age at birth ≤ 36 weeks. Infants with and
without a pre-existent condition were distinguished. Pre-existent condition was defined
as the requirement of care by a pediatrician at any time prior to RSV infection, other than
a single contact following delivery. 
 #
Seventy-three infants were included, 33 were born prematurely. Gestational age in
preterm infants ranged from 27-36 weeks (median 32 weeks), 8 infants had gestational
age < 30 weeks. Of all preterm infants 6 had chronic lung disease. Interestingly, 29 (88%)
infants had a PCA < 45 weeks at the time of intubation for RSV bronchiolitis (Figure
5.1).
Of the four preterm infants with PCA > 44 weeks, 3 had chronic lung disease.
Of 40 healthy term infants 32 (80%) infants had PCA < 45 weeks (Figure 5.2). Medical
conditions found in 9 (26%) of 35 preterm infants and 11 (22%) of 51 term infants (table
5.1). Six healthy term infants had chronological age >4 weeks, who were therefore not
considered neonates. PCA distribution of 11 term infants with pre-existent conditions
was markedly different: only 1 infant (9%) had PCA < 45 weeks.
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The main finding of this study was that previously healthy term and preterm infants who
require mechanical ventilation for RSV infection were characterized by PCA < 45 weeks.
In particular, preterm infants without chronic lung disease, appear to have increased risk
for severe RSV infections resulting in respiratory insufficiency, until the PCA reaches 44
weeks. Thus, the risk for severe RSV infection in preterm infants without chronic lung
disease with PCA > 44 weeks is relatively low. 
This study underscores the importance of maturation-related factors in the pathogenesis
of severe RSV infection in infants without pre-existent conditions (reviewed in
Figure 5.1 Distribution of post-conceptional age (weeks) of mechanically ventilated
preterm infants with RSV bronchiolitis (n=33).
Figure 5.2 Distribution of post-conceptional age (weeks) of mechanically ventilated term
infants with RSV bronchiolitis  (n= 40).
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Chapter 2). The distribution of PCA of infants with pre-existent conditions emphasized
that the pathogenesis of severe RSV infection in these infants is essentially different. This
group of infants is characterized by a variety of cardiac, pulmonary and other diseases,
which apparently facilitate the development of severe disease in case of RSV infection.
The most important consequence of this study is that prevention of RSV infection in
preterm infants without chronic lung disease is most effective in children with PCA < 45
weeks. It remains to be studied whether current prophylactic strategies can effectively
prevent severe RSV in healthy term infants with PCA < 45 weeks. We conclude that future
strategies to prevent severe RSV infection during infancy should focus on a small
subgroup of infants, with PCA < 45 weeks. 
Table 5.1 Pre-existent medical conditions in mechanically ventilated RSV-infected
infants. Pre-existent medical condition was defined as pediatric care before
RSV infection, except single contact following delivery.
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Diagnosis Preterm 
infants (n=9)
Term infants 
(n=11)
Chronic lung disease
Congenital heart disease
Down syndrome
Pierre-Robin malformation
Diaphragm paralysis (previously diagnosed)
Klebsiella urosepsis 2 weeks prior to RSV infection
Neurologic disease after severe birth asphyxia
Transfusions for severe thrombocytopenia
6
2
1
3
2
1
2
1
1
1
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The role of cellular immunity in disease severity in RSV bronchiolitis is largely unknown.
We investigated the association between disease severity and systemic cytokine responses
in hospitalized ventilated and non-ventilated RSV bronchiolitis patients.
In whole blood cultures stimulated with phytohemagglutinin (PHA), we measured
lymphoproliferative responses as well as interferon-γ (IFNγ) and Interleukin-4 (IL-4)
production during acute illness. In addition plasma cytokines were measured. Measure-
ments were repeated in the convalescent phase, 3-4 weeks after admission. 
Fifty patients were included. The median age in ventilated patients was significantly lower
than in non-ventilated patients (1 vs. 4 months, p<0.05). In comparison with non-venti-
lated patients, the ventilated patients had significantly lower lymphoproliferative
responses and lower production of IFNγ and IL-4. In fact, IFNγ and IL-4 production in
ventilated patients was almost completely undetectable. Plasma IL-8 levels in ventilated
patients were significantly higher than in non-ventilated patients. In the convalescent
phase lymphoproliferative and cytokine responses as well as plasma IL-8 levels were
normal in both patient groups. Since RSV bronchiolitis is associated with the subsequent
development of asthma, we investigated possible skewing of the Th1-Th2 cytokine
balance. This was found neither in the acute nor in the convalescent phase. 
Our data indicate that depressed lymphocyte function and elevated plasma IL-8 levels are
markers of severe disease. We suggest that age and maturation related immune mecha-
nisms could explain the occurrence of severe RSV bronchiolitis requiring mechanical
ventilation in young infants.
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Respiratory syncytial virus (RSV) bronchiolitis accounts for a considerable number of
pediatric intensive care admissions during yearly winter epidemics. Risk factors predict-
ing a complicated course in RSV lower respiratory tract illness, eventually necessitating
ventilatory support, include congenital heart disease, prematurity, age under six weeks
and chronic lung disease [1-3]. 
Although knowledge of the immunopathogenesis of RSV bronchiolitis has improved
over the last decades, little is known about the association between immunological
parameters and disease severity [4,5]. To our knowledge RSV-specific IgE titers, hista-
mine release and eosinophil cationic protein titers in respiratory secretions and eosi-
nophil blood counts are the only immunological phenomena associated with disease
severity [6,7]. 
Cellular immunity is the classical defense mechanism against viral infections. However,
the role of cellular immunity in the immunopathogenesis of RSV bronchiolitis is unclear.
In murine models cytotoxic T cells have been associated with both clearance of virus
from the lungs and augmentation of lung pathology [8,9]. Others have suggested CD4
cells are required for the development of immune mediated lung disease in RSV infected
BALB/c mice [10]. In the human population even less is known about cellular immunity
in RSV infection than in animal models. Virus-specific cytotoxicity has been demon-
strated in primary acute infections and appeared to be an important parameter in recov-
ery [11]. Furthermore, it has been suggested that in RSV infected patients with lower
respiratory tract symptoms, lymphoproliferative responses to phytohemagglutinin
(PHA) are depressed, as are IL-4, IFNα and IFNγ production in vitro [12-14]. In particu-
lar these depressed lymphocyte functions suggest that suboptimal cellular immunity
might play a role in the outcome of RSV infections. However, thus far no association has
been demonstrated between cell-mediated immune responses and disease severity. 
RSV bronchiolitis has been related to the subsequent development of asthma [15].
Welliver et al showed that RSV can induce virus-specific IgE, which correlates with recur-
rent episodes of wheezing after RSV infection [6,16]. More recently it has been shown
that subjects with asthma have increased release of Th2 cytokines, including IL-4, and
normal or low production of the Th1 cytokine IFNγ [17]. Increased IL-4/IFNγ ratios have
also been mentioned in the RSV infection and could therefore explain the association
between RSV infection and the subsequent development of asthma [13].
We compared lymphoproliferative and cytokine responses in ventilated and non-venti-
lated children admitted with RSV bronchiolitis in order to determine a possible role for
cellular immunity in disease severity. In addition we investigated possible skewing of the
Th1-Th2 cytokine balance in the course of the disease.
  2
6.3.1  Selection of patients
Children were included during one winter epidemic in 4 hospitals in the Netherlands
(Wilhelmina Children’s Hospital, Utrecht; Beatrix Children’s Hospital, Groningen; St.
Elisabeth Hospital, Tilburg; Rijnstate Hospital, Arnhem). Inclusion criteria were: hospital
admission, lower respiratory tract symptoms, age < 13 months and positive direct
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immunofluorescence for RSV. Patients with severe illness and with non-severe illness
were distinguished by the need for mechanical ventilation. Control children aged < 13
months without evidence of allergy or infection were selected for this study during the
same winter season. Included were infants prior to minor surgery, prior to cardiac
surgery in the absence of hemodynamic compromise, healthy prematurely born infants,
healthy infants screened for congenital disorders and infants with mild anemia. This
study was approved by the Medical Ethical Committee in all participating centers and
parents of subjects and controls gave written informed consent.
6.3.2  Collection of materials
Within 24 hours after admission venous or arterial blood was taken from all patients.
From all subjects blood was obtained in tubes containing ethylenediamine tetracetic acid
(EDTA). Tubes were directly put on ice, plasma was separated and stored at -70ºC. In
addition white cell counts were performed (Technicon H1, Bayer Technicon, New York).
From subjects in the Wilhelmina Children’s Hospital, Utrecht, heparinized blood was
taken simultaneously. Three weeks later, in the convalescent phase, heparinized blood
and plasma were taken from all subjects.
6.3.3  Cell cultures 
Heparinized blood (0.5 ml) was diluted in 4.5 ml RPMI 1640 medium (Life Technologies,
Grand Island, NY) and whole blood cultures were performed. Diluted blood was
cultured in four-fold in 96-well culture plates (Nunc International, Denmark) in the
presence of PHA (50µg/ml) for 48 hours at 37ºC with 5% CO2. Pooled supernatants were
kept at -70ºC. Subsequently lymphocytes were pulsed with 0.25 µCi 3H-thymidine for 18
hours and thymidine incorporation was measured (lymphoproliferative response).
6.3.4  Cytokine assays
In plasma IL-4, IL-8, IL-12 and IFNγ were measured. In supernatants IL-4 and IFNγ were
measured. Concentrations of IL-4 (in supernatants), IL-8 and IFNγ were determined
using ELISA kits supplied by the Dutch Laboratory for Blood Transfusion (CLB, Amster-
dam, the Netherlands), the detection limit for IL-4 was 4.7 pg/ml, for IL-8 2.5 pg/ml and
for IFNγ 25 pg/ml. Plasma concentrations of IL-4 and IL-12 were determined using “high
sensitivity” ELISA kits from R& D (Oxon, United Kingdom), the detection limit for IL-4
was 1.0 pg/ml and for IL-12 0.78 pg/ml. When cytokines were not detectable, the mini-
mum detectable level was used in the calculations.
6.3.5  Statistical analysis
Lymphoproliferative responses are expressed as mean ± SEM. Mann-Whitney U analysis
was used to compare median age of patients and controls and of ventilated and non-
ventilated patients. Chi square test was used to compare relative proportions of prema-
turely born children. One-way ANOVA was used to compare lymphoproliferative
responses. Cytokine levels were analyzed by one-way ANOVA after logarithmic transfor-
mation. If one-way ANOVA analysis showed significant differences, unpaired T-tests
using Bonferroni correction were performed in order to analyze which groups have
significantly different values and to calculate p-values. Pearson’s correlation coefficient
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was used to evaluate the relation between age and lymphoproliferative responses and
cytokine responses. 
  #
6.4.1  Study subjects
Characteristics of patients and controls are shown in table 6.1. A total of 50 patients were
studied, 27 subjects were admitted to Wilhelmina Children’s Hospital and 23 to one of
the other hospitals. Twenty-nine (58%) were boys, median age was 3 months. Fourteen
subjects (28%) needed mechanical ventilation. Median age of ventilated patients was 1
month, of non-ventilated patients 4 months (p<0.05). Eleven patients (22%), including 3
pairs of twins, were born prematurely (range: 29 4/7 – 36 5/7 weeks). Eight of these
required ventilatory support, whereas in one of these children chronic lung disease was
diagnosed. None of the patients had cardiac disease. None of the patients received ribavi-
rin or systemic corticosteroids. All patients survived. Twenty-seven controls were
included, median age was 4 months. Sixty-three per cent were boys. Two controls were
born prematurely. 
6.4.2  Cytokine levels in plasma
Plasma IL-8 levels were measured in 50 patients and in 27 controls. In the acute phase IL-
8 levels were detectable in 48 patients (96%) and in 25 controls (93%). Plasma IL-8 levels
in both ventilated and non-ventilated patients were higher than in controls (p<0.001)
(Figure 6.1). In ventilated patients IL-8 levels were higher than in non-ventilated patients
(p<0.01). Interleukin-8 levels in the convalescent phase were not significantly different
from controls. Interleukin-4, IL-12 and IFNγ levels in plasma were below the detection
level.
6.4.3  Lymphoproliferative response PHA stimulated whole blood cultures
White blood cell counts, relative and absolute lymphocyte numbers of ventilated patients
did not differ significantly from non-ventilated patients, although absolute lymphocyte
numbers in ventilated patients tended to be lower than in non-ventilated patients (3·109/
L vs. 4.2·109/L). Lymphoproliferative responses in the acute phase are shown in Figure
6.2. Mean lymphoproliferative responses in ventilated patients and non-ventilated
Table 6.1 Study population characteristics
Patients Controls
ventilated 
(n=14)
non-ventilated 
(n=36)
total
(n=50) (n=27)
median (range) age (months) 1 (0-11) 4 (0-12)* 3 (0-12) 4 (0-12)
male/female 10/4 19/17 29/21 17/10
prematurely born 8 3* 11 2
* ventilated vs non-ventilated p<0.05
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patients were lower than in controls (14000±2500 and 29000±4500 vs 42000±2800 cpm,
p<0.001). Lymphoproliferative responses in ventilated patients were lower than in non-
ventilated patients (p<0.005). In the convalescent phase lymphoproliferative responses
returned to normal values in both ventilated and non-ventilated patients. 
We related age to lymphoproliferative responses in the control infants, no association was
found (data not shown).
6.4.4  Cytokine production in PHA stimulated whole blood cultures
Levels of IL-4 and IFNγ in the acute phase in supernatants of PHA stimulated whole
blood cultures are shown in Figure 6.3a and 6.3b. In ventilated patients IFNγ and IL-4
levels were below detection level in 11 out of 13 cases (85%), in non-ventilated patients
and in controls cytokine levels could be measured in all samples (p<0.001). In non-venti-
lated patients no significant differences with controls were found for both and IL-4. In
the convalescent phase IFNγ and IL-4 levels were normal in both patients groups. 
We related age to IL-4 and IFNγ responses in control infants (data not shown). Age was
not related to IL-4 responses. A positive correlation was found between age and IFNγ
responses (r=0.52, p<0.01). However, nearly all IFNγ responses in ventilated patients
were below the minimum IFNγ response in non-ventilated patients and control infants.
We could not determine IL-4/IFNγ ratios in the acute phase in ventilated patients, since
in practically all patients IL-4 and/or IFNγ levels were below detection level. IL-4/IFNγ
ratios in non-ventilated patients were not different from controls. In the convalescent
phase IL-4/IFNγ ratios remained normal.
Figure 6.1 Plasma IL-8 levels within 24 hours after admission in ventilated patients,
non-ventilated patients and controls
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In this study, IL-8 plasma levels, lymphoproliferative responses and lymphocyte cytokine
responses in vitro were associated with disease severity in hospitalized patients with RSV
bronchiolitis. Lymphoproliferative responses during acute disease are lower in ventilated
patients than in non-ventilated patients. Most striking is the almost completely negative
response of IFNγ and IL-4 in ventilated patients. In the convalescent phase plasma IL-8,
lymphoproliferative responses and cytokine responses normalize in both ventilated and
non-ventilated patients. 
Young age and prematurity appeared to be important factors determining disease sever-
ity. Median age of the ventilated patients was significantly lower than that of the non-
ventilated patients; except for 1 patient all ventilated patients were less than 3 months old.
Furthermore, we found that more ventilated patients than non-ventilated patients were
born prematurely. Both young age and premature birth are known risk factors for the
development of severe bronchiolitis [18]. 
Age and maturation-related immune mechanisms could explain differences between
ventilated and non-ventilated patients. It is generally acknowledged that neonates can
experience severe morbidity from infections with viral and other intracellular pathogens,
including RSV bronchiolitis [2,19-22]. In the neonatal period antiviral immunity appears
to be diminished and this is accompanied by a general failure of neonatal anti-viral T cells
to mature into protective virus-specific memory [23,24]. In premature neonates this
maturational deficiency is even more pronounced. Severely decreased expression of
CD40 ligand on activated T cells in neonates could play a role in this maturational failure
[25]. Moreover it was demonstrated that neonatal T cells have lower capacity for IFNγ
production after polyclonal stimulation than adult T cells [26]. We confirmed this find-
ing in our control group in which we found a significant correlation between IFNγ
production (but not IL-4 production) and age (r = 0.75, p < 0.001) (data not shown). To
our knowledge, the development of antigen-specific immune responses in human
Figure 6.2 Lymphoproliferative responses induced by PHA within 24 hours after
admission of ventilated patients, non-ventilated patients and controls
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neonates, including cytokine responses, has only been documented in neonatal herpes
simplex virus (HSV) infection; the first 3-6 weeks after delivery, diminished antigen-
stimulated IFNγ and lymphoproliferative responses were reported in HSV-infected
neonates [20]. As far as RSV is concerned, in vitro studies have demonstrated that RSV-
infected human adult lymphocytes show depressed proliferative responses after polyclo-
nal stimulation [27]. Taking together these observations and our results, it appears that
RSV suppresses neonatal lymphocyte function also in vivo, preventing adequate immune
response to RSV proteins. Moreover we speculate that proliferation and cytokine
Figure 6.3 Interferon-γ and IL-4 production in 48 hours PHA-stimulated whole blood
cultures within 24 hours after admission of ventilated patients, non-ventilated
patients and controls
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responses in neonatal lymphocytes may be more sensitive than more mature
lymphocytes to the suppressive effect of RSV. Immature antiviral immunity and
increased sensitivity to suppressive influences of RSV on lymphocyte function may
explain why lymphoproliferative and cytokine responses in (younger) ventilated patients
are more suppressed than in non-ventilated patients. 
Our two patient groups were distinguished by the need for mechanical ventilation. The
effects of mechanical ventilation on immune responses is largely unknown, but reports in
laboratory animals indicate that it can change local as well as systemic inflammatory
responses [28]. As a result we cannot exclude a possible influence of mechanical ventila-
tion on the immune responses found in ventilated patients in our study. However,
samples taken in the acute phase were collected within the first 24 hours after mechanical
ventilation was initiated, in the majority of cases even within 2-6 hours. To our knowl-
edge, in literature no data are available, addressing the kinetics of immune responses
during the first hours of mechanical ventilation. However, it is unlikely that mechanical
ventilation induced changes in immune responses in our patient group, already, during
this short time interval between initiation of mechanical ventilation and blood sampling.
Asthma is characterized by a relative increase in production of Th2 cytokines (e.g. IL-4)
and a relative suppression of production of Th1 cytokines (e.g. IFNγ) [15,17]. Consider-
ing the association between RSV bronchiolitis and the subsequent development of
asthma we investigated possible skewing of the Th1-Th2 cytokine balance by calculating
IL-4/IFNγ ratios [29]. IL-4/IFNγ ratios in both patient groups were normal in the acute
and convalescent phase. However IL-4/IFNγ ratios could not be calculated for ventilated
patients in the acute phase. Roman et al. reported increased IL-4/IFNγ ratios after in vitro
stimulation with pokeweed mitogen in RSV infected children with lower respiratory tract
symptoms [13]. This apparent contradiction may be due to different culture conditions
and a higher median age in their patient group.
The association found between increased plasma IL-8 levels and severe RSV bronchiolitis,
is similar to the findings by Shute, who demonstrated an association between increased
serum IL-8 levels and severe asthma [30]. However, increased IL-8 plasma levels are not
specific for RSV disease, since increased plasma IL-8 levels have been suggested to play a
role in various respiratory diseases, possibly by similar mechanisms, including neutrophil
and eosinophil attraction, IgE mediated lung disease and virus-induced respiratory
inflammation [4,31-35].
During the last decades, data have become available indicating RSV bronchiolitis can be
considered an immune-mediated disease [4]. Early trials with a formalin-inactivated RSV
vaccine resulting in enhanced disease support this hypothesis. However, this theory does
not explain the higher incidence of severe disease observed in young and/or prematurely
born infants. Our findings suggest that an immunological process is not the sole factor in
the pathogenesis of severe disease in RSV bronchiolitis. In young and prematurely born
infants, insufficient antiviral immunity seems to play an important role, particularly with
respect to disease severity.
In summary, we have shown suppressed lymphocyte function and increased plasma IL-8
levels to be markers of severe disease in RSV bronchiolitis. In addition, we propose that
maturation of virus-specific immunity plays a crucial role in the outcome of RSV infec-
tion in young infants. In order to understand the pathogenesis of RSV bronchiolitis and
immunological factors contributing to severity of this disease, we need to focus on the
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development of the specific immune responses to RSV in preterm and term infants.
Elucidating these mechanisms will be important for the development of treatment strate-
gies and vaccines.
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To investigate the role of cell-mediated immunity during respiratory syncytial virus
(RSV) infection interferon (IFN)-γ and interleukin (IL)-10 levels in nasopharyngeal
secretions were measured in infants with lower respiratory tract infection (LRTI) caused
by RSV. A novel technique was used to measure in vivo cytokine levels in nasopharyngeal
aspirates (NPA). Cytokine levels in NPA of 17 mechanically ventilated infants and 43
non-ventilated hospitalized infants were compared. As expected, mechanically ventilated
infants were significantly younger than non-ventilated infants (7 vs 14 weeks). IFN-g
levels in NPA of mechanically ventilated infants were above detection limit in 3 infants
(18%), but in 26 non-ventilated infants (60%). IL-10 levels in NPA in mechanically venti-
lated and non-ventilated infants were comparable. It is hypothesized that maturation-
related mechanisms play a key role in the development of RSV LRTI resulting in mechan-
ical ventilation.
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Interferon (IFN)-γ, a type II interferon, is produced by T cells and natural killer (NK)
cells and has pleiotropic biological effects[1]. The properties of IFN-γ include a direct
antiviral activity, help in the generation and activation of cytotoxic T cells, stimulation of
antigen-presentation through induction of expression of major histocompatibility class I
and II molecules and activation of NK cells[2]. In addition, IFN-γ plays a role in the regu-
lation of the switch of antibody isotypes, including the switch in expression by B cells
from IgM to IgG2a[2]. Taken together these properties, IFN-γ is considered a key
cytokine in inducing protective responses against viral pathogens.
A role for IFN-γ has been mentioned in the pathogenesis of RSV infections. We have
shown that severe RSV LRTI resulting in the need for mechanical ventilation is associated
with low systemic proliferative responses and IFN-γ production[3]. In addition, the
degree of oxygen saturation in the blood during RSV bronchiolitis was shown to be asso-
ciated with decreased mRNA IFN-γ expression in the blood[4]. However, it is not certain
how accurately these measurements in the blood reflect in vivo IFN-γ levels in the respira-
tory tract during RSV infection. 
A few studies have investigated cytokine profiles in nasopharyngeal lavages (NPL) during
RSV LRTI[5-7]. However, one of the difficulties of studying cytokine levels (NPL) is the
unpredictable recovery of volumes of secretions[8]. Consequently, the precise dilution
factor in NPL can not be known. In addition, NPL may lead to dilution of secretions to
an extent that does not allow for detection of immune mediators that are present in low
concentrations in NPL, including IFN-γ. To overcome these disadvantages of NPL, in the
present study we developed a novel method to measure cytokine levels the respiratory
tract. This technique was used to investigated IFN-γ levels in the nasopharynx during
RSV LRTI. We tested the hypothesis that IFN-γ levels in the respiratory tract during RSV
LRTI are associated with disease severity.
" 2
7.3.1  Study population
Children were included during one winter epidemic in 5 hospitals in the Netherlands.
Inclusion criteria were: hospital admission, lower respiratory tract symptoms, age < 13
months and immunofluorescence for RSV infection of epithelial cells in nasopharyngeal
secretions. Symptoms of LRTI were severe chest cough, wheezing, hoarseness, stridor,
shortness of breath[9] as well as cyanosis and apnea. Prematurely born infants with
congenital heart disease, chronic lung disease and infants with wheezing illness prior to
RSV bronchiolitis were not included. Patients with severe and non-severe illness were
distinguished by the need for mechanical ventilation. The study was approved by the
Medical Ethical Committee in all participating centers. Parents of subjects gave written
informed consent.
7.3.2  Nasopharyngeal aspirates (NPA)
Within 24 hours after admission nasopharyngeal secretions were aspirated using a 3.3
mm suction catheter (Vygon, Ecouen, France). Aspirates were placed on ice immediately
and stored at -80ºC. If NPA could not be obtained due to little amount of secretion
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present in the nasopharynx, no second attempt was done later in the course of disease.
Before cytokine measurement, the amount of NPA was weighed, diluted in dilution
buffer (4ºC) of the ELISA kits that were used for the cytokine assays (CLB, Amsterdam,
The Netherlands), sonicated on ice for 2x6 seconds (amplitude 6 µm) and subsequently
centrifuged at 13,000 rpm for 10 minutes at 4ºC. For IL-8 measurement, NPA was diluted
1:15,000, for measurement of other cytokines NPA was diluted 1:15.
Cytokine levels in NPA were used as an approximation for cytokine levels in fluids of the
lower airways. The potential systematic error caused by sampling secretions from the
upper airways was evaluated by correlating cytokine levels (IL-8 and IL-10) in NPA and
tracheobronchial aspirates (TBA)[5]. In a subset of 10 mechanically ventilated RSV bron-
chiolitis patients NPA and TBA were collected simultaneously. Identical methods of aspi-
ration and subsequent analysis were used for NPA and TBA.
7.3.3  Cytokine assays
Concentrations of IL-4, IL-8, IL-10 and IFN-γ were determined using ELISA kits
supplied by the Dutch Laboratory for Blood Transfusion (CLB, Amsterdam, the Nether-
lands). The detection limit of the assay for IL-4 was 2 pg/ml, for IL-8 2.5 pg/ml, for IL-10
2.5 pg/ml, and for IFN-γ 4 pg/ml. IL-12 concentrations were determined using ELISA kits
from R&D (Oxon, United Kingdom), the detection limit for IL-12 was 7.8 pg/ml. 
7.3.4  Statistical analysis
Cytokine levels in NPA had non-parametric distributions. They are expressed as median
values and range. Pearson’s correlation coefficient was used to analyze the relation
between cytokine levels in NPA and TBA. Spearman’s correlation coefficient was used to
analyze the relation between IFN-γ in NPA and age. Mann-Whitney U-test was used to
analyze differences in cytokine levels between ventilated and non-ventilated infants. All
tests of significance were two-sided. A p<0.05 was considered statistically significant.
" #
7.4.1  Subject characteristics
The investigated population consisted of 75 patients. Forty-four patients (59%) were
boys, median age at the time of RSV bronchiolitis was 9 weeks. Seventeen (23%) infants
were born prematurely (median gestational age 34 weeks, range: 27 - 36 weeks). Seven-
teen subjects (23%) needed mechanical ventilation. As expected, median age in mechani-
cally ventilated infants was lower than in non-ventilated infants (7 vs. 14 weeks, p=0.002)
and a significantly higher percentage was born prematurely (47 vs. 14%, p=0.006). None
of the children had immunodeficiency. None of the prematurely born infants had
received RSV prophylaxis. None of the patients received ribavirin or systemic anti-
inflammatory agents, including corticosteroids. All patients survived.
7.4.2  Cytokine levels in nasopharyngeal aspirates
NPA was collected in 17 mechanically ventilated patients and in 43 non-ventilated
patients. In 15 patients (20%) no NPA was obtained. In these cases insufficient amount of
secretion was present in the nasopharynx to be aspirated. These 15 infants were all non-
ventilated infants. IL-8 (range 5-1300 ng/ml) and IL-10 levels (range 40-3600 pg/ml) in.
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NPA were detectable in all patients. IFN-γ could be measured in NPA of 28 infants (53%).
IL-4 and IL-12 levels in NPA were below detection limits in all NPA samples. 
In a subgroup of 10 mechanically ventilated infants with RSV infection NPA and TBA
were collected simultaneously. In 3 patients, the amount of TBA was not sufficient for IL-
10 measurement. The correlation coefficient for IL-8 levels in NPA and TBA was 0.5
(p=0.03) (n=10), for IL-10 the correlation coefficient was 0.91 (p<0.01) (n=7) (Figure
7.1a and 7.1b).
Figure 7.1 Correlation between cytokine levels in nasopharyngeal aspirates and
tracheobronchial aspirates in mechanically ventilated RSV bronchiolitis
patients. Pearson’s correlation coefficients are shown. Correlation for IL-8 is
shown in Figure 7.1a, IL-10 in Figure 7.1b. Aspirates were taken
simultaneously within 24 hours after initiation of mechanical ventilation. 
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Differences in cytokine levels in NPA between ventilated and non-ventilated patients
were analyzed. The geometric mean of IL-8 levels in ventilated and non-ventilated
patients was 214 (95% CI 148-309) respectively 166 (95% CI 129-209) ng/ml (not signif-
icant). The geometric mean of IL-10 levels in ventilated and non-ventilated patients was
347 (95% CI 159-794) respectively 447 (95% CI 309-660) pg/ml (not significant). IFN-γ
levels in NPA were below detection limit in 14 of 17 mechanically ventilated patients
(82%) and in 17 of 43 non-ventilated patients (40%) (p<0.001) (Figure 7.2).
 
To investigate whether differences in IFN-γ in NPA were explained by differences in age
we analyzed the correlation between age and IFN-γ in NPA in non-ventilated infants. No
correlation was found (r=-0.02, p=0.87). Therefore, we consider it unlikely that differ-
ences in age explain differences in IFN-γ in NPA.
" 
The main finding of this study was that in vivo IFN-γ levels in NPA were severely
decreased in mechanically ventilated infants with RSV LRTI as compared with hospital-
ized non-ventilated infants with RSV LRTI who did not required mechanical ventilation.
This is the first study to actually measure local IFN-γ levels during RSV LRTI.
The method to measure cytokine profiles in nasopharyngeal secretion that has been used
most widely is the nasopharyngeal lavage[10]. As a result of the unpredictable recovery of
volumes of secretions the dilution factor in NPL is not known. In a group of 52 infants
with upper respiratory tract infections, estimated dilution factors in nasal lavage fluid
varied widely from 1.8 to 432[8]. Correction for the dilution by normalizing cytokine
levels to albumin concentrations in nasopharyngeal lavage appears no option, because
Figure 7.2 IFN-γ levels in nasopharyngeal aspirates of infants with (n=17) and without
mechanical ventilation during RSV bronchiolitis (n=43). Aspirates were
taken within 24 hours after admission. Mann-Whitney
U-test was used to analyze differences in IFN-γ levels in NPA.
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albumin levels also increase during upper respiratory tract illness due to increased vascu-
lar permeability[10]. This implies that only ratios between cytokines, but not cytokine
concentrations, can accurately be established in nasopharyngeal lavages. Moreover, large
dilutions potentially result in undetectable levels of cytokines which are present in rela-
tively low concentrations, including IL-10 and IFN-γ[7]. In the present study this draw-
back of nasopharyngeal lavages was overcome, although IFN-γ levels in NPA were still
below detection limits in practically all mechanically ventilated infants. Other disadvan-
tages of NPA can be considered. It is conceivable that nasopharyngeal lavage contains
cytokines from the epithelial fluid lining the nasopharynx, which may not be found in
NPA. These cytokines could potentially be most relevant. Another drawback of NPA is
that it can only be performed if nasal secretions are present in amounts that can be aspi-
rated. Consequently, in the present study NPA could not be taken from infants with small
amounts of nasal secretions. In addition, a pilot study in control infants showed that the
amount of secretions in healthy infants was insufficient to be aspirated. The validity of
NPA was estimated by comparing cytokine levels in NPA and TBA[7]. A high correlation
between cytokine levels in NPA and TBA was found, indicating the similarity between
cytokine profiles in NPA and the lower respiratory tract. Taken into account its disadvan-
tages, NPA appears a suitable and easy method to study cytokine levels which are present
at low levels in the respiratory tract.
Evidence exists that insufficient antiviral immunity plays a role in the pathogenesis of
severe RSV LRTI. It was shown that viral titers found in nasopharyngeal samples from
RSV infected infants are associated with disease severity and are highest in mechanically
ventilated infants[11;12]. Hall and colleagues already speculated that direct antiviral
activity of interferons as well as cell-mediated immunity may be important in the patho-
genesis of RSV LRTI. Indirect evidence for this hypothesis came from more recent studies
that showed that RSV LRTI is associated with decreased IFN-γ production by peripheral
blood mononuclear cells[3;4]. The results of the present study directly confirm that
severe RSV LRTI is associated with reduced local levels of IFN-γ. 
Mechanically ventilated infants with RSV LRTI were significantly younger than non-
ventilated infants. Therefore, it is conceivable that maturation-related mechanisms may
explaining low systemic as well as local IFN-γ production in the respiratory tract of
mechanically ventilated infants during RSV LRTI. Indeed, T cell-mediated responses are
delayed during the first 4 to 8 weeks of postnatal age, accompanied by impaired capacity
to produce IFN-γ[13]. In addition to maturation-related mechanisms, reduced IL-12
production by antigen-presenting cells may explain low IFN-γ levels in NPA of mechani-
cally ventilated infants during RSV LRTI. IL-12 is a prerequisite for IFN-γ production by
T cells and NK cells[1]. In line with this hypothesis, we have previously shown that
monocyte IL-12 production is inversely related to duration of mechanical ventilation
during RSV LRTI[14].
In summary, NPA is a novel technique to detect in vivo cytokine levels in the respiratory
tract during RSV LRTI. We have shown decreased IFN-g levels in NPA during RSV LRTI
in infants with most severe disease. This finding strongly suggests an important role for
IFN-γ in the pathogenesis of RSV LRTI.
bontalles.fm  Page 67  Wednesday, May 9, 2001  8:29 AM
68     Chapter 7
#
1 Young HA, Hardy KJ. Role of interferon-gamma in immune cell regulation. J Leukoc Biol 1995; 58:373-
381.
2 Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol
1997; 15:749-795.
3 Bont L, Heijnen CJ, Kavelaars A, Aalderen vWMC, Brus F, Draaisma JMTh, Geelen SM, Vught vHJ,
Kimpen JLL. Association of peripheral blood cytokine responses with disease severity in respiratory syncy-
tial virus bronchiolitis. Eur Respir J 1999; 14:144-149.
4 Bendelja K, Gagro A, Bace A, Lokar-Kolbas R, Krsulovic-Hresic V, Drazenovic V, Mlinaric-Galinovic G,
Rabatic S. Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demon-
strated by cytokine flow cytometry. Clin Exp Immunol 2000; 121:332-338.
5 Sherran P, Jafri H, Carubelli C, Saavedra J, Johnson C, Krisher K, Sanchez PJ, Ramilo O. Elevated cytokine
concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus
disease. Pediatr Infect Dis J 1999; 18:115-122.
6 Lindgren C, Grogaard J. Reflex apnoea response and inflammatory mediators in infants with respiratory
tract infection. Acta Paediatr 1996; 85:798-803.
7 Van Schaik SM, Tristam DA, Nagpal IS, Hintz KM, Welliver RC, Welliver RC. Increased production of
interferon gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol 1999;
103:630-636.
8 Heikkinen T, Shenoy M, Goldblum RM, Chonmaitree T. Quantification of cytokines and inflammatory
mediators in samples of nasopharyngeal secretions with unknown dilution. Pediatr Res 1999; 45:230-234.
9 Stein RT, Sherill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD. Respiratory
syncytial virus in early life and risk of wheeze and allergy by age 13. Lancet 1999; 354:541-545.
10 Noah TL, Henderson FW, Wortman IA, Devlin RB, Handy H, Koren HS, Becker S. Nasal cytokine produc-
tion in viral acute upper respiratory infection of childhood. J Infect Dis 1995; 171:584-592.
11 Buckingham SC, Bush AJ, Devincenzo JP. Nasal quantity of respiratory syncytial virus correlates with dis-
ease severity in hospitalized infants. Pediatr Infect Dis J 2000; 19:113-117.
12 Hall CB, Douglas-RG J, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and
duration of shedding. J Pediatr 1976; 89:11-15.
13 Chandwani S, Borkowski W, Krasinski K, Lawrence R, Welliver RC. Respiratory syncytial virus infection in
human immunodeficiency virus-infected children. J Pediatr 1990; 117:251-254.
14 Bont L, Kavelaars A, Heijnen CJ, van Vught AJ, Kimpen JL. Monocyte interleukin-12 production is
inversely related to duration of respiratory failure in respiratory syncytial virus bronchiolitis. J Infect Dis
2000; 181:1772-1775.
bontalles.fm  Page 68  Wednesday, May 9, 2001  8:29 AM
8 Monocyte interleukin-12 production 
inversely related to duration of respiratory 
failure in RSV bronchiolitis 
L Bont, A Kavelaars, CJ Heijnen, AJ van Vught, JLL Kimpen
J Infect Dis 2000;181:1772-1775
bontalles.fm  Page 69  Wednesday, May 9, 2001  8:29 AM
70     Chapter 8
$ %)
To estimate factors determining the clinical outcome of respiratory syncytial virus (RSV)
bronchiolitis necessitating mechanical ventilation, it was attempted to correlate clinical
and immunological parameters to duration of respiratory failure. At initiation of
mechanical ventilation interleukin (IL)-12 and IL-10 production was measured in 48-
hour peripheral blood cell cultures, stimulated with lipopolysaccharide (LPS) + inter-
feron (IFN)-γ in 30 RSV patients. The ventilation index (VI) correlated with the duration
of mechanical ventilation (r = 0.47 days/(mmHg•cmH20/min), p = 0.013). Age was not
associated with duration of mechanical ventilation. A highly significant inverse correla-
tion was found between IL-12 production at admission and duration of mechanical
ventilation (r = -0.62 days/pg/ml, p<0.001). This correlation was independent of ventila-
tion index. No correlation was found between IL-10 production and duration of
mechanical ventilation. It is hypothesized that low monocyte IL-12 response during
initial RSV infection adversely affects clinical outcome of patients with severe RSV bron-
chiolitis.
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Severe RSV bronchiolitis, resulting in respiratory insufficiency, is an important cause of
admission to Pediatric Intensive Care Units (PICU). Although the mortality rate has been
reduced considerably, the clinical course of RSV bronchiolitis on PICU varies. Analysis of
factors contributing to duration of mechanical ventilation may yield predictors of the
clinical course of RSV bronchiolitis on PICU.
Age < 6 weeks, prematurity with or without chronic lung disease and congenital heart
disease are risk factors for admission to an intensive care unit and for respiratory insuffi-
ciency during an episode of RSV-induced bronchiolitis[1]. We have recently shown that
prematurity without chronic lung disease is a risk factor for respiratory insufficiency
until post-conceptional age reaches 44 weeks[2]. The ventilation index,  a measure of
ventilatory disorder has been shown to have prognostic value in mechanically ventilated
infants with ARDS[3]. It is not known whether ventilation index is related to duration of
mechanical ventilation in RSV bronchiolitis. In addition, it has not been described that
monocyte cytokine responses, which probably play a role in the pathogenesis of viral
infections, have prognostic value in the prediction of the duration of respiratory insuffi-
ciency during RSV bronchiolitis.
IL-12 is a cytokine produced primarily by antigen-presenting cells (APC)[4]. It strongly
promotes the differentiation of naive CD4+ T cells to the Th1 phenotype suggesting a
critical role for IL-12 as regulator of Th1-driven immune responses, including lytic func-
tions of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells. Furthermore, IL-12
greatly enhances the capacity of T cells and NK cells to produce IFNγ and IL-2. Finally, in
animal models endogenous IL-12 has been shown to induce antiviral immune responses.
In this study we investigated the relationship between clinical parameters and duration of
mechanical ventilation in RSV bronchiolitis patients. In addition, we explored the rela-
tionship between monocyte IL-12 production and duration of mechanical ventilation in
RSV bronchiolitis.
$ 2
8.3.1  Clinical characteristics
Infants  <13 months old with respiratory insufficiency, resulting in the need for mechan-
ical ventilation and proven RSV infection (by immunofluorescence on nasopharyngeal
secretions) were included during two winter epidemics. Post-conceptional age (weeks)
was defined as gestational age at birth (weeks) plus chronological age (weeks). Underly-
ing diseases, including chronic lung disease and cardiac disease, were registered. Ventila-
tion indices (VI) were calculated every eight hours during the first 24 hours of
mechanical ventilation, starting eight hours after initiation of mechanical ventilation.
The following formula was used to calculate VI: VI=partial pressure of arterial CO2 (mm
Hg) • peak airway pressure (cm H2O) • respiratory rate (breaths/min)/1000)[3]. The
mean VI was defined as the arithmetic mean of the VI at 8, 16 and 24 hours after initia-
tion of mechanical ventilation. Duration of mechanical ventilation was the main
outcome parameter. This study was approved by the Medical Ethical Committee of the
University Medical Center, Utrecht, The Netherlands. Parents of subjects gave written
informed consent.
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8.3.2  Collection of materials
Within 24 hours after admission heparinized venous or arterial blood was taken from all
patients for whole blood cultures. Simultaneously, routine leucocyte counts were
performed. In addition, blood was obtained in tubes containing ethylenediamine tetrace-
tic acid (EDTA). Tubes were directly put on ice, plasma was separated and stored at -
70ºC.
8.3.3  Whole blood cultures
Freshly taken heparinized blood was diluted 1:10 in RPMI 1640 medium (Life Technolo-
gies, Grand Island, NY) and aliquoted (150 µl) into 96-well culture plates (Nunc Interna-
tional, Denmark). To induce monocyte IL-10, IL-12 and IL-8 production,
lipopolysaccharide (LPS) (100ng/ml)+IFNγ (20 ng/ml) was added and cultures were
incubated for 48 hours at 37ºC  in 5% CO2. It has been established that monocytes are
the main producers of IL-10 and IL-12 in LPS stimulated whole blood cultures[5]. The
number of monocytes per well was defined as the product of total number of leucocytes
per well and the percentage monocytes of total leucocytes. All  cultures were performed
in quadruplicate. Pooled supernatants were kept at -70ºC.
8.3.4  Cytokine assays
Interleukin-10 and IL-12 were measured in supernatants of LPS+IFNγ stimulated blood
cultures. In plasma IL-8 levels were measured. Concentrations of IL-10 and IL-8 were
determined with ELISA kits supplied by the Dutch Laboratory for Blood Transfusion
(CLB, Amsterdam, the Netherlands). The detection limit for IL-10 was 2.5 pg/ml, for IL-
8 1.2 pg/ml. Concentrations of  IL-12 were determined with an ELISA kit from R&D
(Oxon, United Kingdom), the  detection limit was 7.8 pg/ml. When IL-12 concentrations
were below detection limit, the lower limit of detection was used for statistical analysis.
8.3.5  Statistical analysis
Cytokine production, plasma IL-8 levels and duration of mechanical ventilation were
analyzed after logarithmic transformation. Cytokine production per monocyte was
defined as the ratio between cytokine production per well and number of monocytes per
well. 
Chronological age, post-conceptional age, mean VI, production of separate cytokines
and plasma IL-8 levels were analyzed separately in relation to duration of mechanical
ventilation by univariate linear regression. 
Three parameters with the highest regression coefficients were analyzed with multiple
linear regression analysis by a stepwise forward-entry procedure. Selection criterion for
entry was p<0.10. No other parameters were entered in the multiple linear regression
model because of the limited number of patients. The goodness of fit of the model was
estimated by the square of the multiple correlation coefficient (R2).
$ #
8.4.1  Patient characteristics
The patient population consisted of 30 infants. Nineteen patients (63%) were boys,
median age was 5 weeks (range 0-50 weeks). Median post-conceptional age was 41 weeks.
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Thirteen infants (43%) were born prematurely, all had post-term age < 5 weeks. One 11
month old girl had chronic lung disease resulting from mechanical ventilation in the
neonatal period. None of the patients received ribavirin or systemic corticosteroids. All
patients recovered. 
8.4.2  Relation between clinical parameters and duration of mechanical ventilation
The main outcome parameter of this study was duration of mechanical ventilation.
Median duration of mechanical ventilation was 8 days (range 4-38 days). No relation was
found between sex, chronological or post-conceptional age and duration of mechanical
ventilation (table 8.1). The mean ventilation index VI was 39 (range 21-75)
mmHg•cmH2O/min (n=28). A positive correlation was found between mean VI and
duration of mechanical ventilation (r = 0.47 days/(mmHg•cmH20/min), p = 0.013).
8.4.3  Relation between immunological parameters and duration of mechanical ventilation
IL-12 production in whole blood cell culture after stimulation with LPS+IFNγ was below
the detection limit in five patients. No correlation was found between IL-12 production
and chronological age, post-conceptional age or sex. The relation between IL-12 produc-
tion and duration of mechanical ventilation is shown in Figure 8.1. Interleukin-12
production predicted duration of mechanical ventilation (r = -0.62 days/(pg/ml), p <
0.001) (n=30). Interleukin-12 production per monocyte had comparable predictive value
for duration of mechanical ventilation (r = -0.58 days/(pg/ml/monocyte), p = 0.003).
Interleukin-10 production and plasma IL-8 did not predict duration of mechanical venti-
lation (data not shown).
Chronological age, mean VI and IL-12 production were analyzed with multiple regres-
sion analysis, which demonstrated that mean VI and IL-12 production were independ-
ently associated with duration of mechanical ventilation (R2 = 0.46).
$ 
The main finding of this study was that IL-12 production at initiation of mechanical
ventilation is inversely correlated with the duration of mechanical ventilation in RSV
bronchiolitis. In addition, the mean VI during the first 24 hours after initiation of
Table 8.1 Univariate linear regression analyis of candidate predictors for duration of
mechanical ventilation (days)*
Parameter Regression coefficient p-value
Chronological age (weeks)
Post-conceptional age (weeks)
Mean VI (mmHg•H2O/min)
Plasma IL-8 (pg/ml)*
IL-12 production (pg/ml)*
IL-10 production (pg/ml)*
0.13
0.10
0.47
0.11
-0.62
-0.09
0.51
0.59
0.013
0.67
<0.001
0.63
* analysis after logarithmic transformation
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mechanical ventilation appeared to be an independent predictor of duration of mechani-
cal ventilation. This is the first study to specifically assess the value of clinical and immu-
nological parameters in predicting duration of mechanical ventilation in RSV
bronchiolitis.
Wang et al. described clinical parameters, related to increased risk of admission to an
intensive care unit and  of respiratory insufficiency[1]. These parameters included age <
6 weeks, prematurity with or without chronic lung disease and congenital heart disease.
In the present study, no association was found between chronological or post-concep-
tional age and duration of mechanical ventilation. Whether chronic lung disease and
congenital heart disease are associated with prolonged duration of mechanical ventilation
could not be studied in our patient population, because only one patient had chronic
lung disease and none had congenital heart disease.
The VI is a measure of ventilatory disorder, which takes into account variations in venti-
lator management by incorporating both therapy (ventilatory rate and peak inspiratory
pressure) and response to therapy (PaCO2). The correlation between mean VI and dura-
tion of mechanical ventilation is in line with findings of Paret et al., who demonstrated
the prognostic value of VI in children with ARDS at day 3-5 after initiation of mechanical
ventilation[3]. It is of interest that in the present study the mean VI during the first 24
hours after initiation of mechanical ventilation already corresponds with duration of
mechanical ventilation.
Shute et al., but also other investigators have shown that in general plasma IL-8 levels are
markers of disease severity in inflammatory diseases of the lung, including asthma[6].
Figure 8.1 Relation between ex vivo IL-12 production and duration of mechanical
ventilation.
Blood was obtained from RSV bronchiolitis patients within 24 hours after
initiation of mechanical ventilation. Whole blood cultures were stimulated for
48 hours with LPS (100ng/ml) and IFNγ (20 ng/ml). Data represent
individual values and were analyzed after log transformation.
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The same was found recently in a RSV study by our group, in which plasma IL-8 levels
were significantly higher in mechanically ventilated patients than non-ventilated
patients[7]. The present study, however, shows that plasma IL-8 does not predict the
duration of mechanical ventilation in RSV bronchiolitis.
In the present study we did not study IL-12 production in mechanically ventilated infants
without RSV infection. To our knowledge, no data are available describing the relation
between duration of mechanical ventilation and ex vivo IL-12 responses in very young
infants. As a result, we can not exclude the possibility that an illness severe enough to
require prolonged duration of mechanical ventilation, regardless of the cause, may be
associated with low IL-12 production. However, the inverse relation between IL-12
responses and duration of mechanical ventilation suggests a protective role for IL-12 in
RSV infection in infants with respiratory failure. The mechanisms by which IL-12 exerts
this protective effect could be the initiation of an antiviral immune response by induction
of differentiation of naive CD4+ cells into the Th1 phenotype[4]. Cytokines secreted by
Th1 cells, including IFNγ, are a prerequisite to generate protective responses against
viruses and other intracellular pathogens.
Both patient- and virus-dependent factors could have influenced IL-12 responses in the
patients of this study. A patient-dependent factor for IL-12 production is age. In a sepa-
rate study in healthy infants, we found a significant correlation between IL-12 response to
LPS+IFNγ  and age in the first months of life (data not shown). Together with decreased
in vitro IFNγ responses in neonates, this could explain the high frequency of RSV bron-
chiolitis, resulting in mechanical ventilation, among infants < 6 weeks[8]. 
On the other hand, other viruses, including the measles virus, have been shown to inhibit
IL-12 production in vitro by monocytes/ macrophages[9;10]. Although the effect of RSV
on IL-12 production by monocytes/macrophages has not been investigated, it is conceiv-
able that, by inhibition of IL-12 production, RSV itself effectively prevents the initiation
of adequate antiviral immune responses. 
RSV bronchiolitis is often considered as an immune-mediated disease[11;12]. This
theory is supported by the absence of clinical symptoms in T-cell-depleted mice that were
infected with RSV[13]. Furthermore, the vaccination trial with inactivated RSV, that
resulted in augmentation of disease manifestations, provides additional evidence for an
immune-mediated pathogenesis of RSV bronchiolitis[14]. However, is has not been
established whether vaccine trials or  RSV infection in mice are reliable models for natu-
ral human RSV infection. In addition, it was already remarked by Hall et al., that an
immune-mediated pathogenesis of RSV bronchiolitis does not explain the high incidence
of life-threatening RSV infection among neonates[15]. Although cell-mediated immu-
nity might be involved in the induction of RSV bronchiolitis, the relation between IL-12
production and duration of mechanical ventilation in this study indicates that cell-medi-
ated immunity is also needed for convalescence from respiratory insufficiency during
RSV infection.
In summary, this study provides the first model with predictive value for the duration of
mechanical ventilation in RSV bronchiolitis. In addition,  the inverse correlation between
IL-12 production and duration of mechanical ventilation suggests a critical role for the
anti-viral immune response in the convalescence from respiratory failure during RSV
infection.
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To determine the role of respiratory syncytial virus (RSV)-specific cell-mediated immu-
nity (CMI) during natural reinfection we investigated whether RSV-specific T cell
responses protect against reinfection and, subsequently, whether reinfection boosts virus-
specific memory. In a cohort of 55 infants, who were hospitalized for RSV bronchiolitis,
RSV-specific lymphoproliferative responses (LPR) in the peripheral blood were meas-
ured at three time-points: on admission, 4 weeks after admission and one year later,
following the second winter season. Memory was defined as a stimulation-index (SI) >2.
During the second winter season, nasal secretions were collected in every case of a runny
nose. Reinfection was diagnosed if immunofluorescence or PCR was positive for RSV.
Virus-specific memory was found in 1 child on admission for primary RSV infection,
whereas 4 weeks later 44 infants (80%) had memory. Reinfection with RSV was found in
23 infants (43%) during the second winter season. After the second season memory was
found in 20 infants (38%). No differences in SI following the second winter season were
found between infants with and without reinfection (2.3 versus 2.1). However, a highly
significant correlation was found between SI measured 4 weeks after primary RSV infec-
tion and LPR following the second winter season (r=0.40, p=0.001). In conclusion, RSV-
specific T cell responses did not provide protection against reinfection. Moreover, rein-
fection did not boost RSV-specific T cell proliferation. To explain both findings, it is
hypothesized that RSV-specific T cells fail to expand in vivo upon reinfection.
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Respiratory syncytial virus (RSV) is one of the most important respiratory pathogens in
infancy causing the majority of lower respiratory tract infections (LRTI) during the
winter season. Hospitalization rates for RSV illness are 1-30 cases per 1000 infants < 1
year of age[1-3]. In hospitalized infants with RSV bronchiolitis mechanical ventilation is
required in 7-21% of cases[4-6]. Mortality in RSV infected infants with lower respiratory
tract symptoms is <1%[7].
Reinfection with RSV occurs frequently and usually has a mild character with symptoms
of uncomplicated upper respiratory tract infection [8]. Neutralizing antibodies induced
by primary RSV infection appear to provide only partial protection for a limited period
of time, which does probably not last until the subsequent RSV season[8;9]. Evidence
that intact cell-mediated responses play a role in clearance of the virus and protection
against reinfection was derived from animal studies[10]. In humans, little information is
available on the role of virus-specific CMI induced during primary infection in the
protection against reinfection with RSV. 
Currently, no vaccine for RSV is available. In the 1960s a formalin-inactivated vaccine
was used in infants[11]. No protection against naturally-acquired RSV was observed. In
contrast, enhanced disease and increased mortality were observed during RSV infection
following vaccination. CMI has been implicated in the pathogenesis of this phenome-
non[12]. Several strategies for safe and effective vaccination, including immunization
with attenuated strains and sub-unit vaccines are under investigation at the moment[13-
16]. The immune response to a RSV vaccine should be protective, persistent and not
disease enhancing upon subsequent contact with the virus. Similar to other vaccines
strategies, such as measles and pertussis, it is conceivable that boosting is required in
order to maintain virus-specific CMI. For this reason it is important to study the charac-
teristics of the memory response in relation to recurrent infection.
In this prospective follow-up study we investigated the development over time of RSV-
specific T cell responses in a cohort of infants hospitalized for RSV bronchiolitis. The first
aim of study was to determine whether RSV-specific T cell responses induced during
primary RSV bronchiolitis protect against reinfection during the subsequent epidemic.
The second aim of the study was to investigate whether virus-specific T cell responses
acquired during primary infection are boosted by natural reinfection with RSV.
& 2
9.3.1  Study population
Infants were included during one winter epidemic in 5 hospitals in the Netherlands.
Inclusion criteria were: hospital admission, lower respiratory tract symptoms, age < 13
months and positive immunofluorescence for RSV infection of epithelial cells in
nasopharyngeal secretions. Lower respiratory tract symptoms were severe chest cough,
wheezing, hoarseness, stridor, shortness of breath[17] as well as cyanosis and apnea.
Prematurely born infants with chronic lung disease and infants with wheezing illness
prior to RSV bronchiolitis were not included. The study was approved by the Medical
Ethical Committee in all participating centers. Parents of subjects gave written informed
consent.
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9.3.2  Documentation of reinfection
During the second winter season the occurrence of reinfection was studied. Parents
received written and oral information during a home visit during the fall season prior to
this part of this study. During the winter season parents contacted the investigators (J.V.)
in case of respiratory symptoms. To ascertain cooperation by parents a telephone call was
made every 3 weeks. Within 48 hours after onset of respiratory symptoms home visits
were made to perform nasal washes. No physical examination was performed. 
RSV reinfection was confirmed by a commercially available direct immunofluorescence
assay using fluorescein isothiocyanate (FITC)-labeled monoclonal antibodies (DAKO,
Imagen, The Netherlands) and by reverse transcriptase polymerase chain reaction (RT-
PCR). Reinfection was defined as a positive immunofluorescence or PCR on nasal wash-
ings.
9.3.3  RT-PCR
RNA extraction was performed according to the method described by Boom et al[18].
Briefly, 10-100µl respiratory specimen was mixed with 900µl lysis buffer and 50µl silica
and incubated for 10 minutes at room temperature in order to bind the nucleic acid to
the silica particles. Unbound material was then removed by several washing steps. The
RNA was subsequently eluted in 100µl 40 ng/µl polyA RNA before performing a one-tube
reverse transcription (RT)-PCR. 
After viral RNA isolation, an equivalent of 1-10µl of respiratory specimen was used to
reverse transcribe and amplify the NP gene. A one tube RT-PCR was performed essen-
tially as described by Nijhuis et al., using 1.5 mM MgCl2 , 0.4 µM of primer RS-1 (5’-
GGA TTG TTT ATG AAT GCC TAT GGT-3’ (Pharmacia)) and primer RS-2 (5’-TTC
TTC TGC TGT YAA GTC TAR TAC AC-3’). The amount of amplified product was
increased further in a nested amplification. 
Five µl of first PCR product is further amplified in a nested amplification essentially as
described by Nijhuis et al.[19], using 4.5mM of MgCl2 and 0.4µM of primer RS-3 (5’-
GGA TTC TAC CAT ATA TTG AAC AA-3’) and primer RS-4 (5’-CTR TAC TCT CCC
ATT ATG CCT AG-3’).
Five µl of nested PCR products were visualized on an ethidium-bromide stained agarose
gel using UV illumination. A 100-bp marker was used to control fragment lengths.
9.3.4  Virus preparation
Long strain RSV was cultured in Hep-2 cells (courtesy of Dr. A.M. van Loon, dept of
Virology, University Medical Center, Utrecht,) and 1:1 diluted in sucrose-gelatone solu-
tion Z7725a (Laboratory of Vaccine Research, National Institute of Public Health and
Environment, Bilthoven, The Netherlands). Titers were determined in Hep-2 cells using
the TCID50 method described by Karber (TCID50 2x105)[20]. A control antigen was
prepared similarly from uninfected Hep-2 cultures. Virus and control antigen were stored
in aliquots at -80°C.
9.3.5  RSV-specific T cell responses
At three time points heparinized blood was taken from subjects for whole blood cultures.
The first blood sample was taken within 24 hours after admission (t=1). Only in two of
five participating hospitals a blood sample was taken at this time point. The second blood
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sample was taken three to four weeks after the initial admission (t=2). The third sample
was taken immediately following the second RSV epidemic (t=3). At t=3 RSV-specific
LPR, but no cytokine profiles were determined.
Freshly taken heparinized blood was diluted 1:10 in RPMI 1640 medium (Life Technolo-
gies, Grand Island, NY) and aliquoted (150 µl) into 96-well culture plates (Nunc Interna-
tional, Denmark). Whole blood was infected with RSV at a multiplicity of infection
(MOI) of 0.1 - 1.0 or control suspension. Cultures were incubated for 6 days at 37ºC in
5% CO2. Forty-eight hours after infection, pooled supernatants were collected for
cytokine measurement. Five days after infection lymphocytes were pulsed with 0.25 µCi
3H-thymidine for 18 hours and thymidine incorporation was measured (lymphoprolifer-
ative response(LPR)). Stimulation index was defined as the ratio between LPR in cultures
stimulated with RSV and control antigen. A memory response was defined as a stimula-
tion index ≥ 2.0. All cultures were performed in quadruplicate. Pooled supernatants were
kept at -80ºC.
9.3.6  Cytokine assays
Cytokines that were measured in supernatants of RSV-stimulated whole blood cultures
were IL-4, IL-10, IL-12 and IFN-γ. Concentrations of IL-4, IL-8, IL-10 and IFN-γ were
determined using ELISA kits supplied by the Dutch Laboratory for Blood Transfusion
(CLB, Amsterdam, the Netherlands). The detection limit of the assay for IL-4 was 2 pg/
ml, for IL-8 2.5 pg/ml, for IL-10 2.5 pg/ml, and for IFN-γ 4 pg/ml. Concentrations of IL-
12 were determined using ELISA kits from R&D (Oxon, United Kingdom), the detection
limit was 7.8 pg/ml. When cytokine values were not detectable, the minimum detectable
level was used for statistical analysis.
9.3.7  Statistical analysis
Cytokine production and stimulation indices in RSV-stimulated cultures were logarith-
mically transformed and expressed as geometric mean and 95% confidence interval. All
tests of significance were two-sided. A p<0.05 was considered statistically significant.
Pearson correlation coefficient was used to describe the correlation between LPR at t=2
and t=3. Spearman’s correlation coefficient was used to analyze the correlation between
RSV-specific LPR or cytokine responses and age. Paired Student’s t-test was used to
analyze differences in (log transformed) values between different time points. Unpaired
Student’s t-test was used to analyze differences in (log transformed) values between
infants with and without reinfection. All tests of significance were two-sided. A p<0.05
was considered statistically significant.
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9.4.1  Subject characteristics
The investigated population consisted of 55 patients. Thirty patients (55%) were boys,
median age at the time of RSV bronchiolitis was 7 weeks. Ten infants (18%) were born
prematurely (range: 29–36 weeks). Ten infants (18%) needed mechanical ventilation.
One child had cardiac disease, none of the children had immunodeficiency. None of the
prematurely born infants had received RSV prophylaxis. None of the patients received
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ribavirin or systemic anti-inflammatory agents, including corticosteroids. Patients did
not receive inhaled corticosteroids during RSV bronchiolitis. All patients survived.
9.4.2  RSV-specific T cell responses 
A pilot study was performed in samples taken on admission (t=1) and following primary
RSV infection (t=2) in order to determine kinetics of LPR and cytokine responses. At t=2
maximum LPR to RSV were found after 5 days of culture. Maximum IL-10 production
was found at 48 hours. The pattern and magnitude of IL-10 responses at t=1 and t=2
were comparable and unrelated to stimulation indices. Maximum IFN-γ production at
t=1 and t=2 were found after 48 hours and 120 hours, respectively. IFN-γ and IL-10
responses in control antigen-stimulated cultures were undetectable or relatively low at
any time point as compared to RSV-stimulated cultures. IL-4 production in RSV-stimu-
lated cultures remained low (<10 pg/ml) and was not higher than IL-4 production in
cultures stimulated with control antigen. IL-12 production was not detectable at either
t=1 or t=2. We therefore concluded there is no RSV-specific IL-4 or IL-12 production
under these culture conditions. (data not shown)
At t=1, during the acute phase of RSV bronchiolitis, whole blood cultures were
performed in 22 infants. In RSV stimulated whole blood cultures at t=1, only one patient
(4.5%) had a memory response suggesting earlier infection. RSV-induced IFN-γ and IL-
10 responses at t=1 were 13 (95% CI: 4-199) respectively 25.7 (95% CI: 12.5-52.7) pg/ml.
At t=2, during the convalescent phase of RSV bronchiolitis, whole blood culture were
performed in 55 infants. Forty-four patients (80%) had a memory response at t=2, the SI
was 5.1(95% CI: 3.7-8.4). RSV-induced IFN-γ production at t=2 was 60 (95% CI: 48–79)
pg/ml, significantly higher than at t=1 (p<0.01). RSV-induced IFN-γ production was
highly correlated with the RSV-specific LPR (r=0.80, p<0.001). RSV-induced IL-10
production at t=2 was 16 (95% CI: 11-23) pg/ml, not significantly different from t=1. At
t=2 no significant correlation was found between age and RSV-specific LPR or cytokine
responses. Mechanically ventilated infants had higher LPR than non-ventilated infants
(8.5 resp 3.9, p=0.02), which is in line previous reports[21].
At t=3, following the second winter season, RSV-specific lymphoproliferation was meas-
ured in 53 infants. No blood was drawn in two infants (4%). A memory response was
found in 20 infants (38%). RSV-specific LPR was significantly lower than following the
primary RSV infection (SI 2.2 vs. 5.1, p<0.001). RSV-specific LPR at t=2 and t=3 were
highly correlated (r=0.40, p=0.001) (Figure 9.1). 
9.4.3  Reinfection during second winter season
Eighty-five episodes of respiratory tract symptoms were reported, reinfection with RSV
was diagnosed in 23 infants (42%). In all 23 cases PCR was positive, whereas immunoflu-
orescence was positive in only 9 of 23 cases of RSV infection (39%). 
RSV-specific cellular immune responses at t=2 was compared between infants with and
without reinfection to assess whether RSV-specific T cell responses protected against
reinfection. No differences in LPR were found between infants with and without reinfec-
tion (Figure 9.2). In addition, infants with and without reinfection had comparable RSV-
specific IFN-γ (70 vs. 54 pg/ml) and IL-10 production (13 vs. 16 pg/ml) at t=2.
RSV-specific LPR at t=3 was compared between infants with and without reinfection to
assess whether RSV-specific T cell proliferation was boosted by reinfection. No difference
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in LPR at t=3 were found between infants with and without reinfection (2.1 resp
2.3)(Figure 9.3). The correlation between LPR at t=2 and t=3 was separately analyzed for
infants with and without reinfection. In infants with and without reinfection the correla-
tion between LPR at t=2 and t=3 was similar (r=0.41, p<0.05 resp. r=0.40, p<0.05).
& 
The results of this study show that virus-specific T cell responses induced during primary
RSV infection does not protect completely against subsequent reinfection. In addition,
reinfection with RSV did not boost RSV-specific LPR.
Reinfections with RSV occur throughout life[22], implying that immunity induced by
natural infection provides little long-term protection against reinfection. Naturally-
induced and exogenously-administered RSV-specific antibodies provide incomplete
protection, which is of short duration[9;23-25]. To date, sparse data exist on the protec-
tion against reinfection provided by naturally acquired CMI[23;26]. In a follow-up study
from the early 80s no relationship was found between RSV-specific lymphoproliferative
responses induced during primary infection and the risk for subsequent culture-proven
reinfection[23]. However, it can be doubted whether the sensitivity of viral cultures in
this study was suitable to diagnose (usually mild) reinfection[27]. Assuming positive
PCR for RSV indicates RSV infection, the present study shows that the sensitivity of
Figure 9.1 Correlation between RSV-specific lymphoproliferative responses during
primary RSV infection and following the subsequent winter season
Relation RSV-specific lymphoproliferative responses (SI) measured 3-4 weeks
after hospitalization for RSV bronchiolitis (t=2) and following the subsequent
winter season (t=3). Lymphoproliferative responses were determined by
thymidine-incorporation in whole blood cultures stimulated with RSV for 5
days. Pearson’s correlation coefficient is shown.
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immunofluorescence for RSV infection in this patient group was only 39%. Thus PCR,
and not culture or immunofluorescence, is required to adequately establish mild reinfec-
tion with RSV. 
One of the limitations of the present study is that we did not attempt to measure the
degree of respiratory disease. Therefore, we cannot exclude that RSV-specific cell-medi-
ated responses decrease the severity of disease in case of reinfection. In addition, in the
present study RSV-specific CMI is represented by virus-specific LPR. Although this is in
line with previous studies[21;26], it is not known what part of CMI is reflected by RSV-
Figure 9.2 RSV-specific lymphoproliferative responses in infants with and without
reinfection with RSV
RSV-specific lymphoproliferative responses (SI) measured 3-4 weeks after
hospitalization for RSV bronchiolitis (t=2) (Figure 9.2a) and following the
second winter season (t=3) (Figure 9.2b) in infants with and without
reinfection with RSV. Lymphoproliferative responses were determined by
thymidine-incorporation in whole blood cultures stimulated with RSV for
5 days. Geometric means are shown.
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specific LPR. The assay measures proliferation in a pool of heterogeneous cells. There-
fore, LPR may reflect proliferation of cytotoxic T cells (CTL), cytokine-producing cells or
non-specific cells that respond to IL-2 produced in the culture system. Cytotoxicity assays
measure CTL responses by CD8+ cells and reflect a more accurate effector function of
CMI. However little data are available on CTL responses in infants during RSV infec-
tion[28;29].
To address the role of RSV-specific CTL in protection against infection in the mouse
model, vaccination studies with vaccinia virus expressing the M2 protein of RSV were
performed. It was shown that protection against RSV infection largely depended on CTL
formation[30]. CTL responses waned within 45 days after vaccination, which was paral-
leled by a loss in protection.
In the present study RSV-specific LPR was induced by primary RSV infection in the
majority of infants, which is in line with previous studies[21]. Memory was found in one
child during the acute phase of disease, whereas 3 to 4 weeks later memory to RSV was
found in 80% of the infants. To our surprise we did not find evidence that reinfection
boosted virus-specific CMI, since infants with and without reinfection had similar RSV-
specific LPR at t=2 and t=3. Moreover, RSV-specific LPR at t=2 and t=3 were highly
correlated. Therefore, it can be concluded that RSV-specific LPR induced during primary
RSV bronchiolitis partially persists for more than a year and is not boosted by naturally
acquired reinfection.
The physiological role of RSV-specific T cells during reinfection is not well understood.
First, RSV-specific T cell responses did not protect against reinfection. Second, virus-
specific LPR were induced by primary RSV infection, but not boosted by reinfection.
Both findings may be explained by an absence of in vivo expansion of RSV-specific T cells
during a re-encounter with RSV. It is uncertain, however, why RSV-specific memory T
cells are formed during primary infection, but do not proliferate in vivo during reinfec-
tion. 
The immune response during reinfection with RSV is apparently effective, since symp-
toms are usually mild and last for a short period. If RSV-specific T cells do indeed fail to
expand in vivo during reinfection, it can be questioned whether T cell memory plays a
major role in the immune response during reinfection. B cell memory may be more
important during reinfection. This is supported by a prominent rise in neutralizing anti-
bodies observed following reinfection with RSV [8]. In addition, non-adaptive immunity
could have a function in the elimination of RSV during reinfection. Natural killer (NK)
cells are important in the defense against viruses because the are capable of providing
cytotoxicity and producing cytokines, including IFN-g[31]. Although in humans no data
exist on the role of NK cells during RSV infection, this cell type has been implicated in
the immune response during RSV infection in mice[32;33]. In addition, type I interfer-
ons (IFN-α/β) could play a role in the anti-viral immune response. These cytokines with
direct anti-viral properties are produced in high amounts by airway epithelium upon
infection with RSV [34] and they are found in the airways of RSV infected infants[35].
An important aim in the development of a vaccine against viruses is the induction of
virus-specific memory. Subsequent encounter with the virus should result in expansion
of at least part the pool of memory T cells. The present study clearly shows that memory
cells do not necessarily expand during reinfection. If a future RSV vaccine for humans
induces RSV-specific T cells, which lack the potential to expand in vivo upon natural
bontalles.fm  Page 85  Wednesday, May 9, 2001  8:29 AM
86     Chapter 9
infection, this could have implications for the effectiveness of the vaccine. Limited
protection by memory T cells would be expected, the effect of the vaccine would than
largely depend on the formation of B cell memory. It remains to be seen whether B cell
memory is sufficient for protection against reinfection 
In conclusion, the present study shows that RSV-specific T cell responses do not protect
against reinfection. Moreover, reinfection does not boost RSV-specific LPR. Together,
these findings suggest that RSV-specific T cells do not expand in vivo upon reinfection
with RSV, which could bear relevance for the development of an effective vaccine. 
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Respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) is frequently
followed by recurrent wheezing. Thus far, no clinical risk factors have been identified to
predict which infants will have wheezing episodes subsequent to RSV LRTI. To objective
of the present study was to determine clinical predictors for airway morbidity following
RSV LRTI. In a one year follow-up study, we investigated the predictive value of ausculta-
tory findings characteristic of airflow limitation (wheezing) during RSV LRTI for subse-
quent airway morbidity. Clinical characteristics, including the presence or absence of
signs of airflow limitation, of hospitalized infants with RSV LRTI were prospectively
recorded during two winter epidemics. During a one year follow-up period parents of
130 infants recorded daily airway symptoms. Recurrent wheezing defined as ≥2 episodes
of wheezing. Signs of airflow limitation during RSV LRTI were absent in 47 (36%) infants
and present in 83 (64%) infants. Recurrent wheezing was recorded in 10 (21%) infants
without signs of airflow limitation and in 51 (61%) with signs of airflow limitation
during initial RSV LRTI (relative risk 0.29, p<0.001). In a multiple logistic regression
model airflow limitation during initial RSV LRTI proved independent from other clinical
parameters, including age, parental history of asthma and smoke exposure. We conclude
that signs of airflow limitation during RSV LRTI is the first useful clinical predictor for
subsequent recurrent wheezing. 
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Acute RSV LRTI, one of the most common respiratory diseases in infancy, occurs in
winter epidemics. Numerous epidemiological studies have suggested an increased risk for
recurrent episodes of wheezing following acute RSV bronchiolitis.[1-5] In addition to
respiratory symptoms, abnormalities of infant respiratory function subsequent to RSV
bronchiolitis have been reported in many but not all studies. [6-10] Recently, a prospec-
tive study showed that during the first three years of life, RSV LRTI is a risk factor for
recurrent wheezing up to age 11 years, but not at age 13.[11] 
Several studies have attempted to delineate clinical risk factors for airway morbidity
following RSV LRTI.[3;4] However, no clinical risk factors have thus far been identified.
Most earlier reports have used standardized questionnaires filled in by parents to
obtained information on airway morbidity. An important limitation of questionnaires is
that parents might have forgotten earlier occurrence of respiratory symptoms (recall
bias). Signs of airflow limitation, as evidenced by wheezing on auscultation of the chest
during the acute phase of RSV LRTI, as a risk factor for recurrent wheezing following
RSV LRTI has not been investigated.
In the present study, we prospectively obtained detailed quantitative information on
respiratory symptoms following RSV LRTI using a simple diary during a one year
follow-up period. We tested the hypothesis that the absence of physical sounds of airflow
limitation in infants with RSV LRTI predicts a lower incidence of airway morbidity
during a one year follow-up period than in infants with the more classical picture of RSV
bronchiolitis with airflow limitation.
3 2
10.3.1  Study population 
Children at 6 hospitals in the Netherlands were prospectively included during two winter
epidemics. Two hospitals had a pediatric intensive care unit (PICU). Inclusion criteria
were: hospital admission, lower respiratory tract symptoms, age < 13 months and
immunofluorescence for RSV in epithelial cells from nasopharyngeal secretions. There
were no standard criteria used for hospitalization. Symptoms of LRTI were severe chest
cough, wheezing, hoarseness, stridor, shortness of breath[11] as well as cyanosis and
apnea. Infants with wheezing respiration prior to RSV infection were excluded. A history
of premature birth, chronic lung disease, congenital heart disease as well as the presence
of fever >38.5 ºC and the presence of physical sounds of airflow limitation on admission
(expiratory wheeze or prolonged expiration) were prospectively recorded during hospi-
talization. On admission all infants were examined by a pediatrician. Standardized forms
were used to record findings on physical examination on admission, including the pres-
ence of respiratory wheeze. During subsequent hospitalization a resident daily performed
physical examination as part of clinical routine. 
A single investigator (J.V.) retrospectively analyzed the main presenting symptom (as
noted by the pediatrician) from the patient histories, without having information on
follow-up data. Pediatricians did not always chart one main presenting symptom. The
main presenting symptom was subjectively categorized into apnea, respiratory insuffi-
ciency resulting in mechanical ventilation, feeding problem, dyspnea or “RSV infection
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not specified” on admission. In general, when “dyspnea” was noted as the main present-
ing symptom, this was followed by supplemental oxygen treatment during hospitaliza-
tion. When “feeding problems” were noted as the main presenting symptom, feeding
measures were subsequently taken. 
This study was approved by the Medical Ethical Committee in all participating centers.
Parents of subjects gave written informed consent. 
10.3.2  Follow-up 
Diaries – Starting three weeks after hospital discharge parents recorded respiratory
symptoms, airway medication and doctor’s visits on a daily basis in a diary. A single
investigator (L.B.) instructed parents how to use the diary. Respiratory symptoms that
were recorded were “runny nose”, “coughing” and “wheezing”. Symptoms were graded in
severity on a scale from 0-3 (absent, moderate, severe, very severe). The absence of respi-
ratory symptoms was also noted. In order to enhance compliance telephone contact was
maintained every three months. The completed diaries were returned to the investigators
by mail every three months. 
In order to quantify respiratory symptoms during the first year following RSV bronchi-
olitis, the number of episodes the child experienced coughing and/or wheezing were
counted. A disease episode was defined as the presence of respiratory symptoms for two
or more consecutive days. In addition, the number of days the child experienced cough-
ing and/or wheezing during the first year were counted. To estimate the role of upper
respiratory tract infections during episodes of coughing and/or wheezing, the occurrence
of preceding or concurring symptoms of a “runny nose” were analyzed. 
Physician diagnosis of asthma – In order to evaluate respiratory morbidity with a differ-
ent method less dependent on the perception of parents, we contacted the general practi-
tioner of all infants by telephone one year following discharge and inquired whether an
asthma diagnosis had been made following RSV LRTI. 
10.3.3  Statistical analysis 
The number of episodes and days of wheezing or coughing were expressed as median
values. Diffences in sex, prematurity, requirement of mechanical ventilation, parental
history of asthma, presence of fever, main presenting symptom, frequency of recurrent
wheezing and physician-diagnosed asthma between infants with and without signs of
airflow limitation during the initial RSV LRTI were analyzed using Chi-square. Differ-
ences in age, number of episodes of wheezing or coughing and number of days of cough-
ing or wheezing between infants with and without signs of airflow limitation during the
initial RSV LRTI were analyzed using Mann-Whitney U test. Univariate logistic regres-
sion was used to analyze predictive values for recurrent wheezing. The predictive value of
chronological age was analyzed after log transformation, although the distribution
remained skewed to the right after transformation. Forward stepwise logistic regression
was used to separately analyze the predictive value of signs of airflow limitation, age, sex,
respiratory insufficiency and parental history of asthma as candidate predictors during
RSV LRTI for recurrent wheezing in one prediction model. No other parameters were
entered in the multiple logistic regression model because of the limited number of
patients. The goodness of fit of the model was estimated by the square of the multiple
correlation coefficient (R2).
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10.4.1  Patient characteristics 
One-hundred-thirty-six children with RSV LRTI were enrolled, 130 were followed for
one year. Six children did not return one or more 3-month diaries and were considered
lost to follow-up. Seventy-one (55%) were boys, median age was 2 months. Thirty-nine
patients (30%), were born prematurely (median: 34 weeks, range: 25-36 weeks). Twenty-
nine subjects (22%) needed mechanical ventilation. Four patients (3%) had cardiac
disease, 2 (2%) had chronic lung disease. Signs of airflow limitation were noted in 83
(64%) patients. Clinical characteristics and main presenting symptom of patients with
and without signs of airflow limitation are shown in table 10.1. The main presenting
symptom noted by the pediatrician in infants with signs of airflow limitation during
initial RSV LRTI was dyspnea in 42 infants (51%), whereas respiratory insufficiency
resulting in mechanical ventilation was the main presenting symptom in 40% of infants
without signs of airflow limitation during initial RSV LRTI. None of the patients received
ribavirin or systemic corticosteroids during their initial RSV LRTI. All patients survived. 
Table 10.1 Clinical characteristics of infants with RSV LRTI with and without signs of
airflow limitation (n=130)
Variable Airflow limitation 
during initial
RSV LRTI (n=83)
No airflow limitation 
during initial
RSV LRTI (n=47)
p-value
Male (%)
Prematurity (%)
Median chronological age in weeks (range)
Median post-conceptional age in weeks 
(range)
Mechanical ventilation during RSV(%)
Paternal history of asthma
Maternal history of asthma
Parental history of asthma
Fever > 38.5 °C during initial infection (%)
Smoke exposure (%)
Main presenting symptom apnoea (%)
respiratory insufficiency (%)
feeding problems (%)
dyspnea (%)
not specified (%)
47 (57)
22 (27)
11 (0-52)
50 (37-91)
10 (12)
10 (12)
4 (5)
14 (17)
20 (24)
18 (22)
0
7 (8)
14 (17)
42 (51)
20 (24)
24 (51)
17 (36)
6 (1-50)
42 (34-92)
19 (40)
1(2)
3 (6)
4 (9)
9 (19)
4 (9)
3 (7)
19 (40)
8 (16)
9 (18)
8(16)
NS*
NS*
<0.001#
0.002#
0.004*
0.05*
NS*
NS*
NS*
NS*
NS*
<0.001*
NS*
<0.001*
NS*
* Chi square test
# Mann-Whitney U test
NS not significant
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10.4.2  Wheezing and coughing symptoms during follow-up 
Follow-up characteristics are shown in table 10.2 and 10.3. In total, 241 episodes of
wheezing were reported. All but two episodes were accompanied by a runny nose and
coughing. Recurrent wheezing was reported in 51 (61%) of the infants with signs of
airflow limitation and in 10 (21%) of the infants without signs of airflow limitation
during the initial RSV LRTI (p<0.001).
One year after hospitalization for RSV LRTI the family doctors of the infants were
contacted by telephone. An asthma diagnosis had been made by the general practitioner
in 42 (32%) infants. Recurrent wheezing was noted in 37 (88%) of these cases with physi-
cian-diagnosed asthma. Physician-diagnosed asthma was reported in 35 (42%) of the
infants with signs of airflow limitation and in 7 (15%) of the infants without signs of
airflow limitation during the initial RSV LRTI (p=0.003).
During the initial RSV LRTI mechanical ventilation was required in significantly more
infants without signs of airflow limitation than in infants with signs of airflow limitation
(table 10.1). We therefore separately investigated the relation between signs of airflow
limitation during initial RSV LRTI and recurrent wheezing or physician-diagnosed
asthma in non-ventilated infants. Recurrent wheezing was reported in 39 (53%) of the 73
infants with signs of airflow limitation and in 4 (14%) of the 28 infants without signs of
airflow limitation during the initial RSV LRTI (p<0.001). Physician-diagnosed asthma
was found in 28 (38%) infants of the 73 infants with signs of airflow limitation and in 2
(7%) of the 28 infants without signs of airflow limitation during the initial RSV LRTI
(p<0.001).
During follow-up 8 (7%) children had to be readmitted to the hospital for wheezing
respiratory illness. All had signs of airflow limitation during initial RSV LRTI. One child
had to be readmitted twice. Two of the re-admissions occurred during the first month
following discharge. 
Four children (3%)HT did not have any episode of coughing during follow-up, 75 chil-
dren (58%) had between one and five episodes of coughing and 51 children (39%) had
six or more episodes of coughing during the follow-up period. All episodes of coughing
were accompanied by a runny nose. Striking was that in 36 children (28%) ≥100 days of
coughing were reported during the follow-up period. Of these children, 6 (17%) never
wheezed during follow-up. 
Table 10.2 Respiratory symptoms during first year following RSV LRTI (n=130)
Follow-up findings Median Range
Number of disease episodes
Number of episodes of wheezing
Number of days of wheezing
Number of episodes of coughing
Number of days of coughing
Mean during of episode of coughing (days)
6
2
11
6
75
14
1–12
0–11
0–135
0–12
0–316
1–31
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10.4.3  Prediction of recurrent wheezing and physician-diagnosed asthma following RSV 
LRTI
The relation between separate clinical characteristics or symptoms during initial RSV
LRTI and recurrent wheezing or physician-diagnosed asthma are shown in table 10.4a. A
statistically significant relation was only found between signs of airflow limitation during
the initial RSV LRTI and recurrent wheezing during the first year of follow-up. A compa-
rable association was found between signs of airflow limitation during the initial RSV
LRTI and physician-diagnosed asthma. Signs of airflow limitation during the initial RSV
LRTI appeared an independent predictor of recurrent wheezing and physician-diagnosed
asthma using multiple linear regression analysis (R2 = 0.21 respectively 0.13) (table
10.4b). The relative risk of recurrent wheezing in infants without signs of airflow limita-
tion during initial RSV LRTI was 0.29 (95% CI 0.16 – 0.56). For non-ventilated infants
without signs of airflow limitation this was 0.20 (95% CI 0.08 – 0.52). The relative risk of
physician-diagnosed asthma in infants without signs of airflow limitation during initial
RSV LRTI was 0.35 (95% CI 0.16 – 0.75). For non-ventilated infants without signs of
airflow limitation this was 0.18 (95% CI 0.05 – 0.65).         
Table 10.3 Airway morbidity during a one year follow-up period following RSV LRTI
with and without signs of airflow limitation (n=130)
Follow-up findings Signs of airflow 
limitation 
during initial 
RSV LRTI 
(n=83)
No signs of 
airflow limitation 
during initial 
RSV LRTI (n=47)
p-value
Number of disease episodes per infant (median) 6 5 0.013#
Recurrent wheezing (%)
Number of wheezing episodes (median)
Number of days of wheezing per infant (median)
51 (61)
2
15
10 (21)
1
3
<0.001*
<0.001#
0.007#
Number of coughing episodes (median)
Number of days of coughing (median)
5
82
4
54
0.031#
NS#
Use of inhalation steroids (%)
Use of bronchodilating inhalants (%)
33 (40)
42 (51)
10 (21)
12 (25)
0.024*
0.004*
Hospitalization for airway symptoms during 
follow-up (%)
8 (10) 6 (13) NS*
Physician diagnosis of asthma (%) 35 (42) 7 (15) 0.003*
* Chi square test
# Mann-Whitney U test
NS not significant
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In the present study we show that 47% of infants hospitalized for RSV LRTI reported
recurrent wheezing during a one year follow-up. The incidence of recurrent wheezing
during follow-up was significantly lower for infants without signs of airflow limitation
(21%) than for infants with signs of airflow limitation during the acute RSV infection
(61%). Signs of airflow limitation during initial RSV LRTI appeared to be an
Table 10.4a Predictive value of separate candidate predictors for recurrent wheezing and
physician diagnosed asthma following RSV LRTI (n=130) using univariate
logistic regression analysis
Candidate predictor p value
Recurrent 
wheezing
Physician diagnosed 
asthma
Signs of airflow limitation during initial RSV LRTI
Paternal history of asthma
Maternal history of asthma
Parental history of asthma
Mechanical ventilation during initial RSV LRTI
Sex
Fever during initial RSV LRTI
Prematurity
Smoke exposure
Chronological age (in weeks)*
0.001
0.26
0.37
0.22
0.87
0.64
0.76
0.39
0.82
0.30
0.006
0.89
0.53
0.72
0.39
0.09
0.49
0.32
0.71
0.22
* analysis after log transformation
Table 10.4b Forward stepwise logistic regression analysis of candidate predictors for
recurrent wheezing following RSV LRTI (n=130)
Step Candidate predictor p value
Recurrent wheezing Physician-diagnosed asthma
1 Signs of airflow limiation during 
initial RSV LRTI <0.001 <0.001
Not included
Mechanical ventilation during 
initial RSV LRTI
Sex
Parental history of asthma
Smoke exposure
Age (weeks)*
0.10
0.31
0.36
0.45
0.92
0.10
0.40
0.72
0.80
0.10
* analysis after log transformation
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independent predictor for subsequent recurrent wheezing. The same pattern was seen for
physician-diagnosed asthma. To our knowledge, this is the first longitudinal report esti-
mating the risk for recurrent wheezing and physician-diagnosed asthma in a cohort of
children hospitalized for RSV LRTI without signs of airflow limitation. Moreover, the
inverse relation between the absence of signs of airflow limitation and subsequent recur-
rent wheezing is the first clinical predictor for the development of recurrent wheezing
following RSV LRTI.
It has been difficult to quantify respiratory symptoms following RSV bronchiolitis. Some
studies were performed retrospectively, inquiring about initial respiratory symptoms
years later.[1;3;4] Thus far, prospective studies have assessed respiratory symptoms at
various time intervals using standardized questionnaires, which were filled in by parents.
In these studies respiratory symptoms are collected closer to the period when the symp-
toms occurred than in retrospective studies.[6] However, it is conceivable that even
parental recall of symptoms over a one-year period is biased. In the present study these
limitations were overcome by the daily information on airway symptoms from the
diaries.
A limitation of the present study is that physical examination during initial RSV LRTI
was performed by different physicians. In addition, there are no follow-up data of healthy
age-matched controls. Therefore, we can not determine whether infants without signs of
airflow limitation during RSV LRTI have normal or increased incidence of recurrent
wheezing.
Several studies attempted to delineate clinical predictors for airway morbidity following
RSV LRTI. In these studies different inclusion criteria were used. In some studies proven
RSV infection during LRTI was required for inclusion,[3-5;12;13] while in others wheez-
ing on auscultation was a prerequisite for inclusion.[6;8;14;15] Attempts to associate
recurrent wheezing following RSV LRTI with clinical and social parameters, including
sex, age and disease severity were not successful.[3;4;6;14;15] In the present study we
confirmed that these clinical parameters have no predictive value for airway morbidity
following RSV LRTI. 
In the present study parental history of asthma and airway morbidity following RSV
LRTI were not associated. The prevalence of recurrent wheezing and lung function
changes following RSV LRTI have been shown to be unrelated to atopy.[11;13;15] For
this reason, we studied the predictive value for airway morbidity following RSV LRTI of
maternal and paternal history of asthma but not eczema, rhinitis, allergy or other atopy
related symptoms in family members. It has been suggested recently that asthma in the
mother, but not in the father, is a risk factor for asthma in infants who were not sensitized
to Alternaria in the U.S. Southwest desert environment.[16] In a different study it was
also suggested that childhood asthma might be more related to maternal than paternal
factors. This form of probably non-atopic asthma could be closely related to asthmatic
symptoms following RSV LRTI.[11] In the present study we did not find an association
between parental history of asthma and recurrent wheezing following RSV LRTI, which
is in line with most previous studies.[3;14;15] The different findings with respect to the
role of maternal asthma as a risk factor for childhood asthma could be explained by
climate or other environmental differences between the studies. On the other hand,
airway morbidity following RSV LRTI could be a separate disease with a different patho-
genesis from other closely related forms of early onset non-atopic asthma.
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Exposure to cigarette smoke before or after RSV LRTI was no risk factor for subsequent
recurrent wheezing, which is in line with previous studies.[6;17] In the present study we
did not investigate maternal cigarette smoking during pregnancy. Recently it was shown
that maternal cigarette smoking during pregnancy is a risk factor for wheezing during
early childhood[18]. Whether this is also true for wheezing following RSV LRTI is not
known. The absence of a relation between cigarette smoke exposure and airway morbid-
ity following RSV LRTI is in striking contrast with findings in studies on risk factors for
asthma in infants who were not hospitalized for RSV.[19] This discrepancy might be
explained by a smaller number of follow-up studies on RSV than childhood asthma.
However, it is conceivable, again, that airway morbidity following RSV LRTI is a separate
disease with a different pathogenesis from other closely related forms of early onset non-
atopic asthma.
It has been shown by Martinez and colleagues[20] that lower levels of lung function in
newborns are associated with subsequent incidence of lower respiratory tract illness with
or without wheezing in the first year of life. It was suggested that RSV lower respiratory
tract illness might also result from congenital lower levels of lung function, but this still
needs to be established.[11]
Detailed quantitative information of respiratory symptoms during follow-up was
obtained. Among infants with recurrent wheezing, large differences in frequency of
airway symptoms were shown. Parents of some infants only reported one or two episodes
for which they did not consult a physician whereas others reported frequent episodes of
airway symptoms for which even hospitalization was required. Our study also shows that
some children report more than 100 days of coughing during a follow-up period of one
year without any report of wheezing respiration. It has been shown recently that a large
proportion of children with cough as a sole symptom can be diagnosed as having
asthma.[21-23] Although no healthy controls were included in our study, it appears likely
that not only recurrent wheezing but also recurrent or persistent cough may be associated
with RSV LRTI. 
In conclusion, airflow limitation during RSV LRTI is a useful predictor for the develop-
ment of recurrent wheezing and physician-diagnosed asthma during early childhood. We
hypothesize that airway morbidity after RSV LRTI is a separate form of childhood
asthma because risk factors well-known in childhood asthma do not appear to play a role
in airway morbidity after RSV LRTI.
#
1 Murray M, Webb MSC, O’Callaghan C, Swarbrick AS, Milner AD. Respiratory status and allergy after
bronchiolitis. Arch Dis Child 1992; 67:482-487.
2 Hall CB, Hall WJ, Gala CL, McGill FB, Leddy JP. Long-term prospective study in children after respiratory
syncytial virus infection. J Pediatr 1984; 105:358-364.
3 Pullan CR, Hey EN. Wheezing, asthma and pulmonary dysfunction 10 years after infection with respira-
tory syncytial virus infection in infancy. BMJ 1982; 284:1665-1669.
4 Sims DG, Downham MA, Gardner PS. Study of 8-year-old children with a history of respiratory syncytial
virus bronchiolitis in infancy. BMJ 1978; 1:11-17.
5 Eisen AH, Bacal HL. The relationship of acute bronchiolitis to bronchial asthma - a 4 tot 14 year follow-up.
Pediatrics 1963; 31:859-861.
6 Sly PD, Hibbert ME. Childhood asthma following hospitalization with acute viral bronchiolitis in infancy.
Pediatr Pulmonol 1989; 7:153-158.
bontalles.fm  Page 98  Wednesday, May 9, 2001  8:29 AM
Airflow limitation during RSV predicts recurrent wheezing     99
7 Gurwitz D, Mindorff C, Levinson H. Increased evidence of bronchial reactivity in children with a history of
acute bronchiolitis. J Pediatr 1981; 98:551-555.
8 McConnochie KM, Mark JD, McBride JT, Hall WJ, Brooks JG, Klein SJ, Miller RL, McInerny TK, Nazarian
LF, McWhinney JB. Normal pulmonary function measurements and airway reactivity in childhood after
mild bronchiolitis. J Pediatr 1985; 107:54-58.
9 Dezateux C, Fletcher ME, Dundas I, Stocks J. Infant respiratory function after RSV-proven bronchiolitis.
Am J Respir Crit Care Med 1997; 155:1349-1355.
10 Merth IT, de Winter JP, Zonderland HM, Brand R, Quanjer PH. Pulmonary function during the first year
of life following acute viral bronchiolitis. Am J Respir Crit Care Med 1996; 154:689-694.
11 Stein RT, Sherill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD. Respiratory
syncytial virus in early life and risk of wheeze and allergy by age 13. Lancet 1999; 354:541-545.
12 Webb MSC, Henry RL, Milner AD, Stokes GM, Swarbrick AS. Continuing respiratory problems three and a
half years after acute viral bronchiolitis. Arch Dis Child 1985; 60:1064-1067.
13 Mok JYQ, Simpson H. Symptoms, atopy, and bronchial reactivity after lower respiratory infection in
infancy. Arch Dis Child 1984; 59:299-305.
14 McConnochie KM, Roghmann KJ. Predicting clinically significant lower respiratory tract illness in child-
hood following mild bronchiolitis. Am J Dis Child 1985; 139:625-630.
15 Sims DG, Garner PS, Weightman D, Turner MW, Soothill JF. Atopy does not predispose to RSV bronchioli-
tis or postbronchiolitic wheezing. BMJ 1981; 282:2086-2091.
16 Halonen M, Stern DA, Lohman C, Wright AL, Brown MA, Martinez FD. Two subphenotypes of childhood
asthma that differ in maternal and paternal influences on asthma risk. Am J Respir Crit Care Med 1999;
160:564-570.
17 Duff AL, Pomeranz ES, Gelber LE, Weyman Price G, Farris H, Hayden FG, Platts-Mills TAE, Heymann PW.
Risk factors for acute wheezing in infants and children: viruses, passive smoke, and IgE antibodies to inhal-
ant allergens. Pediatrics 1997; 92:535-540.
18 Stein RT, Holberg CJ, Sherrill D, Wright AL, Morgan WJ, Taussig L, Martinez FD. Influence of parental
smoking on respiratory symptoms during the first decade of life: the Tucson Children’s Respiratory Study.
Am J Epidemiol 1999; 149:1030-1037.
19 Tager I.B., Hanrahan JP, Tosteson TD, Castile RG, Brown RW, Weiss.S.T., Speizer FE. Lung function, pre-
and post-natal smoke exposure, and wheezing in the first year of life. Am Rev Respir Dis 1993; 147:811-817.
20 Martinez FD, Morgan WJ, Wright AL, Holberg CJ, Taussig LM. Diminished lung function as a predisposing
factor for wheezing respiratory illness in infants. N Engl J Med 1988; 319:1112-1117.
21 Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Joseph LK, Symington P, O’Toole S, Myint SH,
Tyrell DAJ, Holgate ST. Community study of role of viral infections in exacerbations of asthma in 9-11 year
old children. BMJ 1995; 310:1225-1228.
22 Pattemore PK, Asher MI, Harrison AC, Mitchell EA, Rea HH, Stewart AW. The interrelationship among
bronchial hyperresponsiveness, the diagnosis of asthma, and asthma symptoms. Am Rev Respir Dis 1990;
142:549-554.
23 Kelly YJ, Brabin BJ, Milligan PJM, Reid JA, Heaf D, Pearson MG. Clinical significance of cough and wheeze
in the diagnosis of asthma. Arch Dis Child 1996; 75:489-493.
bontalles.fm  Page 99  Wednesday, May 9, 2001  8:29 AM
bontalles.fm  Page 100  Wednesday, May 9, 2001  8:29 AM
11 Monocyte IL-10 production during 
respiratory syncytial virus bronchiolitis is 
associated with recurrent wheezing in a 
one year follow-up study
L Bont, CJ Heijnen, A Kavelaars, WMC van Aalderen, F Brus, JThM Draaisma,
SM Geelen, JLL Kimpen
Am J Respir Crit Care Med 2000;161:1518-1523
bontalles.fm  Page 101  Wednesday, May 9, 2001  8:29 AM
102     Chapter 11
 %)
Respiratory syncytial virus (RSV) bronchiolitis is associated with subsequent recurrent
wheezing episodes. To determine whether cytokine responses during infection can be of
predictive value for the development of recurrent wheezing, we performed a follow-up
study in 50 hospitalized children with RSV bronchiolitis. Monocyte and lymphocyte
cytokine responses in vitro were studied during the acute phase of disease, and again
during the convalescent phase, 3-4 weeks later. Monocyte cytokine responses, including
interleukin-10 (IL-10), were measured in whole blood cultures, stimulated with lipopoly-
saccharide and interferon-g (LPS+IFNγ). In addition, T cell cytokine responses, includ-
ing IFNγ and IL-4 production, were measured in whole blood cultures, stimulated with
phytohemaglutinin (PHA) or αCD2+αCD28. Cytokine responses were analysed in rela-
tion to the development of recurrent episodes of wheezing, documented by parents in a
diary during a one year follow-up period. IL-10 responses during the acute phase of RSV
bronchiolitis were comparable to healthy controls. During the convalescent phase, IL-10
responses were significantly increased in patients as compared to healthy controls
(p<0.001). At follow-up, 27 children (58%) had recurrent episodes of wheezing. IL-10
levels, measured during the convalescent phase, were significantly higher in patients who
developped recurrent wheezing during the year following RSV bronchiolitis than in
patients without recurrent episodes of wheezing (p=0.006). Moreover, IL-10 responses
during the convalescent phase correlated significantly with the number of wheezing
episodes (r=0.42, n=46, p=0.004). Interestingly, no association was found between IFNγ
responses, IL-4 responses or IFNγ/IL-4 ratios and recurrent wheezing. We conclude, that
monocyte IL-10 responses in vitro upon stimulation with nonspecific stimuli may have
predictive value for the development of recurrent wheezing following RSV bronchiolitis.
Moreover, our results indicate, that not only allergen-driven Th2 cytokine responses can
lead to asthmatic symptoms, but also virus-induced changes in cytokine responses may
result in asthmatic symptoms.
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The occurrence of recurrent episodes of wheezing in early childhood following respira-
tory syncytial virus bronchiolitis has been well documented (1-5). Actually, RSV bronchi-
olitis is followed by recurrent wheezing in 20-80% of the cases (6-8). It is thought, that
these wheezing episodes are triggered by viral upper respiratory tract infections and they
appear to be independent of atopy (9). In addition, follow-up studies show bronchial
hyperresponsiveness 4 to 8 years after hospitalization for RSV bronchiolitis (6,7,10). 
Although RSV infection induces cytokine production by a number of cells in vivo and in
vitro, the relation of these cytokine responses to recurrent wheezing is largely unknown.
CD4+ T cells can be functionally divided into Th1 and Th2 cells (11). This division is
based on the profile of cytokine production. Th1 cells selectively secrete IFNγ and
promote cell-mediated immunity. In contrast, Th2 cells secrete IL-4, IL-5 and IL-13.
These cytokines are involved in humoral immunity and are thought to contribute to
allergic asthmatic inflammation. Recent studies suggest that a Th2 cytokine profile
during RSV bronchiolitis is associated with wheezing during follow-up (12,13).
To our knowledge, the role of monocytes/macrophages in recurrent wheezing following
RSV bronchiolitis is unknown. However, it is evident that alveolar macrophages partici-
pate in the immune response during RSV infections. Alveolar macrophages recovered
from bronchoalveolar lavage (BAL) fluid from children with severe RSV bronchiolitis are
quantitatively the most important cell type (14). In vitro data show that monocytes can
readily be infected by RSV (15,16). They have the ability to produce a spectrum of
cytokines, including IL-12 and IL-10. Interleukin-12 is required for the initiation of the
antiviral immune response (17,18), whereas IL-10 has several properties, including
down-regulation of cytokine production by Th1-like T cells and inhibition of antigen
presentation by antigen presenting cells (APC) (19,20). Alveolar macrophages in BAL
fluid from RSV bronchiolitis patients show increased expression of pro-inflammatory
cytokines, including IL-1b and TNFα, as compared to healthy controls (21). In addition,
in vitro data show induction of IL-6, IL-8 and IL-10 production by macrophages infected
with RSV (22). 
The aim of this study was to determine whether cytokine responses during the acute and
convalescent phase of RSV bronchiolitis are associated with the subsequent development
of recurrent wheezing. We therefore studied T cell and monocyte cytokine responses in
hospitalized children with RSV bronchiolitis and related these cytokine responses to
recurrent episodes of wheezing in a one year follow-up period.
 2
11.3.1  Study population
Fifty children were included during one winter epidemic in 4 hospitals in the Netherlands
(Wilhelmina Children’s Hospital, Utrecht; Beatrix Children’s Hospital, Groningen; St.
Elisabeth Hospital, Tilburg; Rijnstate Hospital, Arnhem). Inclusion criteria were: hospital
admission, lower respiratory tract symptoms, age < 13 months and immunofluorescence
for RSV infection of epithelial cells in nasopharyngeal secretions. Infants with wheezing
illness prior to RSV bronchiolitis were not included. One investigator (L.B.) took the
history of atopy of parents, grandparents and siblings (asthma, documented food allergy,
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eczema, hay fever) and inquired whether either parent had smoked in the presence of the
infant during the follow-up period. Twenty-seven control children aged < 13 months
without evidence of atopy or infection were selected for this study during the same winter
season. Included were infants prior to minor surgery, prior to cardiac surgery in the
absence of hemodynamic compromise, healthy prematurely born infants, healthy infants
screened for congenital disorders and infants with mild anemia. The study was approved
by the Medical Ethical Committee in all participating centers. Parents of subjects and
controls gave written informed consent.
11.3.2  Whole blood cultures
Heparinized venous or arterial blood was taken within 24 hours after admission, from
subjects in the Wilhelmina Children’s Hospital, Utrecht (n=24). Three to four weeks
later, during the convalescent phase, heparinized blood was taken from all subjects
(n=50). Freshly taken heparinized blood was diluted 1:10 in RPMI 1640 medium (Life
Technologies, Grand Island, NY) and aliquoted (150 µl) into 96-well culture plates (Nunc
International, Denmark).
The whole blood culture stimulated with LPS is a suitable ex vivo method to study mono-
cyte cytokine production under conditions in which many of the physiologically relevant
cellular interactions remain intact (23). To induce monocyte IL-10 and IL-12 production,
lipopolysaccharide (LPS) (100ng/ml)+IFNg (20 ng/ml) was added and cultures were
incubated for 48 hours at 37ºC in 5% CO2. It has been shown that maximal monocyte IL-
10 production is observed after 48 hours, which is relatively late compared to that of
monocyte pro-inflammatory cytokines (20). Also monocyte IL-12 production is
(sub)optimally induced after 48 hours stimulation (24). Furthermore, it has been estab-
lished that monocytes are the main producers of IL-10 and IL-12 in LPS stimulated whole
blood cultures (25). 
To induce lymphocyte cytokine production, phytohaemagglutinin (PHA) (50µg/ml) or
anti-CD2,1 (1:12000)+anti-CD2,2 (1:12000)+anti-CD28 (1:3000) monoclonal antibod-
ies (anti-CD2/28 Moabs, CLB, Amsterdam, The Netherlands) were added and cultures
were incubated for 48 hours at 37ºC in 5% CO2. 
All cultures were performed in quadruplicate. Pooled supernatants were kept at -70ºC.
11.3.3  Cytokine assays
In supernatants of LPS+IFNγ stimulated blood cultures IL-12 and IL-10 were measured.
In supernatants of PHA stimulated cultures IFNγ and IL-4 were measured. Concentra-
tions of IL-10, IFNγ and IL-4 were determined using ELISA kits supplied by the Dutch
Laboratory for Blood Transfusion (CLB, Amsterdam, the Netherlands). The detection
limit for IL-10 was 2.5 pg/ml, for IFNγ 25 pg/ml and for IL-4 1.0 pg/ml. Concentrations
of IL-12 were determined using ELISA kit from R&D (Oxon, United Kingdom), the
detection limit was 7.8 pg/ml. This assay recognizes only the IL-12 heterodimer and not
the individual subunits of the dimer. When cytokine values were not detectable, for
statistical analysis the minimum detectable level was used. When IL-10 responses were
above the maximum detectable level (300 pg/ml), this level was used.
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11.3.4  Follow-up evaluations
Follow-up data were collected during one year following discharge. Follow-up was
performed using diaries, which were developed for this study. One investigator instructed
parents how to use the diary. Starting three weeks after discharge from the hospital,
parents noted the presence of “coughing” and “wheezing” on a daily base. A disease
episode was defined as the presence of symptoms for two or more consecutive days. At
the end of the follow-up period, patients were classified as “recurrent wheezing” if more
than one episode of wheezing was noted following discharge. In addition, at the end of
the study period, one investigator contacted the general practitioners of the patients by
telephone and inquired if “asthma” had been diagnosed. 
11.3.5  Statistical analysis
Cytokine production and IFNγ/IL-4 ratios were analyzed after logarithmic transforma-
tion. Mean (geometric mean) and standard error of mean (SEM) of cytokine levels are
calculated of logarithmically transformed values. Chi-square test was used to evaluate
whether gender, the need for mechanical ventilation and the presence of a positive family
history of atopy were associated with recurrent wheezing. Differences in age at onset of
disease, IL-10 and IL-12 responses and IFNγ/IL-4 ratios between infants with and with-
out recurrent wheezing and infants with and without a family history of atopy were
analyzed with unpaired Student’s t-test. The relation between cytokine response in the
acute and convalescent phase were analyzed with paired Student’s t-test. Pearson’s corre-
lation coefficient was used to analyze the relation between cytokine levels and the
number of reported wheezing episodes. All tests of significance were two-sided.
 #
11.4.1  Subject characteristics
The investigated population consisted of 50 patients and 27 controls. Twenty-nine
patients (58%) were boys, median age was 3 months. Eleven patients (22%), including 3
pairs of twins, were born prematurely (range: 29 4/7 - 36 5/7 weeks). In the control
group, 17 children were boys (63%), the median age was 4 months and 2 controls were
born prematurely. Thirty-six patients (72%) and 18 controls (67%) had a positive family
history of atopy. Respiratory distress was present in all children. Three infants had had
apnea prior to admission. Fourteen subjects (28%) needed mechanical ventilation. In
one child chronic lung disease was diagnosed, none of the patients had cardiac disease or
an immunodeficiency. None of the patients received ribavirin or systemic anti-inflamma-
tory agents, including corticosteroids. Patients did not receive inhaled steroids during
RSV bronchiolitis. All patients survived.
11.4.2  Cytokine responses
Cytokine responses in LPS+IFNγ stimulated whole blood cultures from patients during
the acute phase (n=24) and convalescent phase (n=50) are shown in Figure 11.1 and 11.2.
During the acute phase, IL-12 production was significantly lower in patients than in
controls (geometric mean 28 vs 66 pg/ml, p = 0.007). During the convalescent phase, IL-
12 responses in patients increased to levels that were not significantly different from
controls (44 pg/ml). In contrast, the amount of IL-10 produced during the acute phase
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was not significantly different from controls (26 vs 38 pg/ml). During the convalescent
phase, however, IL-10 production (112 pg/ml) was significantly higher than in the acute
phase (p<0.001) and higher compared to controls (p < 0.001).
In PHA-stimulated whole blood cultures of patients during the acute phase of disease,
both IL-4 and IFNγ responses were low (n=24). Actually, in 11 patients, levels of either
cytokine were below detection limits. During the acute phase of disease, IL-4 production
was lower than in controls (2.9 vs 9.6 pg/ml, p < 0.001), as were IFNγ responses (89 vs
602 pg/ml, p = 0.001). In the convalescent phase both IL-4 and IFNγ responses returned
to values that were not significantly different from controls (n=49). In one patient no
supernatant of PHA-stimulated whole blood cultures was collected for technical reasons.
In cultures stimulated with αCD2+αCD28 the same response pattern of IL-4 and IFNγ
were seen. During the acute phase, in comparison to controls, we found decreased
production of IL-4 (4.2 vs 8.1 pg/ml, p = 0.03) and IFNγ (8.1 vs 186 pg/ml) (p < 0.001).
In the convalescent phase IL-4 response (6.6 pg/ml) and IFNγ response (170 pg/ml) were
comparable to controls.
11.4.3  Follow-up data
Diaries were returned of 46 (92%) patients in follow-up, whereas 4 patients were lost in
follow-up. Twenty-seven children (59%) had 2 or more episodes of wheezing (range 2-11
wheezing episodes). In patients requiring mechanical ventilation, 43% had recurrent
episodes of wheezing in the follow-up period, which was not significantly different from-
non-ventilated infants. The number of episodes of wheezing correlated strongly with the
number of episodes of coughing (r = 0.76, p<0.001).
One or more episodes of coughing in follow-up was documented in 43 patients (93%). In
4 patients (9%) one episode of coughing was noted, in 7 children (15%) 2 episodes of
coughing were noted and in 32 patients (70%) 3 or more episode of coughing was noted.
Asthma was diagnosed by a physician in 16 patients (35%). These patients had all more
than one documented episode of wheezing. 
A positive history of atopy was noted in 19 infants with recurrent wheezing (70%) and in
15 infants without recurrent wheezing (79%), which was not significantly different. Six
infants were exposed to tobacco smoke by at least one parent during follow-up, three had
recurrent episodes of wheezing. Age at onset of disease and gender were not associated
with the occurrence of recurrent wheezing.
IL-10 responses during the convalescent phase were significantly higher in infants with
recurrent wheezing than without recurrent wheezing (p=0.006) (Figure 11.3). The differ-
ence was found between IL-10 responses in the convalescent phase in infants with and
without physician diagnosed asthma (p=0.004). Moreover, IL-10 levels during the conva-
lescent phase correlated with the number of episodes of wheezing (r=0.42, p=0.004)
(Figure 11.4).          
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Figure 11.1 Ex vivo IL-12 production during the acute and convalescent phase of RSV
bronchiolitis. Blood was obtained from RSV bronchiolitis patients within 24
hours after admission to the hospital (acute phase) and 3-4 weeks later
(convalescent phase) and controls. Whole blood cultures were stimulated for
48 hours with LPS (100ng/ml) and IFNγ (20 ng/ml). Data represent
individual values and mean ± SEM. Data were analyzed after log
transformation.
Figure 11.2 Ex vivo IL-10 production during the acute and convalescent phase of RSV
bronchiolitis. Samples and cultures as described in the legends to Figure 11.1.
Data represent individual values and mean ± SEM. Data were analyzed after
log transformation.
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We considered the possibility that the association between IL-10 responses and recurrent
wheezing could only be found during the first months of the follow-up period following
RSV bronchiolitis. We therefore evaluated the association between IL-10 responses
during the convalescent phase and wheezing during the last 3 months of the study period
(the winter season). During this period 20 patients had ≥ 1 wheezing episode, and again,
a difference was found in IL-10 responses was found between infants with and without a
wheezing episode (p = 0.02).
Interleukin-12 responses were not associated with recurrent wheezing during follow-up.
In addition, no differences in IL-4 and IFNγ responses in both PHA and αCD2+αCD28
stimulated blood cultures were found between wheezing and non-wheezing infants.
Moreover, IFNγ/IL-4 ratios in PHA stimulated cultures (Figure 11.5a) during the conva-
lescent phase were comparable for wheezing and non-wheezing infants. As expected, in
infants with a positive family history of atopy, decreased IFNγ/IL-4 ratios were found in
PHA stimulated cultures (p<0.05) (Figure 11.5b). In αCD2+αCD28 stimulated cultures
the same association was seen, although this did not reach a significant level. Monocyte
cytokine responses, including IL-10 responses during the convalescent phase, were not
associated with family history of atopy.
Figure 11.3 Ex vivo IL-10 production in patients with and without subsequent recurrent
wheezing and physician-diagnosed asthma.
Blood was obtained from RSV bronchiolitis 3-4 weeks after admission
(convalescent phase) and controls. Cultures as described in the legends to
Figure 11.1. Data represent individual values and mean ± SEM. Data were
analyzed after log transformation.
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The results of this study demonstrate that increased monocyte IL-10 response in vitro
upon stimulation with aspecific stimuli during the convalescent phase of RSV bronchioli-
tis is associated with the development of subsequent recurrent episodes of wheezing,
during a one year follow-up period. Moreover, there was a highly significant correlation
between IL-10 production in the convalescent phase and the number of wheezing
episodes. The same association was found between IL-10 response and physician-diag-
nosed asthma. Recurrent wheezing during the year following clinical bronchiolitis was
not associated with a family history of atopy. In agreement with the latter finding, T cell
cytokine responses (IFNg and IL-4) in vitro upon stimulation with nonspecific stimuli
were not associated with recurrent wheezing. 
Clinical risk factors for the development of recurrent wheezing following RSV bronchi-
olitis were established by previous investigators (9,26-28). These risk factors include male
gender, low age at onset of disease, and disease severity. In our study, boys were not more
likely to develop recurrent wheezing than girls, consistent with findings of Sims et al., but
not with findings of McConnochie and Roghmann, who found an increased risk for boys
(6,29). Furthermore, we did not find a relation between either age at onset or disease
severity during RSV bronchiolitis and subsequent recurrent wheezing, consistent with
most other studies (3,6,7). Finally, some reports indicate an increased risk for post-bron-
chiolitis wheezing in children with a positive family history of atopy, but most recent
reports, including ours do not support this suggestion (6,8,30).
Figure 11.4 Relation between ex vivo IL-10 production and number of wheezing episodes
during a one year follow-up period.
Blood was obtained from RSV bronchiolitis patients 3-4 weeks after admission
(convalescent phase). Cultures as described in the legends to Figure 11.1. Data
represent individual values. Linear regression line is drawn.
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Ex-vivo IL-10 production was significantly increased during the convalescent phase of
RSV infection. Although IL-10 can be produced by different cell types, including mono-
cytes, Th2 cells and B cells, it has been shown that IL-10 in LPS stimulated whole blood
cultures, IL-10 is most likely monocyte derived (19,20,25). In the LPS+IFNg stimulated
cultures in the present study, IL-8 was decreased significantly (data not shown), indicat-
ing that the increased IL-10 response is not explained by a general increase in monocyte
cytokine responses.
Two mechanisms can explain changes in cytokine responses by monocytes in peripheral
blood during RSV bronchiolitis. The presence of RSV ribonucleic acid (RNA) in the
blood and the potential to cause productive infection in vitro in monocytes suggest that
during RSV bronchiolitis, changes in monocyte function could result from direct infec-
tion (15,31). Another explanation is that changes in monocyte cytokine responses are the
systemic consequence of local production of cytokines and other mediators by epithelial
cells and macrophages in the respiratory tract during RSV infection. Finally, we note that
the immune response in respiratory tract and changes in cytokine production by local
macrophages are potentially different from what is found in circulating monocytes. More
research is required to evaluate whether cytokine responses by circulating monocytes
reflect cytokine responses by macrophages in the respiratory tract.
Figure 11.5a Relation between ex vivo IFNγ/IL-4 ratios in PHA stimulated whole blood
cultures and the development of recurrent wheezing following RSV bronchio-
litis. 
Blood was obtained from RSV bronchiolitis patients 3-4 weeks after admission
to the hospital (convalescent phase) and from controls. Whole blood cultures
were stimulated for 48 hours with PHA (50µg/ml). Data represent individual
values and mean ± SEM. Data were analyzed after log transformation.
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Ex-vivo IL-12 production was significantly decreased during the acute phase of RSV
bronchiolitis. Different viruses, including measles virus, have been shown to inhibit IL-12
production in vitro by monocytes/ macrophages (24,32). Although the effect of RSV on
IL-12 production by monocytes/macrophages has not been investigated, it is conceivable
that, RSV itself effectively inhibits IL-12 production. More study is needed to evaluate
whether low IL-12 responses play a role in the pathogenesis of acute RSV bronchiolitis.
We propose two possible mechanisms by which increased production of monocyte IL-10
leads to recurrent wheezing. On the one hand, increased monocyte/macrophage IL-10
responses in vivo may result in suppression of Th1 cells and enhancement of Th2 cells by
antagonizing IL-12 (33-35). As a result, this could then lead to allergic asthmatic airway
inflammation. This latter possibility is not supported by our data, that show the absence
of an association between IFNg/IL-4 ratios and recurrent wheezing. On the other hand, it
is conceivable that in vivo increased IL-10 production leads to decreased antiviral immu-
nity in the lower airways, as a result of suppression of antigen presentation by pulmonary
macrophages. One could then speculate that viral infections in the upper respiratory
tract more easily leads to infection and inflammation of the lower respiratory tract, lead-
ing to wheezing and bronchial hyperresponsiveness. This explanation is in line with the
Figure 11.5b Ex vivo IFNγ and IL-4 production and IFNγ/IL-4 ratios in PHA stimulated
whole blood cultures in patients with a positive/negative family history of
atopy.
Samples and cultures as described in the legends to Figure 11.5a. Data
represent individual values and mean ± SEM. Data were analyzed after log
transformation.
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clinical picture of wheezing following RSV bronchiolitis, usually associated with upper
respiratory symptoms (8).
In this study we found decreased IFNγ and IL-4 responses in patients in the acute phase
of RSV bronchiolitis. We recently described this finding and showed in addition, that
depressed lymphocyte proliferative responses and T cell cytokine responses are markers
of disease severity (36).
Overwhelming evidence is available that a Th2-like cytokine response pattern leads to
allergic asthmatic airway inflammation. Therefore, one could hypothesize, that a Th2-
like cytokine response pattern also plays a role in recurrent wheezing following RSV
bronchiolitis. For example, CD4+ T-cells, specific for the RSV attachment protein
(protein G) secrete IL-4 and IL-5, but little IL-2 (i.e. a Th2-like pattern) when stimulated
with antigen (37). This hypothesis is supported by the study of Renzi et al. showing an
association between a Th2 cytokine response after allergen (Dermatophagoides farinae)
stimulation 5 months after hospitalization for bronchiolitis, and subsequent wheezing in
26 infants (13). In contrast to our study, in Renzi’s study 43% of the patients were nega-
tive for RSV and patients requiring mechanical ventilation or with radiographic evidence
for bacterial infection were excluded. Interestingly, in our study we did not find evidence
for an association between IFNg/IL-4 ratios and the subsequent development of recur-
rent wheezing. In the present study, IFNγ/IL-4 ratios in both PHA and αCD2+αCD28
stimulated cultures were comparable for infants with and without recurrent wheezing in
the follow-up period. We were capable of detecting a lower IFNγ/IL-4 ratio in infants
with a family history of atopy, which resulted mainly from differences in IFNγ responses.
These data demonstrate that our methods are suitable to detect biologically significant
differences in IFNγ/IL-4 ratios. We note, however, that other Th2-like cytokines, includ-
ing IL-5 and IL-13, have not been measured. When other Th2-like cytokines are used to
assess the Th1-Th2 cytokine balance or when other in vitro stimuli are used, it is conceiv-
able that other results can be found with respect to role of the Th1-Th2 cytokine balance
in recurrent wheezing following RSV bronchiolitis.
We conclude that monocyte IL-10 production increases during the course of RSV bron-
chiolitis and that increased IL-10 production is associated with the development of recur-
rent wheezing and physician diagnosed asthma. We did not find support for a role of
IFNγ/IL-4 balances in the development of recurrent wheezing following RSV bronchioli-
tis. This study indicates that not only allergen-driven Th2 cytokine responses can result
in asthmatic symptoms, but also virus induced changes in monocyte cytokine responses
can lead to asthmatic symptoms.
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The principal aim of the cohort study described in this report was to investigate the
predictive value of clinical and immunological parameters during RSV bronchiolitis for
short-term and long-term airway morbidity. The results of the studies have expanded our
knowledge on clinical and non-clinical factors during RSV bronchiolitis determining
disease outcome (table 12.1). 
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The occurrence of RSV bronchiolitis resulting in MV in infants with severe pre-existing
pulmonary or cardiac morbidity is likely the direct result of the pre-existing condition
(Chapter 2). Immunological mechanisms that are either protective or disease-enhancing,
are probably of considerably less importance. The most intriguing question, however, has
been why neonates (term and preterm) without pre-existent medical conditions are at
risk for RSV bronchiolitis resulting in MV. 
Airway inflammation is the hallmark of RSV bronchiolitis resulting in MV. Two different
mechanisms appear to contribute to airway inflammation. On the one hand, airway
inflammation results from necrosis of airway epithelial cells which is directly caused by
the cytopathological effect of RSV[1-3]. Decreased cellular immunity in young infants
would hereby allow for more widespread viral replication resulting in more extensive
damage to the airways. On the other hand, the immune response to RSV may directly
damage the airways resulting in inflammation and more airway destruction. Indeed,
animal studies have supported the concept that T cells can directly cause airway inflam-
mation[4;5]. In T cell-depleted RSV-infected mice disease was milder as compared to
non-depleted infected mice. In addition, transfer of RSV-infected T cells to gamma-irra-
diated RSV-infected mice resulted in severe respiratory disease and airway inflamma-
tion[4]. However, support for a T cell-mediated pathogenesis of naturally-acquired RSV
in humans, however, is not available. 
Immaturity of the immune system in preterm infants and neonates could play a role in
RSV bronchiolitis resulting in MV. Fetal and early post-natal life are associated with a
physiological immune deficiency[6-8]. Deficient immune function in neonates is charac-
terized by relatively deficient functioning of innate and antigen-specific immunity[8-10].
Functional deficits of cells of the innate immune system consist of delayed recruitment of
neutrophils and monocytes to infected tissue and diminished NK cell cytotoxicity[11].
During the neonatal period antigen-presentation by macrophages and dendritic cells
(DC) is less efficient, possibly due to insufficient IL-12 production, resulting in slow
development of antigen-specific immunity[7;8;12]. In addition, T cell-mediated
responses are delayed during the first 4 to 8 weeks of post-natal age, accompanied by
impaired capacity to produce IFN-γ[6;8-10;13]. The results of our study indeed indicate
an important role for immature cell-mediated immune responses in RSV resulting in MV
(Chapter 6 to 8)[14;15]. We found that ex vivo-produced IFN-g (Chapter 6) as well as
IFN-γ levels in the nasopharynx (Chapter 7) is practically absent in infants requiring MV
for RSV, but less so in other hospitalized infants with RSV LRTI. In addition, the inverse
relation between monocyte IL-12 production and duration of MV (Chapter 8) points
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out that initiation of virus-specific cellular immunity is probably of importance to
recover from RSV LRTI resulting in MV.  
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Infants who recover from respiratory syncytial virus (RSV) lower respiratory tract infec-
tion (LRTI) have an increased risk for the subsequent development of recurrent wheezing
during early childhood[16-30]. Most studies have shown that approximately half of
infants with RSV LRTI will have recurrent episodes of wheezing during childhood. Both
Table 12.1 Clinical and immunological factors described to determine short-term and
long-term airway morbidity associated with RSV bronchiolitis
Short term airway morbidity Long-term airway morbidity
Clinical risk factors Clinical predictors
– Maturation-related:
– Neonatal status[87]
– Prematurity[88-90]
– Post-conceptional age < 45 weeks*[91]
Pre-existent medical conditions:
– Chronic lung disease[92]
– Congenital heart disease[93]
– Signs of airflow limitation during
RSV*[94]
– Atopy(?)[26]
Immunological correlates Immunological predictors
– RSV-specific IgE in respiratory tract[95;96]
– Histamine release in respiratory tract [96]
– Leukotriene C4 in respiratory tract [97;98]
– Eosinophilic cationic protein in respiratory tract
[99;100]
– Low IFN-γ levels in respiratory tract*[15]
– Low peripheral blood T cell IFN-γ production*[74]
– Low monocyte IL-12 production*[14]
– Elevated allergen-specific serum
IgE[26]
– RSV-specific IgE in respiratory
tract [25;101]
– High monocyte IL-10
production*[72]
Virological correlates
– High viral load[102;103]
– RSV type A[104] 
Miscellaneous (short-term and long-term airway 
morbidity)**
– Pre-existent low level of lung function[30;105]
– Substance P and other neurogenic factors[106-108]
* described in this thesis
** suggested in literature, but not formally studied
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early and more recently published data indicate that airway morbidity following RSV
LRTI is transient and subsides during school age[16;30].
We have shown that the signs of airflow limitation during RSV LRTI is a powerful predic-
tor for subsequent airway morbidity (Chapter 10). To date this is the first practically
applicable predictor for airway morbidity following RSV LRTI. In addition, this finding
emphasises that inclusion criteria used in RSV follow-up studies determine the preva-
lence of airway morbidity that will be found. Strict inclusion of RSV-infected infants with
classical bronchiolitis will result in a higher observed incidence of airway morbidity[16]
than in inclusion of RSV-infected infants with any lower respiratory tract symptom[30].
Atopy as well as Th2 responses have been mentioned as potential key mechanisms under-
lying the development of recurrent wheezing following RSV bronchiolitis[26;28;29].
However, our cohort study did not show an association between family history of atopy
and recurrent wheezing during the follow-up period (Chapter 11), which is consistent
with most other studies (reviewed in chapter 3). In addition, we showed that recurrent
wheezing following RSV is not associated with Th2-like cytokine production by periph-
eral blood mononuclear cells upon non-specific stimulation (Chapter 11). Moreover, in
vivo cytokine profiles in nasopharyngeal secretion did not suggest the involvement of
Th2-type immune responses in recurrent wheezing following RSV LRTI (data not
shown). The mixed Th1/Th2 cytokine pattern is consistent with most studies on primary
RSV infection in the mouse model[31-33], although some studies show a predominant
Th1 response[34;35]. To our knowledge, no major role for Th2-type cytokines have been
found in primary RSV infection in the mouse model. In conclusion, it appears that atopy
and Th2-type immune responses do not play an important role in the development of
airway morbidity following RSV bronchiolitis.
One of the major findings in the cohort study presented in this thesis is the association
between monocyte IL-10 production during the convalescent phase of RSV infection and
subsequent recurrent wheezing (Chapter 11). IL-10 was originally described as soluble
mediator that inhibits cytokine production by Th1 clones[36]. Later, it was established
that IL-10 can also decrease the production of IL-4 and IL-5 by Th2 clones[37]. As a
result of its down-regulating effect, IL-10 has even been considered as potential treatment
for inflammatory diseases of the airways[38]. However, contrasting data have been
reported on the role of IL-10 in lung inflammation. In asthmatics reduced IL-10 expres-
sion was found in BAL lymphocytes[39]. Others reported elevated IL-10 levels in BAL
fluid from allergic asthmatics[40]. 
In our study we found an association between monocyte IL-10 response during RSV and
recurrent wheezing, that was independent of a family history of atopy or Th2-type
responses in the lymphocyte populations (Chapter 11). Thus, if monocyte IL-10 plays a
role in the development of recurrent wheezing following RSV infection, the underlying
mechanism appears to be unrelated to Th2-type responses. Recurrent wheezing following
RSV infection is strongly associated with bronchial hyperresponsiveness[30;41;42]. A
potential mechanism by which virus-induced IL-10 production could lead to recurrent
wheezing is interference with normal antigen-presentation[43]. Infection of monocyte-
derived DC with rhinovirus induces IL-10-mediated MHC II down-regulation and a
concomitantly decreased capacity to stimulate CD4+ T cells[44]. It is conceivable that
this virus-induced suppression of APC function, can result in decreased anti-viral immu-
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nity in the lower airways. One could then speculate that viral infections in the upper
respiratory tract more easily lead to infection and inflammation of the lower respiratory
tract, leading to wheezing and bronchial hyperresponsiveness. This explanation is in line
with the clinical picture of wheezing following RSV bronchiolitis, usually associated with
upper respiratory symptoms[45]. Other Th2-independent mechanisms involved in bron-
chial hyperresponsiveness include altered neural regulation of airway tone[46;47], hyper-
trophy of airway smooth muscle[48], mucus hypersecretion[49] and airway epithelial
damage[50]. Recent studies in different animal models have shown that IL-10 is required
for the induction of airway hyperresponsiveness by Th2-independent mecha-
nisms[51;52]. Makela and colleagues reported data on airway responsiveness in ovalbu-
min-induced IL-10 knockout mice[51]. In this established mouse model of allergic
airway inflammation, deficiency of IL-10 did not lead to any interference with allergen-
induced production of IgE, leukotriene C4 or Th2-like cytokines. However, bronchial
hyperresponsiveness was completely abolished in these mice. Intranasal inoculation of an
adenoviral construct with the IL-10 gene reconstituted IL-10 production and also the
development of airway hyperresponsiveness. These data strongly suggest the possibility
that IL-10 plays an important role in Th2-independent induction of airway hyperrespon-
siveness. 
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We have demonstrated that ex vivo production of monocyte IL-10 during the convales-
cent phase of RSV bronchiolitis has predictive value for subsequent recurrent wheezing
(Chapter 11)[15]. Together with the inverse relation between monocyte IL-12 responses
and duration of MV during RSV infection (Chapter 8), this cohort study directly points
to a critical role for antigen-presenting cell function in the pathogenesis of recurrent
wheezing following RSV. 
It was shown that monocytes and, to a lesser extent, alveolar macrophages in vitro are
permissive to RSV infection and subsequent viral replication[53-56]. Subsequent to
infection with RSV these APC release of soluble immune mediators, such as prostaglan-
din E2 (PgE2), tumor necrosis factor (TNF)-a and IL-6[57], but also IL-10[55;58;59]. A
recent study reveiled that the cytokine response to RSV by human monocytes is mediated
by CD14, the major receptor for lipopolysaccharide (LPS)[60]. Using macrophages from
CD14 knock-out mice, it was shown that immune responses to the RSV F protein are
fully dependent on the expression of CD14. In addition, it was shown that Toll-like recep-
tor (TLR)-4, which is required for LPS-induced signal transduction, was required for
RSV-induced cytokine responses by macrophages in vitro as well as elimination of the
virus in a mouse model system. The depency of CD14 and TLR-4 expression emphasizes
the potential role of the innate immune system in the pathogenesis of RSV infection.
In addition to the ability to infect monocytes and macrophages, it was shown that RSV
can infect DC from cattle by endocytosis[61]. For humans or rodents no in vivo or in
vitro data are available on RSV infection of DC. 
Alveolar macrophages and DC are the main professional APC in the lung. The role of
each of these cell types in presenting RSV antigen to T cells is not known. Alveolar
macrophages are found throughout the lung. However, they possess poor antigen-
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presenting capacity and may therefore play a minor role in presentation of RSV anti-
gen[62]. 
DC are not only highly specialized in the induction of primary immune responses, but
also form an extensive network above the basement membrane of the airway epithelium
that ensures accessibility to inhaled antigens[63]. After encountering antigen the DC
actively translocates to secondary lymphoid tissue where they transform to mature DC
capable of antigen-presentation[64;65]. Mature DC most effectively present antigen in
the context of either MHC I or II molecules[66]. One of the factors enabling mature DC
to present antigen is the density of both MHC I and II on the surface of DC, which is
higher than on other APC[67]. Taking into account these properties, the DC is an excel-
lent candidate to play an important role in antigen-presentation during RSV infection.
Surprisingly, practically no data exist on this subject. One of the potential roles of DC in
the pathogenesis of RSV infection is induction of virus-specific cytotoxic T cell genera-
tion. For influenza A virus, it was shown in an in vitro model, that monocyte-derived
mature DC can elicit the generation of CD8+ virus-specific T cells[68]. In this model,
help from CD4+ T cells was not required for the induction of anti-viral immunity. Taken
together the physiological properties of DC and the available data on the role of DC in
other respiratory viral pathogens, DC may well play a prominent role in RSV infection in
humans as well as animals.
MHC I molecules are required for antigen-presentation to CD8+ cells resulting in the
generation of cytotoxic T cells [69]. MHC-I restricted antigen-presentation could be of
relevance in RSV infection. Virus-specific CTL have been implicated, at least in the
mouse model, in viral clearance from the lung as well as disease-enhancement[5]. MHC
II molecules are involved in priming naive CD4+ T cells, after which the CD4+ will
develop into the T-helper phenotype[65;70]. Data from the mouse model have clearly
shown an important role for T-helper cells in the pathogenesis of RSV infection [5;71].
As mentioned before, the role of T-helper cells, in particular Th2-cells in human RSV, has
been mentioned, but is still subject of debate[15;28;29;72]. 
Finally, the role of epithelial cells should be discussed. This “non-professional” APC is
quantitatively the most important cell type in the lung. Although epithelial cells are capa-
ble of expressing MHC II molecules and providing appropriate co-stimulation, they do
not usually do so[69]. RSV infection of epithelial cell lines has been shown to result in the
up-regulation of MHC I molecules, which potentially results in better recognition by
CD8+ cells[73]. As mentioned in the previous paragraph, mouse model studies have
shown MHC I-restricted antigen-presentation to CD8+ cells could be most relevant in
the pathogenesis of RSV infection[5]. Therefore, the interaction between RSV and
epithelium might be important for the induction of disease-enhancing immune
responses mediated by CD8+ cells.
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A potentially powerful mechanism by which RSV could decrease anti-viral immunity is
interference with the production of cytokines or cytokine signaling. IFN-γ has anti-viral
activity, up-regulates expression of MHC I and II molecules, activates macrophages and
has a regulatory role in cell-mediated immunity. Decreased production of IFN-γ could
allow RSV to escape from anti-viral immunity. Whether this truly occurs in vivo is not
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known. However, we and others have shown that severe RSV in humans is associated
with decreased IFN-γ production (Chapter 6)[29;74]. This could partially be due to a
down-regulatory effect of RSV on IFN-γ-producing cells in vivo. It is also conceivable that
RSV decreases the capacity of APC to produce IL-12 which is required for initiation of
cellular immunity. This mechanism would be in line with findings in another paramyxo-
virus study, in which it was shown that measles virus can interfere with APC IL-12
production[75;76]. It has also been shown that in vitro infection with RSV of alveolar
macrophages results in the production of regulatory cytokines such as IL-10[58]. It was
suggested that RSV-induced IL-10 production has an immune suppressive effect poten-
tially leading to ineffective elimination of the virus, but this still needs to be shown[58].
A potentially different strategy by RSV to prevent viral destruction is prevention of apop-
tosis (programmed cell-death)[77]. Replicating virus, in general, may lead to apoptosis of
the host cell, for example by inducing TNF-α secretion[77]. Premature cell-death limits
the time for virus to produce new virions. It was shown by Krilov that RSV is capable of
decreasing DNA strand breaks upon in vitro infection of peripheral blood mono-
cytes[78]. Although the mechanism explaining this phenomenon has not net been
provided, this finding indicates that RSV may, indeed, prevent monocyte apoptosis.
Considering the ability RSV to replicate in monocytes and macrophages[55], prolonga-
tion of the life of the infected cell could result in enhanced viral replication. 
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12.6.1  Development of animal models for neonatal RSV infection 
The studies on RSV infection resulting in MV have lead to questions that will not be
easily answered by human studies. The association between decreased cellular immunity
and RSV infection resulting in MV likely reflects impaired cellular immune function of
the immature neonate. To prove this hypothesis pre-existent immune function should be
measured. In addition, it could be that RSV enhances the effects of this immaturity
through a depressing action on cellular immunity. In order to study further the develop-
ment of severe RSV in neonates, new animal models should be evaluated for their rele-
vance. As noted before, the mouse model does not appear to be the first candidate[71].
Suitable animal models for neonatal RSV infection may be found among other primates.
Of all primates humans are genetically most accurately approached by chimpanzees. The
scarcity and the costs involved in caring for these animals make them less practical for
research purposes. Limited data are available on primary RSV infection in chimpanzees,
mainly obtained in vaccine studies[79-81]. It is not known whether chimpanzees are
more affected by RSV during infancy than later in life. Neonatal RSV infection of chim-
panzees, however, remains a model that appears worthwhile to explore. Of interest is a
1976 study by Prince and Porter who studied RSV infection in ferrets[81]. Following
nasal RSV inoculation no illness was observed, but inflammation and concomitant repli-
cating virus were found in nasal tissue in ferrets of all age. However, inflammation and
viral replication in the lungs was only found in infant ferrets during the first 1-2 weeks of
life (life expectancy 4 years). To date, this is the only animal model in which an age-
dependent pulmonary inflammation has been documented[82]. Disadvantages of ferrets,
however, include the lack of inbred strains and immunologic reagents.
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12.6.2  The role of DC in RSV infection
The data presented in this study suggest that the role of APC in RSV infection requires
further study. The best candidate to fulfill this role is the DC. Human studies do not
easily allow for study of airway DC, because a main site of DC are the non-accessible
regional lymphoid tissue[65]. Therefore, it appears more feasible to explore the role of
DC in RSV primarily in in vitro and animal models.
Future study should focus on the role of DC in the initiation of anti-viral immunity
during primary RSV infection. More knowledge is required on the exact interaction
between RSV, DC and T cells. The potential interference by RSV with normal antigen-
presentation by DC, including inhibition of adequate IL-12 production, should be
further explored. The mechanism by which RSV-specific CD4+ and CD8+ T cells are
generated and activated in vivo are largely obscure. However, it is likely that DC play an
important role in the process.
Finally, it is conceivable that DC play a role in recurrent wheezing following RSV bron-
chiolitis. DC-secreted mediators, such as IL-10, might have a direct effect on airway
epithelium and smooth muscle[51]. DC are capable to polarize T cell function. For influ-
enza A virus it was shown that infection of DC results in the generation of either IFN-γ or
IL-4 secreting T cells (Th1 respectively Th2-response) depending on the dose of infection
of the DC[37;83]. In addition to T cell polarization, RSV could interfere with tolerance
induction or sensitization to common aero-allergens. In a mouse model of influenza A a
potential role of DC in virus-associated induction of allergic responses has been shown
[84]. In this model allergic sensitization to ovalbumin during influenza A co-infection
was associated with DC migration to airway epithelium and MHC II upregulation.
Whether the same interaction between RSV and allergic sensitization exists remains to be
investigated. However, these studies stress that interaction between viral infection and
DC-mediated immune responses is a promising subject for further study.
12.6.3  Prevention of severe RSV and long-term sequelae
RSV-specific antibodies have been proven to be effective to reduce hospitalization in case
of RSV infection in high-risk infants treated until the age of 6-12 months[85;86].
However, no evidence exists whether antibody prophylaxis prevents RSV infection result-
ing in MV. To address this question, new intervention studies are required. Because of the
relative low frequency of RSV infection resulting in MV (even in high-risk infants) a large
study population will likely be required. To minimize the size of the study population,
study designs should be chosen in which the largest potential effect of prophylaxis is
expected. A possible study design could include administration of RSV-specific antibod-
ies to neonates and/or preterm infants until post-conceptional age of 44 weeks is reached
and assess reduction in RSV infection resulting in MV (Chapter 5).
To date, one of the major challenges in the area of clinical RSV research is the develop-
ment of strategies to prevent long-term effects. With the current widespread use of anti-
body prophylaxis in high-risk infants, data will become available whether prevention of
RSV infection requiring hospitalization will reduce the risk for recurrent wheezing
during early childhood in this group of infants. However, it is unlikely that antibody
prophylaxis will be used in the general pediatric population to prevent long-term airway
morbidity. Therefore, alternative interventions should be developed. The follow-up stud-
ies described in this thesis do not easily give direction to the nature of intervention stud-
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ies. However, the identification of clinical (Chapter 10)[72] predictors can improve
selection of infants with the highest risk for long-term airway morbidity. 
" 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The present follow-up study has resulted in the description of the first clinical predictors
for RSV associated short-term and long-term airway morbidity. They can be used in clin-
ical practise, but can also be incorporated in predictive models on RSV associated airway
morbidity. In addition, we have shown a potential role for APC in both RSV LRTI result-
ing in MV and recurrent wheezing following RSV LRTI. The exact mechanisms by which
APC, in particular DC, are stimulated and activated during RSV infection in vivo are
challenged to be elucidated in the future.
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Respiratory syncytial virus (RSV) infection is the most frequent cause of bronchiolitis
during infancy. During the winter season RSV bronchiolitis is one the most common
causes of hospitalization as well as mechanical ventilation (MV). Risk factors for RSV
bronchiolitis are prematurity with or without chronic lung disease and neonatal status as
well as congenital heart disease and immunodeficiencies. The disease typically begins
with signs of a common cold, followed after a few days by coughing, dyspnea and an
expiratory wheeze. Following RSV bronchiolitis 30-70% infants develop recurrent
episodes of wheezing. It is not yet possible to predict which children will go on to have
wheezing following RSV bronchiolitis.
Chapter 1 is a general introduction to this thesis. The pathogenesis of RSV bronchiolitis
is not well understood. Evidence exists that symptoms during RSV bronchiolitis are
caused by a pathological immune response to the virus. In the airways of patients RSV-
specific immunoglobulin E (IgE) is found. In addition, there are signs of eosinophil acti-
vation during RSV bronchiolitis. Moreover, the relation with recurrent wheezing suggests
that possibly atopy is the underlying mechanism of both the acute disease as well as the
sequelae. However, an aberrant immune response does not easily explain why preterm
infants without chronic lung disease as well as healthy neonates have increased risk for
severe course of disease in case of RSV infection.
No treatment for RSV bronchiolitis is available. Anti-viral drugs are not effective. The
effectiveness of corticosteroids is controversial, but in general no great benefit can be
expected in mild and moderately severe RSV bronchiolitis. Currently, no vaccine for RSV
is available. In the 1960s a formalin-inactivated vaccine was used in infants. No protec-
tion against naturally-acquired RSV was observed. In contrast, enhanced disease and
increased mortality were observed during RSV infection following vaccination. In the
absence of a vaccine, passive immunization strategies were developed. Both donor-
derived and a humanized RSV-specific monoclonal antibody have been proven to be safe
and effective in reducing hospitalization in case or RSV infection in high-risk infants.
Chapter 2 reviews potential mechanisms that play a role in the development of RSV
infection resulting in MV. Pre-existent cardiac or pulmonary compromise have been
documented as clinical risk factors for severe RSV bronchiolitis. However, a larger
proportion of mechanically ventilated RSV bronchiolitis patients are previously healthy
preterm or term infants. In general, infants at this early age have maturation-related defi-
cient cell-mediated immunity (CMI). Several studies show an association between
decreased CMI and severe RSV bronchiolitis, indeed suggesting that a maturation-related
defect of the cellular immune system facilitates severe RSV. In addition, low virus-specific
antibody titers prior to RSV bronchiolitis have been shown to be a risk factor for severe
RSV bronchiolitis. Studies in the mouse model have demonstrated that the immune
system, in particular T cells, can enhance pulmonary inflammation during RSV infec-
tion. However, it is not yet clear in what way RSV in the animal model bears relevance to
RSV bronchiolitis during infancy. 
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Chapter 3 is a review of the relation between RSV bronchiolitis and recurrent wheezing.
Despite differences in study design, follow-up studies consistently show that approxi-
mately half of the patients with RSV bronchiolitis during infancy go on to have recurrent
wheezing episodes during childhood. Respiratory symptoms are associated with abnor-
mal lung function, including bronchial hyperresponsiveness. Wheezing symptoms
following RSV bronchiolitis gradually decrease and it appears that during school age
airway morbidity is no longer related to RSV bronchiolitis during infancy. Mechanisms
underlying the association between RSV bronchiolitis and long-term airway morbidity
are poorly understood. On the one hand, abnormal airway function that is congenitally
present or acquired before RSV bronchiolitis occurs could be the cause of both RSV LRTI
and subsequent recurrent wheezing. On the other hand, it is possible that RSV bronchi-
olitis causes changes in the lower airways or the immune system that result in long-term
airway morbidity. Animal models suggest RSV infection can promote the development of
allergic sensitization, but most studies in humans do not indicate a role for atopy in the
development of recurrent wheezing following RSV infection.
New strategies have become available to prevent severe RSV infection in prematurely
born infants, including palivizumab, a humanized monoclonal antibody. It is not known
for how long prevention of RSV infection in preterm infants should be considered. We
hypothesized that the duration of the period that children are at risk for severe RSV infec-
tion, is limited by the post-conceptional age (Chapter 5). Post-conceptional age distribu-
tion was studied in mechanically ventilated preterm RSV bronchiolitis patients. It was
shown that preterm infants, without chronic lung disease have increased risk for severe
RSV infection until post-conceptional age reaches 44 weeks. 
To study the role of CMI in disease severity during RSV lower respiratory tract infection
(LRTI) we compared the immune response in the blood and nasopharyngeal aspirates
between RSV-infected infants with and without the requirement of MV. Mechanically
ventilated infants were characterized by decreased lymphoproliferative responses and
IFN-γ production by peripheral blood cells upon non-specific stimuli (Chapter 6). In
addition, in vivo IFN-γ levels in the nasopharynx were lower in RSV-infected infants
requiring MV (Chapter 7). To further investigate potential mechanisms underlying
decreased CMI in RSV-infected infants requiring MV, we studied monocyte IL-12
production in the blood. IL-12 is a prerequisite for the initiation of CMI. We showed that
monocyte IL-12 production was inversely related to duration of MV (Chapter 8). In this
chapter we present the first model to predict the clinical outcome in infants with RSV
LRTI requiring MV. Taken together, these data suggest that severe RSV LRTI is associated
with decreased level of CMI and that initiation of CMI is required for the convalescence
of MV during RSV LRTI.
In addition to a role for CMI during primary RSV infection, we investigated whether
RSV-specific CMI, induced during primary RSV LRTI, protected against reinfection by
RSV during the subsequent winter season. (Chapter 9). We found that RSV-specific
memory is induced in the majority of infants during RSV LRTI, but that RSV-specific
memory responses did not protect against reinfection. Moreover, reinfection did not
boost CMI, which may have consequences for the development of future vaccines against
RSV. 
Studies in the past have attempted to relate clinical parameters during RSV LRTI to long
term airway morbidity. Sex, age at onset of RSV LRTI and disease severity appeared not
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to be associated with subsequent recurrent wheezing of lung function abnormalities. In
Chapter 10 we demonstrate that signs of airflow limitation during RSV LRTI is the first
useful clinical predictor for subsequent recurrent wheezing.
In Chapter 11 we evaluated the predictive of atopy and cytokine profiles during RSV
LRTI for subsequent airway morbidity. Family history of atopy as well as Th2-like
cytokine profiles in the blood during RSV LRTI were not related to subsequent recurrent
wheezing. However, the predictive value of monocyte IL-10 production in the blood
during the convalescent phase of RSV LRTI for subsequent recurrent wheezing is one of
the major findings presented in this thesis. 
This thesis has demonstrated that the majority of previously healthy infants with RSV
LRTI requiring MV have a post-conceptional age < 45 weeks. Therefore, it is conceivable
that immaturity of the immune system, and possibly also of the airways, plays a key role
in the pathogenesis of this severe form of RSV LRTI. We showed that RSV LRTI requiring
MV is associated with decreased level of CMI, which may interfere with adequate viral
clearance. Furthermore, this thesis has shown that monocyte IL-12 and IL-10 production
have predictive value for short-term, respectively long-term airway morbidity. These
findings lead to the conclusion that antigen-presenting cells (APC) could play an orches-
trating role in the immune response during RSV bronchiolitis. Therefore, we conclude
that future research should focus on the role of APC, including dendritic cells, in the
pathogenesis in RSV LRTI.
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Respiratoir syncytieel virus (RSV) infectie is de meest voorkomende oorzaak van bron-
chiolitis bij kinderen tot de leeftijd van 12 maanden. Gedurende de wintermaanden
worden in Nederland jaarlijks ongeveer 1000-2000 kinderen opgenomen wegens RSV
bronchiolitis. Ongeveer 100-150 kinderen moeten worden beademd op een Pediatrische
Intensive Care Afdeling. Risicofactoren voor RSV bronchiolitis zijn prematuriteit en leef-
tijd onder de 5 weken (neonatale status). Tijdens de wintermaanden is RSV bronchiolitis
de meest voorkomende reden van opname op een Algemene Pediatrische Afdeling of een
Pediatrische Intensive Care Afdeling. Het typische ziektebeeld begint met neusverkoud-
heid, na een paar dagen gevolgd door hoesten, benauwdheid en een piepende uitade-
ming. Deze piepende uitademing duidt op vernauwing van de lagere luchtwegen. Na
herstel van RSV bronchiolitis ontwikkelt 30-70% van de kinderen terugkerend episodes
van piepen. Niet duidelijk is of dit beeld van “post-bronchiolitis piepen” onderdeel is van
atopisch astma, waarbij in de regel ook allergie met een familiaire predispositie gezien
wordt. Het is niet mogelijk om te voorspellen welke kinderen luchtwegklachten ontwik-
kelen na RSV bronchiolitis. 
Hoofdstuk 1 is een algemene inleiding tot dit proefschrift. De oorzaak van RSV bronchi-
olitis is niet geheel duidelijk. Er zijn aanwijzingen dat symptomen tijdens RSV infectie
worden veroorzaakt door een pathologische afweerreactie tegen het virus. Zo wordt in de
luchtwegen van patienten RSV-specifiek immunglobuline E (IgE) gevonden. Ook zijn er
tijdens RSV bronchiolitis tekenen van activatie van eosinofiele granulocyten. Bovendien
suggereert de relatie met recurrent piepen dat mogelijk atopie de oorzaak is van zowel
RSV bronchiolitis als de daaropvolgende luchtwegmorbiditeit. Echter, een aberante
afweerreactie verklaart niet eenvoudig waarom gezonde prematuur geboren kinderen en
gezonde neonaten een verhoogd risico hebben op een ernstig verlopende RSV infectie. 
Er is geen behandeling voor RSV bronchiolitis. Anti-virale medicatie is niet effectief. De
effectiviteit van corticosteroïden is omstreden. In het algemeen mag van corticosteroïden
geen groot effect verwacht worden, tenzij miscchien bij de meest ernstig zieke patiënten.
Ook een vaccin voor RSV is er nog niet. Een studie in de jaren ’60 met een formaline-
geïnactiveerd vaccin is desastreus verlopen. RSV bronchiolitis werd niet voorkomen door
het vaccin en kinderen die nadien met RSV werden geinfecteerd werden ernstiger ziek
met zelfs toegenomen mortaliteit als gevolg. In de afwezigheid van een vaccin zijn RSV-
specifieke antistoffen (passieve immunisatie) ontwikkeld die bij risicokinderen een deel
van de ziekenhuisopnames voor RSV bronchiolitis voorkomen. 
Het doel van de cohortstudie beschreven in dit proefschrift was het ontwikkelen van
prognostische modellen voor het acute beloop van RSV bronchiolitis en voor luchtweg-
morbiditeit op de langere termijn. Dit werd gedaan door de potentiële voorspellende
waarde te bepalen van klinische en immunologische factoren voor korte en lange termijn
luchtwegmorbiditeit.
Hoofdstuk 2 is een literatuuroverzicht van klinische, virologische en immunologische
factoren die een rol spelen bij kinderen die beademd worden in verband met RSV bron-
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chiolitis. Er wordt ingegaan op de pathofysiologie van RSV infectie die leidt tot kunstma-
tige beademing van gezonde prematuur en à term geboren kinderen en neonaten. In het
algemeen hebben zeer jonge kinderen een verlaagd nivo van cellulaire immuniteit wat
samenhangt met immunologische onrijpheid. Dit maakt deze kinderen kwetsbaar voor
virale infecties. Of dit ook geldt voor RSV is nog niet zeker. Naast verlaagde cellulaire
immuniteit lijken lage titers van RSV-specifieke antistoffen in het bloed het risico op
ernstige RSV infectie te verhogen. 
Hoofdstuk 3 is een overzicht van de literatuur over de relatie tussen RSV bronchiolitis en
de daaropvolgende luchtwegmorbiditeit. Ondanks verschillen in onderzoeksmethoden,
tonen de meeste onderzoeken dat ongeveer de helft van de kinderen na RSV bronchiolitis
recurrent episodes van piepen ontwikkelt. Deze klachten zijn geassocieerd met afwij-
kende longfunctie, zoals bronchiale hyperreactiviteit. De ernst van de luchtwegsympto-
men neemt geleidelijk af en op de leeftijd van 6 jaar wordt piepende ademhaling niet
vaker gevonden dan bij andere kinderen van dezelfde leeftijd. De mechanismen die ten
grondslag liggen aan lange termijn luchtwegmorbiditeit na RSV bronchiolitis zijn onze-
ker. Aan de ene kant zijn er aanwijzingen dat aangeboren longfunctieafwijkingen de
oorzaak zijn van zowel RSV bronchiolitis als de luchtwegmorbiditeit die daarop volgt.
Aan de andere kant is het mogelijk dat RSV veranderingen in de lagere luchtwegen of het
immuunsysteem induceert die resulteren in luchtwegmorbiditeit. Diermodellen suggere-
ren dat RSV infectie de ontwikkeling van allergie kan stimuleren, maar de meeste studies
bij kinderen tonen dat atopie geen belangrijke rol speelt bij de ontwikkeling van recurrent
piepen volgend op RSV bronchiolitis.
Sinds de introductie van RSV profylaxe is er behoefte aan selectie van kinderen die de
meeste baat hebben bij profylaxe. Om die reden onderzochten wij gedurende welke
periode prematuur geboren kinderen zonder chronisch longlijden risico lopen op RSV
leidend tot mechanische beademing (Hoofdstuk 5). Wij vonden dat na de post-concep-
tionele leeftijd van 44 weken het risico op deze ernstige vorm van RSV infectie relatief
laag is.
Om de rol van cellulaire immuniteit tijdens RSV lagere luchtweginfectie (LLWI) te bestu-
deren werd de immuunrespons in het perifere bloed en in neusslijm tijdens RSV LLWI bij
beademde en niet beademde kinderen vergeleken. De rol van T cel IFN-γ and monocytair
IL-12 stond hierbij centraal. Bij beademde kinderen vonden wij een verlaagde lymfopro-
liferatieve respons en IFN-γ productie door cellen in het perifere bloed na niet-specifieke
stimulatie in vitro (Hoofdstuk 6). Ook in vivo concentraties van IFN-g in neusslijm
waren lager bij beademde patiënten (Hoofdstuk 7). Om verder de oorzaak van verlaagde
cellulaire immuniteit tijdens RSV LLWI bij beademde kinderen te onderzoeken hebben
wij monocytair IL-12 productie in het bloed gemeten. IL-12 productie door monocyten
was verlaagd bij beademde patienten en was bovendien omgekeerd gerelateerd met
beademingsduur tijdens RSV LLWI (Hoofdstuk 8). Op basis van deze bevindingen
hebben wij geconcludeerd dat RSV LLWI leidend tot mechanische beademing samen-
hangt met verminderde cellulaire immuniteit en dat cellulaire immuniteit waarschijnlijk
nodig is voor herstel tijdens beademing als gevolg van RSV LLWI.
Wij onderzochten vervolgens of RSV-specifieke cellulaire immuniteit, geïnduceerd
tijdens de primaire RSV LLWI, beschermt tegen reïnfectie met RSV in het volgende
winterseizoen (Hoofdstuk 9). Wij vonden dat bij vrijwel alle kinderen RSV-specifiek
geheugen werd geïnduceerd tijdens de primaire infectie, maar dat dit geen bescherming
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bood tegen reïnfectie. Ook bleek reïnfectie het RSV-specifieke geheugen niet te versterken
(boosting effect). Deze bevindingen zijn wellicht relevant voor de toekomstige ontwikke-
ling van een RSV vaccin.
In het verleden is zonder succes gezocht naar klinische parameters tijdens RSV LLWI met
voorspellende waarde van het vervolgens ontwikkelen van luchtwegmorbiditeit.
Geslacht, leeftijd bij opname voor RSV LLWI, ziekte-ernst waren niet gerelateerd aan
luchtwegmorbiditeit volgend op RSV LLWI. Wij vonden dat de aanwezigheid van symp-
tomen van bronchusobstructie tijdens RSV LLWI een positief voorspellende waarde had
voor recurrente episodes van piepen tijdens de follow-up periode, zoals geregistreerd in
dagboekjes door de ouders (Hoofdstuk 10). Wij vonden verder dat een positieve familie-
anamnese voor atopie, en ook Th2 cytokine profielen, niet geassocieerd waren met recur-
rent piepen volgend op RSV LLWI  (Hoofdstuk 11). Echter, de voorspellende waarde van
monocytaire IL-10 productie tijdens de herstelfase van RSV LLWI voor recurrent piepen
is één van de belangrijkste resultaten uit dit proefschrift (Hoofdstuk 11). 
Dit proefschrift laat zien dat de meerderheid van de kinderen zonder onderliggend lijden
met RSV LLWI leidend tot kunstmatige beademing een post-conceptionele leeftijd van <
45 weken heeft. Het ligt daarom voor de hand dat onrijpheid van het immuunsysteem, en
wellicht ook van de luchtwegen, een belangrijke rol speelt in de pathogenese van deze
ernstige vorm van RSV LLWI. Zo hebben wij getoond dat RSV LLWI leidend tot kunst-
matige beademing samenhangt met verlaagde cellulaire immuniteit. Dit leidt mogelijk tot
verminderde of vertraagde afweer tegen het virus. Verder heeft dit proefschrift getoond
dat monocytair IL-12 en IL-10 voorspellers zijn voor korte respectievelijk lange termijn
luchtwegmorbiditeit. Deze bevindingen leiden tot de conclusie dat de antigeen-presente-
rende cel (APC) mogelijk een orkestrerende rol vervult in de immuunrespons tijdens
RSV bronchiolitis. Onderzoek naar de rol van andere APC, zoals dendritische cellen, in
de pathogenese van RSV bronchiolitis is daarom gerechtvaardigd.
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scherpte, Annemieke, in mijn begeleiding was dit proefschrift niet tot stand gekomen.
Jullie bijdrage gaat veel verder dan het bijbrengen van een aantal laboratoriumtechnie-
ken. Jullie stonden aan de basis van een goed doordachte opzet om cytokineprofielen te
bepalen bij de patiënten in mijn onderzoek. Het cytokine-onderzoek was haalbaar en
naar mijn inzicht toch volledig. De combinatie van haalbaarheid en volledigheid was toch
een van de grootste uitdagingen van het cytokine-onderzoek. Ik weet dat jullie mij graag
wat meer kneepjes van de experimentele wetenschap hadden bijgebracht en het spijt me
dat dat er maar zo zelden van is gekomen. Tenslotte wil ik jullie bedanken dat jullie mij in
de eerste “eenzame” maanden in de groep hebben opgenomen en hebben laten meege-
nieten van de bourgondische avonden aan het Wilhelminapark. 
De andere directe mede-onderzoekers: Prof.dr. H.A. van Vught, dr. W.M.C. van Aalderen,
dr. F.Brus, dr. J.M.Th. Draaisma, dr. J.A.A.M. van Diemen-Steenvoorde, drs. M. Pekel-
haring-Berghuis, dr. S.M. Geelen. Beste Hans, Wim, Frank, Jos, Ronnie, Martha en Sybil,
jullie maakten mijn onderzoek mogelijk. Jullie betrokken houding was stimulerend en
jullie inhoudelijke bijdrage heeft het onderzoek verrijkt. Bovendien hebben jullie zorg
gedragen voor de inclusie van de patiënten, waarmee de basis van het onderzoek werd
gelegd.
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Beste Nathalie, Boris, Erik, Jorien, Minh, Jettie, Wendy en Sandra. Als student namen
jullie gedurende een aantal maanden deel aan het onderzoek. Het was een groot plezier
om met jullie samen te werken. Met ongekende energie hebben jullie een groot deel van
het onderzoek uitgevoerd. Afname van vragenlijsten, telefonisch enqueteren, thuisbezoe-
ken, vergelijken van sensitiviteit/specificiteit van immuunfluorescentie en PCR voor RSV,
uitvoeren van immunologische bloedkweken en longfunctieonderzoek bij kinderen op de
leeftijd van 2 jaar. Ik hoop dat jullie nooit het enthousiasme zullen verliezen, dat ik heb
mogen meemaken.
Beste Marijke, Rogier, Arieke, Yvet, Michiel, Jeanne-Marie en alle andere (tijdelijke)
bewoners van de “flex-kamer” op de vierde verdieping van het nieuwe WKZ. Hartelijk
dank voor onvergetelijke en gezellige jaren. We deelden de frustraties van patiëntgebon-
den onderzoek en het plezier van mooie nieuwe data. En ook koekjes, ijsjes en andere
geneugten. Beste Marijke, terwijl ik dit schrijf leid jij het hele RSV project. Het gemak
waarmee je in het onderzoek stapte en het geduld dat je had met mijn eigenwijsheid
bewonder ik. Ik heb genoten van de samenwerking. Rogier, de vele discussies over “wel of
niet Th2” en andere raakvlakken tussen RSV en koemelkeiwitallergie waren essentieel
voor dit proefschrift. Ik hoop dat onze wegen nog vaak zullen kruisen.
Alle AIO’s, post-docs en andere medewerkers van het Immunologie laboratorium van het
WKZ. Het begrip voor mijn onervarenheid en stommiteiten op jullie lab heb ik als een
steun ervaren. Ik wil jullie daarnaast ook bedanken voor alles wat ik van jullie heb
geleerd. Ik had vooraf aan mijn onderzoek letterlijk nog nooit een pipet vastgehouden.
Marion, Jitske en Anita, jullie wil ik in het bijzonder bedanken voor de hulp bij de bloed-
kweken, ELISA’s en het analyseren van de snottebellen.
En dan nog een paar mensen die ik wil bedanken. Beste Corine, als poli-assistente in het
Sint Elisabeth Ziekenhuis in Tilburg heb je veel werk verricht voor deze cohort-studie.
Beste Cuno, bedankt voor je epidemiologische ondersteuning. Beste Carla, bedankt voor
je bijdrage bij de data-beheer. De medewerkers van het seretariaat Algemene Kinderge-
neeskunde, beste Bea, Ellen en Marieke, jullie waardeer ik voor diverse diensten, die jullie,
belangeloos, ten gunste van dit onderzoek uitvoerden. In het bijzonder wil ook alle
artsen, verpleegkundigen en andere medewerkers van de Intensive Care Algemene Pedia-
trie van het WKZ/UMC bedanken, omdat ik me op jullie afdeling altijd zo bijzonder
welkom heb gevoeld.
Beste ouders van de kinderen uit deze cohortstudie. Jullie kinderen zijn het onderzoek.
Jullie waren bereid lastige vragen te beantwoorden terwijl jullie baby opgenomen was met
een ernstige RSV infectie. En daarbij gaven jullie nog toestemming voor bloed-en slijm-
afname. En later nog meer prikken en longfunctieonderzoek. Voor mij was het meest
indrukwekkend dat het jullie lukten om gedurende enkele jaren dagelijks luchtwegklach-
ten te noteren. Jullie bereidheid mee te werken aan dit RSV onderzoek heeft mijn
verwachtingen steeds opnieuw overtroffen. Bedankt!!!
Professor Garofalo. Dear Roberto, although my work in Galveston has not been part of
this thesis I felt that my work at your lab was a logical consequence of my study in the
Netherlands. I thank you for the opportunity to work with you and for the inspiring
supervision. I learned how to perform RSV research in a mouse model. I have realized
that this type of work will provide answers to important questions that can not be
addressed in human studies. I also thank Antonella and you for your very warm hospita-
lity that made our Galveston adventure a thrill.
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Dr Haeberle. Dear Helene, I want to thank you for everything you have taught me. You
have introduced me to the mouse work. Your patience allowed me to learn, your
enthusiasm and energy have made a great environment for experiencing the fundamen-
tals of basic research.
Lieve mama, dank zij jou is dit een prachtig boekje geworden. Terwijl ik in de Verenigde
Staten verblijf, zorg jij, met oog voor alle details, voor de laatste loodjes van dit proef-
schrift. Lieve papa, natuurlijk bedank ik jou ook. Jij en ma hebben mij opgevoed met
respect. Respect voor mij, respect voor elkaar en respect voor anderen. Maar ook respect
voor nieuwsgierigheid en wetenschap. Verder wil ik jullie bedanken voor zaken waar ik
geen woorden voor heb kunnen vinden. Ik hoop deze dank op een andere manier over te
brengen.
En tenslotte Corine, Marin en Neil. You have rocked my world!
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